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CHAPTER I 
 
Introduction 
 
Experiences, like learning, stress, and even physical practice change the brain by altering the 
pathways and strengths of connection between neurons. These experiences modify our brain 
function by changing synaptic transmission between cells, referred to as synaptic plasticity. 
Neurons are connected through structures that protrude from the cell called synapses (Kandel, 
2013). Synapses create a point of contact between two cells where an activated cell can release 
neurotransmitters to induce signaling to a synaptic partner cell. Connections in the brain can be 
strengthened (potentiated) or the connections can be made weaker (depressed), meaning that 
synaptic strength at excitatory synapses is modified bidirectionally (Citri and Malenka, 2008). 
These modifications are caused by different patterns of synaptic activity that are translated by the 
cell. This process of strengthening and weakening different synapses is important to the proper 
function of the brain. Too much in either direction can be a cause for neurological disorders. 
Understanding the mechanisms involved in plasticity are important to understanding basic brain 
function, connections between brain areas, and overall impact of the brain on health and behavior 
(Bliss et al., 2014). The molecular mechanisms that underlie proper regulation of this process are 
important to understand so that we can determine the processes underlying both normal and 
pathological brain function. 
One classically studied process in plasticity is that of learning and memory. Memories are thought 
to form based on potentiation of synapses in the hippocampus, and so this brain region has been 
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well studied (Bliss and Collingridge, 1993). Potentiation of synaptic signaling can occur on 
different time scales. Different types of stimulation can lead to a long-term persistence of the 
enhancement or reduction of synaptic strength (Citri and Malenka, 2008). When these changes are 
long-lasting they can last for hours or presumably even days and this cellular response is referred 
to as long-term potentiation (LTP) or long-term depression (LTD) (Malenka and Bear, 2004). In 
addition to long lasting forms of neuronal plasticity, short-term plasticity is also being investigated 
by various groups. These short-term changes are thought to play a role in adapting short-term 
inputs such as changes in sensory inputs (Zucker and Regehr, 2002). Because glutamatergic 
signaling has been well studied, we will begin with an overview of ionotropic glutamate receptors 
and their roles in plasticity.  
Glutamate Receptors 
Synaptic plasticity has been most intensively studied at synapses that release the major excitatory 
neurotransmitter in the brain, glutamate. Glutamatergic synaptic terminals connect to a post-
synaptic dendritic spine where they can release glutamate to induce signaling in the post-synaptic 
cell through chemical and electrical gradients. These receptors are located in and around the post-
synaptic density (PSD) of spines. The PSD is an electron dense area of the synapse where synaptic 
proteins are concentrated and ready to mediate cellular changes due to synaptic activity. Many 
protein-protein interactions and signaling regulators spatially and temporally decode messages 
from presynaptic signals (Sheng and Hoogenraad, 2007). A number of different ionotropic 
glutamate receptors (iGluRs) and metabotropic glutamate receptors (mGlu receptors) mediate 
normal glutamatergic transmission and affect the intracellular signaling and downstream effects in 
different ways. These signals are major translators of the chemical neurotransmitter signal that 
	3	
results in prolonged changes in synaptic strength defined as LTP and LTD. We will first discuss 
the receptors important to these processes. Differences in presynaptic release or postsynaptic 
interpretation of these signals by receptors such as ionotropic and metabotropic glutamate 
receptors can lead to disorders in normal brain function. I will review both of these types of 
glutamate receptors, but mGlu receptors will be the main focus of this thesis. 
Ionotropic Glutamate Receptors  
α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs): 
AMPARs have been shown to play a large role in glutamatergic synaptic plasticity. These 
receptors are responsible for the fast excitatory synaptic transmission in the brain. These receptors 
are concentrated in the protein-rich PSD. AMPARs quickly relay pre-synaptic glutamate release 
into a post-synaptic signal by allowing the influx of Na+ ions to flow into the postsynaptic neuron 
leading to a depolarization of the cell. The function, surface expression, and subcellular 
localization of AMPARs are important because AMPARs are largely responsible for the strength 
of a synapse. Cellular activity can lead to the insertion of AMPARs at the post-synaptic density, 
resulting in an increase in synaptic strength, and under the right conditions can lead to LTP. 
Alternative signaling that leads to a reduction in synaptic strength causes LTD by the 
internalization of AMPARs.  
These receptors are made up of four subunits that can form combinations of four separate genes 
encoding GluA1-GluA4. These AMPAR subunits differ in their intracellular C-tails which can be 
modified by alternative splicing and in protein-protein interactions. AMPAR-interacting proteins 
can affect cellular strength by altering AMPAR permeability to ions, cellular localization, and 
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trafficking. Kinases have also been shown to be important regulators of AMPAR function by 
altering synaptic localization and trafficking, open probability, and channel conductance. Cellular 
depolarization by AMPARs is a precondition for opening of another ionotropic glutamate receptor, 
N-methyl-D-aspartate receptor (NMDARs). 
N-methyl-D-aspartate receptor (NMDARs): 
NMDARs are ligand and voltage-gated cation channels that play important roles in synaptic 
plasticity and learning and memory. Endogenously, NMDARs are activated by glutamate but are 
named because they are activated by the ligand N-methyl-D-aspartate, which is inactive at other 
glutamate receptors. Under low levels of cellular activity, NMDARs are inactive because of the 
voltage-dependence of the NMDAR. At resting membrane potentials, extracellular Mg2+ can block 
the pore of the NMDAR and inhibit cation flow through these channels. Excitatory synaptic 
transmission stimulated by glutamate is initially mediated by the activation of AMPARs in a fast 
and transient manner. Basal excitatory events that are not strong enough to remove the Mg2+ block 
do not cause ion flux through NMDARs. Stronger cellular depolarizations release the NMDAR 
Mg2+ block and allow for a flow of Na+ and Ca2+ into the cells as well as K+ out of the cell. In this 
way the NMDAR works as a molecular coincidence detector because activation requires a 
sufficient cellular depolarization and presynaptic glutamate release. Detection of this type of event 
by the NMDAR has important implications for the function of the synapse because of the ability 
to activate Ca2+ dependent signaling cascades. In addition, NMDARs have a slow activation and 
deactivation that allows for the complex Ca2+ signals. These signals are decoded by the cells to 
alter synaptic activity. Activation of NMDARs has been shown to play a role in synaptic 
potentiation as well as depression in many different brain areas.  
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Metabotropic glutamate receptors (mGlus)  
The iGluRs including AMPA and NMDARs function as ion channels, opening in response to 
glutamate activation. Metabotropic glutamate receptors, on the other hand, are G-protein coupled 
receptors. G-protein coupled receptors (GPCRs) are the most abundant receptor gene family in the 
human genome (Niswender and Conn, 2010). These membrane-bound proteins respond to 
extracellular ligands such as hormones and neurotransmitters to transduce intracellular signals 
through second messenger systems. GPCRs couple to heterotrimeric G proteins composed of α, β, 
and γ subunits to induce signal transduction. Activation of a GPCR by a ligand results in a 
conformational change that causes an exchange from inactive, GDP-bound α subunit of the G 
protein to the active GTP-bound form. Activated G protein subunits can have a number of 
intracellular effects such as modulation of enzymatic activity and cellular transcriptional 
regulation. When the bound GTP is hydrolyzed to GDP, the G protein is then inactive and the 
heterotrimeric form of the G protein can reassemble. About 35% of approved drugs target GPCRs 
highlighting the importance of understanding these receptors (Sriram and Insel, 2018).  
mGlu receptors belong to class C GPCRs, which form constitutive dimers. These receptors are 
distinguished from other GPCR classes by the presence of a large extracellular N-terminal domain 
termed the Venus flytrap domain (VFD), which contains the glutamate-binding site. Crystal 
structures of VFDs of mGlus shows that each VFD has two lobes. Evidence suggests that two 
VFDs dimerize together, back to back, and large conformational changes are induced when 
agonists bind to one or both VFDs. Different VFD states exist. The inactive conformation is 
stabilized by antagonists, and ligands induce the active conformation of these receptors (reviewed 
by Niswender and Conn, 2010), (Figure 1.1).  
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Figure 1.1 General mGlu receptor structure and activation states. mGlu receptors form dimers 
that contain two large extracellular domains called the Venus flytrap domains (VFDs), which bind 
glutamate and other orthosteric ligands. The VFD is linked to the  cysteine-rich domain to connect 
the extracellular domain to the transmembrane domains of the receptor and the intracellular C-
terminus. The open-open state (left) is the inactive state. This state can be stabilized by antagonists 
as shown in the crystal structure below of the VFDs. In the structure, the antagonist is shown in 
red. Either one or two VFDs can bind an orthosteric agonist resulting in active receptor 
conformations that lead to VFD closure. In the structural depiction the agonist is shown in green 
Adapted from Niswender & Conn, 2010 and Ronard & Pin, 2015.    
 
There are eight mGlus (mGlu1-8) subclassified into three groups based on sequence homology, G-
protein coupling, and ligand selectivity (Figure 1.2). Group I includes mGlu receptors 1 and 5, 
Group II includes mGlu receptors 2 and 3, and Group III includes mGlu receptors 4, 6, 7, and 8. 
This dissertation will largely focus on the Group I mGlu receptors discussed in more detail below.  
Open-open
inactive
Closed-open Closed-closed
active
Venus Flytrap Domains Glutamate (orthosteric)binding site
Cysteine-rich
domains
Transmembrane
domains
C-terminus
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Figure 1.2 mGlu receptor families I, II, and III. mGlu receptors are comprised of eight receptor 
subtypes divided into three groups based on their sequence homology, pharmacology, and second 
messenger signaling pathway association. Group I mGlu receptors are the main focus of this 
dissertation and are coupled primarily to Gq (but also Gs) proteins and their activation stimulates 
PLC and production of IP3 and diacylglycerol, stimulating intracellular Ca2+ release from the 
endoplasmic reticulum and PKC activation. mGlu receptors of groups II and III are coupled 
predominantly to Gi/o proteins and inhibit adenylyl cyclase (AC). Activation of mGlu receptors 
modulates downstream signaling through these pathways. Figure from Pereira et al., 2017. (Pereira 
et al., 2017). 
 
Group I mGlu receptors (mGlu1/5) 
mGlu1 and mGlu5 and constitute the Group I subclass of mGlu receptors that are canonically linked 
to the Gαq/11 heterotrimeric G proteins. Group I mGlu receptors function as modulators of neuronal 
physiology and synaptic transmission and have been the target of therapeutic drug development 
for pathologies including Fragile X syndrome, schizophrenia, addiction and obsessive compulsive 
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disorder (Ade et al., 2016; Ayala et al., 2009; Ayoub et al., 2012; Ghoshal et al., 2017; Kinney et 
al., 2003; Michalon et al., 2012; Niswender and Conn, 2010; Pomierny-Chamiolo et al., 2014; Pop 
et al., 2014; Scharf et al., 2015; Vinson and Conn, 2012). A better understanding of the signaling 
of these receptors will lead to greater therapeutic potential in the future.  
Distribution and Downstream Signaling 
Group I mGlus are broadly expressed in the brain, but do show different patterns of expression. 
Staining for mGlu1 is found in the olfactory bulb, cerebellar Purkinje cells, neurons of the lateral 
septum, the pallidum and in the thalamus (Ferraguti and Shigemoto, 2006) (Figure 1.3A). 
Expression of mGlu5 is most highly expressed in the cerebral cortex, hippocampus, subiculum, 
olfactory bulb, striatum, nucleus accumbens and lateral septal nucleus (Figure 1.3B). Although 
mGlu1 and mGlu5 are both expressed in the hippocampus, their expression is complementary 
(Figure 1.3 B,C from Ljuan et al., 1996). mGlu1 is most prominent on interneurons in the alveus 
and stratum oriens of the CA1 regions and throughout CA3 and the molecular layer of the dentate 
gyrus (Figure 1.3C). mGlu5 expression is strongest in the CA1 region while expression is less 
strong in the CA3 region and the molecular layer of the dentate gyrus (Figure 1.2D). Both Group 
I receptors are typically post-synaptically located in the perisynaptic space of dendritic spines 
(Lujan et al., 1996). This allows for these receptors to rapidly regulate excitatory synaptic strength.  
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The extracellular VFD of these receptors contains the orthosteric binding site and a cysteine-rich 
domain (Cao et al., 2009). Covalent receptor dimerization occurs in the extracellular domain 
(Kunishima et al., 2000; Romano et al., 1996). Binding of agonists to the VFD transduces 
information from the extracellular domain to intracellular signaling systems. These receptors 
couple to the Gq /G11 heterotrimeric G-protein. This coupling activates phospholipase Cβ, causing 
the hydrolysis of phosphoinositides and generation of inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG) resulting in the mobilization of intracellular Ca2+ and activation of protein 
kinase C (PKC). Response to mGlu1/5 activation can differ between neuronal cell types, but 
activation of mGlu1/5 has also been shown to activate the mitogen-activated protein 
A	 B
C D
Figure 1.3. Group I mGlu receptor distribution Staining for A. mGlu1 and B. mGlu5 distribution 
across the brain. A closer look at the hippocampus shows the differential distribution of C. mGlu1 
and D. mGlu5. (Adapted from Ferraguti and Shigemoto, 2006 and Lujan et al., 1996)  
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kinase/extracellular receptor kinase (MAPK/ERK) and the mammalian target of rapamycin 
(mTOR) pathways and these have been shown to be important to changes in synaptic plasticity 
(Hou and Klann, 2004; Page et al., 2006).  
Alternative splicing allows for translation of different proteins from a single gene. The production 
of spliced mRNAs results in proteins that differ in their amino acid sequence that can affect protein 
function. Splice variants of these two receptors exist and can alter the receptor signaling. Four C-
terminal splice variants exist of mGlu1 (mGlu1a, b, c, and d), and mGlu5 exists as two main splice 
variants: mGlu5a and mGlu5b. The mGlu5 splice variants have been shown to be developmentally 
regulated, but no major differences in signaling between the two mGlu5 splice variants have been 
reported (Joly et al., 1995; Minakami et al., 1995; Romano et al., 1996). There is at least one 
allosteric binding site within the seven-transmembrane domain. Allosteric modulators at this site 
can modulate mGlu1/5 activity specifically and have been useful in a number of pharmacological 
studies to determine differences between mGlu1 and mGlu5 signaling in neurons (Niswender and 
Conn, 2010), discussed later in this chapter.  
mGlu5 expression is highly regulated, with higher levels found in developing animals (Romano et 
al., 1996). An antibody that specifically reacts with the mGlu5b insert was used to measure the 
distribution of mGlu5b in the mouse and rat brain. It has been shown that mGlu5b is more highly 
expressed in adult animals and mGlu5a is more of a neonatal variant. It seems that most of the 
developmental alteration in total mGlu5 is due to a reduction in the expression of mGlu5a through 
development (Figure 1.4). Comparison of mGlu5 protein and mRNA levels indicates that post-
transcriptional regulation is different across brain regions (Romano et al., 2002).  
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Figure 1.4 mGlu5 expression through development A. Western blot analysis of mGlu5 from rat 
hippocampal and striatal lysates shows that mGlu5 is developmentally regulated with the highest 
protein levels occurring around P7-P11 and stabilizing in adulthood. B. Expression of mGlu5 
mRNA splice variants. RNA was prepared from adult and P7 rat brain regions. All brain regions 
showed enhanced early expression of mGlu5a at P7 which undergoes a marked decrease in 
expression with maturation. In contrast, mGlu5b does not decline between P7 and adult stages 
making it the predominant form in adulthood. Shown are hippocampus and striatum. (adapted from 
Romano et al., 1996)  
 
Cellular Ca2+ signaling 
Both excitable and non-excitable eukaryotic cells rely on intracellular signaling and the ubiquitous 
cation Ca2+ supports many of these processes. Ca2+ controls many aspects of cellular function by 
acting as a diffusible second messenger that allows for communication across the cell. Rises in 
intracellular Ca2+ occurs in specific spatial and temporal patterns that must be received and 
decoded by cells. Although Ca2+ signaling is important in many cell types, the properties controlled 
by Ca2+ are cell-specific, such as the contraction and relaxation of muscles (Carafoli, 2002). To 
generate the appropriate response to a Ca2+ signals, cells are equipped with specific proteins that 
allow for proper translation and transduction of the Ca2+ stimulus.  
Cells are incredibly well-equipped to handle calcium and intracellular Ca2+ concentrations under 
basal conditions falls in the 10-50 nM range, but activation of signaling can lead to transient rises 
Hippocampus Striatum
mGlu5 Western Blot 
Hippocampus
Striatum
mGlu5 mRNA 
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to .5–1 µM or more (Berridge, 2004). These increases can be much higher in the microdomains 
surrounding points of Ca2+ entry (Parekh, 2011).  Increases caused by cellular stimulation result 
in Ca2+ entry from extracellular sources or intracellular stores like the endoplasmic or sarcoplasmic 
reticulum. This entry is balanced and opposed by removal of cytosolic Ca2+ by Ca2+ -ATPases 
(transporters), Na+/Ca2+ exchangers, and fast-acting Ca2+ buffering proteins such as calbindin, 
calretinin, and parvalbumin (Berridge et al., 2003; Fedrizzi et al., 2008) (Figure 1.5). Abnormal 
Ca2+ regulation and signaling can also lead to pathophysiology (Berridge, 2014; Berridge, 2017) 
Many tissues in the body rely heavily on Ca2+ signaling but this dissertation will focus on neuronal 
calcium signaling.  
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Figure 1.5 Mechanisms of Ca2+ regulation in cells. Cells display complex mechanisms to control 
levels of intracellular Ca2+. These include plasma membrane Ca2+ channels gated by voltage, 
ligands or by the emptying of intracellular Ca2+ stores on the endoplasmic and sarcoplasmic 
reticulum, the nuclear membrane, mitochondria, and the Golgi apparatus. Ca2+-binding proteins 
(Ca2+-BP) such as calmodulin can process the Ca2+ signal. (adapted from Fedrizzi et al., 2008). 
 
Calmodulin 
Some of the effects of Ca2+ are due to Ca2+ binding directly to different proteins to cause changes 
in function, but cells also express a large number of Ca2+ sensor proteins. The ubiquitous Ca2+ 
sensor calmodulin (CaM) is present in all eukaryotic cells. CaM is a small, acidic, 17 kDa protein. 
The monomeric protein is part of the EF-hand family of Ca2+-binding proteins. The structure of 
CaM is made up of two nearly symmetrical lobes that resemble a dumbbell, but with a flexible 
joint in the middle (Meador et al., 1992). The Ca2+ binding sites are largely unoccupied at the 
resting cell Ca2+ concentrations, but become highly occupied at the higher levels after a stimulus. 
The four Ca2+-binding EF hands of calmodulin have distinct affinities for Ca2+ , but binding of 
Ca2+ to each lobe increases the affinity of other sites and make CaM a unique decoder of Ca2+ 
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signals (Zhang et al., 2012). Binding of Ca2+ is associated with a large change in the CaM 
conformation that leads to the exposure of hydrophobic surfaces within each domain. This 
conformational change allows CaM’s Ca2+ sensor activity by allowing it to interact with target 
proteins (Hoeflich and Ikura, 2002). A number of CaM-binding proteins have been described that 
regulate different cellular functions such as activation of kinases and modulation of gene 
expression. In the brain, CaM is important for the synthesis of neurotransmitters and activation of 
kinases important for synaptic plasticity and it is also and is found enriched in postsynaptic 
membranes (Sola et al., 2001). The role of CaM in different neuronal cell types can be controlled 
by variables such as the presence of specific binding partners, expression level, and subcellular 
localization (Teruel et al., 2000).  
Calmodulin-dependent kinases  
While Ca2+ can directly bind to some kinases like PKC to regulate kinase activation, others are 
regulated by Ca2+ sensors or “transducers”. CaM-dependent kinases (CaMKs) are a class of kinase 
affected by CaM. These kinases alter cellular function by phosphorylation of other proteins at 
serine or threonine residues in a specific, rapid, and reversible manner. Phosphorylation by CaMKs 
acts as a signal to control a number of different cellular processes including synaptic plasticity, 
gene transcription, translation, and apoptosis in response to ligand- or voltage-dependent increases 
in intracellular Ca2+ (Swulius and Waxham, 2008).  As the name implies, activation of these 
kinases is initially dependent on the binding of (Ca2+ bound) CaM to the kinases. Some of the 
CaMKs are capable of becoming Ca2+/CaM-independent after activation or require further 
modification to become full activated (Soderling and Stull, 2001). These differences in regulation 
and activation allow for a broad range of cellular functions from these kinases.  
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Structurally, CaMKs include a catalytic domain that is followed by a regulatory component that 
harbors both an autoinhibitory domain and a CaM-binding domain. At resting levels of Ca2+, the 
autoinhibitory domain renders the kinases inactive by inhibiting substrate binding to the kinase, 
making the catalytic domain inoperative. Increased intracellular Ca2+ results in CaM binding to 
Ca2+ allowing for binding to the CaM-binding domain of CaMKs (Hook and Means, 2001). CaM 
binding releases autoinhibition by disrupting the interaction between the autoinhinitory domain 
and the catalytic domain, allowing CaMKs to bind to substrates and phosphorylate their substrates.  
There are two classes of CaMKs. These are substrate specific CaMKs (CaMKIII, phosphorylase 
kinase, and the myosin light chain kinases) that only have one known downstream target, and 
CaMKs (CaMKK, CaMKI, CaMKII and CaMKIV) with multiple downstream targets including 
other CaMKs. Some CaMKs can phosphorylate themselves in a regulatory event called 
autophosphorylation. The general consensus sequence for CaMKs is (R-X-X-S/T), but this is not 
always strictly followed(White et al., 1998). It is clear that the CaMKs have evolved as important 
regulators of Ca2+ signaling within cells. We will focus on the multifunctional CaMKII in this 
dissertation. 
CaMKII 
CaMKII is the best-studied member of the CaMK protein family and is the experimental focus of 
this dissertation. CaMKII phosphorylates Ser/Thr residues in many substrates involved in 
processes including cardiac function and learning and memory (Erickson, 2014; Shonesy et al., 
2014b). Similar to other CaMKs, all of the CaMKII isoforms contain a catalytic and autoregulatory 
domain. Unlike the other CaMKs, CaMKII forms a holoenzyme because of the presence of an 
association domain. The native CaMKII holoenzyme is dodecameric, containing two rings of six 
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subunits. CaMKII is derived from four distinct genes (α, β, γ and δ). CaMKIIα and β are highly 
expressed brain-specific isoforms that constitute about 1% of total protein in the forebrain (Erondu 
and Kennedy, 1985).  
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Figure 1.6 Domain organization and structure of CaMKII. A. The two major neuronal isoforms 
of CaMKII, CaMKIIα and CaMKIIβ, have a similar overall domain organization with the 
exception of an F-actin-binding domain inserted in CaMKIIβ. B. Structure of an individual 
“autoinhibited” CaMKII subunit. This individual subunit structure was “excised” from a structure 
(PDB:3SOA) of an intact inactive CaMKIIα holoenzyme structure using PyMol (DeLano 
Scientific). Domains and key residues in CaMKII were colored as in A. The yellow structure in 
the center is a CaMKII inhibitor bound in the kinase active site C. Schematic of the compact 
inactive CaMKII holoenzyme structure. The kinase catalytic domains (pink) decorate the outside 
of a central hub formed by the association domains (teal), linked by the regulatory domains. 
Autoinhibitory interactions of the regulatory and catalytic domains hold the kinase domains in a 
compact closed conformation. For clarity, the illustration includes a single ring, whereas the intact 
dodecameric holoenzyme consists of a stacked pair of rings. D. Cartoon illustrating the 
conformation associated with CaMKII activation. Binding of Ca2 +/CaM disrupts interactions of 
the regulatory (blue) and catalytic (pink) domains; the kinase domains swing away from the hub 
of the holoenzyme in an open conformation such that the active site is accessible to ATP and 
protein substrates. (From Shonesy et al., 2014).  
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CaMKII works to decode Ca2+ signals through its unique activation properties. During basal 
conditions, when intracellular Ca2+ concentrations are low, CaMKII is inhibited by the interaction 
of the catalytic domain to the regulatory domain in a state of auto-inhibition that holds the kinase 
in a compact closed conformation. Binding of Ca2 +/CaM to the regulatory domain disrupts the 
binding interaction between the regulatory and catalytic domains, allowing for the kinase domain 
to hinge open away from the central hub of the dodecameric structure (Figure 1.6). In this 
conformation, the CaMKII active site is accessible to ATP and CaMKII binding partners and 
substrates. The regulatory domain of CaMKII allows for a form of Ca2+/CaM-independent 
activation that allows prolonged transduction of a Ca2+ signal even after levels of intracellular Ca2+ 
have returned to a resting state. To produce Ca2+/CaM-independent activity, CaMKII undergoes 
an autophosphorylation at Thr286 in CaMKII α (Thr287 in β) (Schworer et al., 1988). This 
autophosphorylation requires coincident Ca2+/CaM binding between neighboring subunits within 
a holoenzyme. Individual neighboring subunits act as a kinase as well as a substrate when they are 
bound to Ca2+/CaM. Autophosphorylation at the Thr286/7 (α/β) residue is both necessary and 
sufficient for subunits to retain autonomous activity in the absence of Ca2+/CaM (Fong et al., 
1989). Phosphorylation of Thr286 increases the affinity of CaMKII for Ca2+/CaM. CaMKII has 
been referred to as a “memory molecule” because of this ability to transduce Ca2+ signals after 
intracellular Ca2+ levels have returned to baseline.  
In addition to an autoregulatory phosphorylation site that increases its activity, CaMKII also has a 
mechanism to reduce its own activation. This is through autophosphorylation at a site within the 
CaM binding region, Thr305 and/or Thr306 (Colbran and Soderling, 1990) Autophosphorylation 
at these inhibitory sites block the binding of Ca2+/CaM to the kinase (Colbran, 1993). CaMKII that 
is sequentially phosphorylated at Thr286 and Thr305 or 306 remains active until Thr286 is 
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dephosphorylated. Although I have cited a few sources for these findings, many laboratories have 
contributed to the work surrounding CaMKII autoregulation and this subject has been reviewed in 
more detail (Andy Hudmon and Howard, 2002; Coultrap and Bayer, 2012; Lisman et al., 2002; 
Shonesy et al., 2014b). 
These autophosphorylation mechanisms have important physiological consequences. This was 
demonstrated in mice with a phosphoinhibitory mutation of Thr286 to Ala. The inability for 
Thr286 to be phosphorylated inhibits autonomous CaMKII activity and caused a reduction in 
CaMKII targeting to the PSD, suggesting the importance of this regulatory site in CaMKII 
targeting (Gustin et al., 2011). These mice also show a reduction hippocampal LTP (Giese et al., 
1998). Behaviorally, these mice displayed cognitive impairments and showed deficiencies in 
learning and memory tasks (Giese et al., 1998; Gustin et al., 2011).  
Autophosphorylation at Thr305/6 has also been shown to be important for synaptic regulation and 
learning and memory tasks. Knock-in mice expressing phosphoinhibitory mutations at Thr305/306 
showed that blocking inhibitory phosphorylation increases CaMKII in the PSD and lowered the 
threshold for hippocampal LTD. Alternatively, mice harboring mutations that mimicked 
phosphorylation at these sites showed decreased CaMKII in the PSD, a reduction hippocampal 
LTD, and learning impairments (Elgersma et al., 2002).  
These results demonstrate that activated CaMKII is sufficient to trigger LTP and that CaMKII 
activation is necessary for the induction of LTP and certain forms of learning. It has been shown 
that the extent of CaMKII activity is dependent on the frequency and amplitude of Ca2+ 
oscillations. In this way CaMKII can decode Ca2+ signals to finely tune synaptic signaling (Bayer 
et al., 2002; De Koninck and Schulman, 1998; Li et al., 2012).  
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Calcium signaling in neurons 
Proper control of intracellular Ca2+ concentrations in neurons is important for a number of different 
neuronal functions including neurite growth and development, synaptic remodeling, 
transcriptional regulations, and control of synaptic strength (Brini et al., 2014). There are a number 
of different surface Ca2+ channels that determine both spontaneous and evoked neuronal activity 
and pre-synaptic Ca2+ is important for neurotransmitter release essential for chemical signal 
transduction at synaptic terminals. Certain induction protocols for both LTP and LTD require 
intracellular Ca2+ increases. Activity-dependent Ca2+ signals also create a path for communication 
that extends to the nucleus of neurons to regulate transcriptional regulators and gene transcription. 
The effects of Ca2+ are diverse in neurons and in many cases seem to be specific to the cell-type 
and source of calcium.  
As discussed earlier, a main mechanism of Group I mGlu signaling occurs through intracellular 
Ca2+ release. This is particularly interesting when examining the differences between mGlu1, 
which causes a single sustained Ca2+ release, and mGlu5 that presents with oscillatory increases in 
cytosolic Ca2+ levels in heterologous cell systems (Dale et al., 2001; Kawabata et al., 1996). 
Oscillations in Ca2+ are observed in many different cells types, suggesting that they represent a 
universal signaling method. The most simple model of mGlu5 oscillations suggests that mGlu5 
activation occurs through activation of PLC, leading to increases in IP3 concentrations and Ca2+ 
from intracellular stores by activation of the IP3 receptor (IP3R). Byproducts of PLC activation 
lead to the activation of PKC which can feedback to phosphorylate mGlu5 and cause uncoupling 
from the G protein. During this period, IP3 levels fall along with intracellular Ca2+ concentrations. 
Dephosphorylation of the receptor resets the cycle and allows for succeeding oscillations. 
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(Kawabata et al., 1996). Alterations in the frequency or amplitude of intracellular Ca2+ oscillations 
can activate distinct Ca2+-responsive pathways. This is particularly interesting in the case of 
CaMKII because it’s activity has been shown to be modulated by specific frequencies of Ca2+ (De 
Koninck and Schulman, 1998; Li et al., 2012). Modulation of this system is one way that mGlu5 
binding partners can impact signaling downstream of mGlu5.  
Mechanisms of synaptic plasticity 
Understanding behavior has been a major motivator of neuroscience research. It is thought that 
experience modifies behavior through modifications of synaptic strength. The study of these 
processes allow us to progress our understanding of brain regions important for specific behaviors 
and how disorders can alter the normal transduction of cellular signals. The development of tools 
to study these mechanisms has allowed us to understand some of the requirements for induction 
and maintenance of changes in synaptic plasticity. Plasticity can be studied in in vivo and in vitro 
preparations. In vivo studies are performed by implanting electrodes to stimulate and record 
synaptic potentials in living animals. Much of our understanding of LTP comes from in vitro 
studies of the hippocampal CA1 pyramidal neurons where transverse slices of the brain are cut and 
maintained for hours to study synaptic responses (Figure 1.7). I will touch on several aspects of 
LTP and LTD, but I will largely focus on evidence suggesting the role of Group I mGlu receptors 
in these processes.  
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Figure 1.7. Studying LTP and LTD in vitro. A. Sample experiments illustrating LTP and LTD in 
the CA1 region of the hippocampus. Synaptic strength, defined as the initial slope of the field 
excitatory postsynaptic potential (fEPSP; normalized to baseline) is plotted as a function of time. 
Left panel demonstrates LTP elicited by high-frequency tetanic stimulation (100 Hz stimulation 
for 1 s; black arrowhead). Right panel illustrates LTD elicited by low-frequency stimulation (5 Hz 
stimulation for 3 min given twice with a 3 min interval; open arrow). B. A schematic diagram of 
the rodent hippocampal slice preparation, demonstrating the CA1 and CA3 regions as well as the 
dentate gyrus (DG). (SC=Schaffer collateral; MF=mossy fiber). Typical electrode placements for 
studying synaptic plasticity at Schaffer collateral synapses onto CA1 neurons are indicated 
(Stim=stimulating electrode; Rec=recording electrode) (Adapted from Citri and Malenka, 2008). 
 
LTP 
For the reasons expressed above, LTP has been a major focus of many research studies to 
understand behavioral outcomes of LTP and how these mechanisms relate to typical and 
disordered neuronal function. In slice studies, LTP is induced by electrical stimulation of axons 
and recording of postsynaptic responses in the cells body of CA1 pyramidal neurons (Figure 1.7) 
(Citri and Malenka, 2008). Several forms of LTP have been described in many brain regions, but 
the most common form of LTP is induced by applying high frequency stimulation. In CA1 
pyramidal cells, this results in a long-lasting LTP that is dependent upon NMDAR postsynaptic 
increases in intracellular calcium, and depolarization (Collingridge et al., 1983; Dunwiddie and 
Lynch, 1978; Lynch, 1989).  
A. B.
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The involvement of postsynaptic mGlu1 and mGlu5 receptors have also been studied in this 
process. One group showed a reduced CA1-LTP and impairment of context-specific learning in 
mGlu1 KO mice (Aiba et al., 1994a), but this reduction in mGlu1-dependent LTP was not observed 
in a separate study (Conquet et al., 1994). Additionally, a mGlu1 antagonist prevented the induction 
but not maintenance of LTP (Neyman and Manahan-Vaughan, 2008). In vitro, several studies 
indicate that mGlu1 activation increases the number of functional NMDARs on the postsynaptic 
membrane (Lan et al., 2001a; Lan et al., 2001b; Skeberdis et al., 2001) While mGlu1 may 
participate in regulation of LTP, the role of mGlu1 in the induction and maintenance of LTP has 
not been completely consistent across studies (Francesconi et al., 2004; Naie and Manahan-
Vaughan, 2005; Neyman and Manahan-Vaughan, 2008). 
The other Group I mGlu receptor, mGlu5, has been highly implicated as a major regulator of 
hippocampal LTP. Similarly to mGlu1, genetic knockouts of mGlu5 (Jia et al., 1998; Lu et al., 
1997) and mGlu5-selective antagonists (Francesconi et al., 2004) impair hippocampal LTP. mGlu5 
plays a role in both the induction and maintenance of LTP. Positive modulation of mGlu5 can 
enhance hippocampal LTP  (Ayala et al., 2009) and antagonism of mGlu5 disrupts LTP persistence 
(Francesconi et al., 2004).  Regulation of LTP by mGlu5 activation may be partly attributed to 
mGlu5 potentiation of NMDAR currents (Fitzjohn et al., 1996; Mannaioni et al., 2001) and the 
mGlu5 contribution to induction of de novo protein synthesis necessary for LTP (Deadwyler et al., 
1987; Francesconi et al., 2004; Frey et al., 1988; Stanton and Sarvey, 1984). The potentiation of 
NMDAR currents by mGlu5 activation has been well studied. For instance, in hippocampal 
neurons, positive modulators of mGlu5 in the presence of a subthreshold agonist concentrations 
can potentiate NMDAR currents, phosphorylation, and LTP (Liu et al., 2006; O'Brien et al., 2004; 
Rosenbrock et al., 2010). The regulation of this process differs across distinct brain regions For 
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instance, co-activation of NMDARs and mGlu5 is required for the enhancement of NMDAR 
currents and a long lasting potentiation of excitatory synaptic transmission in hippocampal cultures 
(Kotecha et al., 2003). In CA3 pyramidal cells, activation of mGlu5-mediated enhancement of 
NMDAR currents required G-protein activation, PKC, and Src while mGlu1 potentiated NMDAR 
currents via a G-protein-independent mechanism involving Src kinase activation (Benquet et al., 
2002). In cortical neurons, activation of mGlu1 induced enhanced NMDAR currents that were 
dependent on the activation of Src-family kinases and independent of PKC (Heidinger et al., 2002). 
In contrast, hypothalamic melanin-concentrating hormone neurons demonstrated a PKA and PKC 
activity-dependent DHPG-induced enhancement of NMDA-evoked currents (Huang and van den 
Pol, 2007). 
CaMKII in LTP  
Although several different proteins are important in LTP, CaMKII has been studied as a necessary 
mediator of this process. Genetic mutations of CaMKII to inhibit proper activation (Giese et al., 
1998; Silva et al., 1992) or use of peptides to inhibit CaMKII (Malinow et al., 1989) can block 
LTP. These reductions in LTP coexist with deficits in learning and memory in these mice. 
Increasing CaMKII activity can also increase synaptic strength (Lledo et al., 1995; Pettit et al., 
1994). These studies have strengthed the role of CaMKII as a mediator of LTP and a memory 
molecule.  
During the induction of LTP, Ca2+ entry into the postsynaptic cells occurs largely through 
NMDARs induced by the presence of glutamate and concurrent strong postsynaptic 
depolarization. Once activated by calcium entry through NMDARs, CaMKII is translocated from 
the cytoplasm to the synapse (Leonard et al., 1999; Shen and Meyer, 1999; Strack and Colbran, 
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1998; Strack et al., 2000). CaMKII is capable of binding to the GluN2B subunit of the NMDAR 
(Leonard et al., 1999; Strack and Colbran, 1998). The CaMKII-GluN2B complex is largely 
increased after NMDA activation in the hippocampus and this interaction is important for CaMKII 
translocation, LTP, and learning and memory. A GluN2B mutant that does not bind CaMKII or 
overexpression of the CTD of GluN2B reduces LTP and causes learning deficits  (Barria and 
Malinow, 2005; Zhou et al., 2007). 
CaMKII can phosphorylate the GluN2B at Ser1303 (Omkumar et al., 1996) which enhances 
NMDAR desensitization (Sessoms-Sikes et al., 2005; Tavalin and Colbran, 2017)  and causes a 
reduction in the CaMKII-NMDAR complex (Raveendran et al., 2009; Strack et al., 2000). CaMKII 
binding to GluN2B also increases CaMKII affinity for ATP, increases the catalytic parameters of 
CaMKII and locks the kinase in an active conformation that allows for prolonged formation of the 
NMDAR-CaMKII for times exceeding 60 minutes (Bayer et al., 2001; Bayer et al., 2006; Cheriyan 
et al., 2011; Pradeep et al., 2009). This process is thought to be important for the maintenance of 
LTP because it was shown that CaMKII inhibitors that block the CaMKII interaction with the 
NMDAR can reverse saturated LTP (Sanhueza et al., 2011). This suggests that, in addition to the 
catalytic action of CaMKII, there is a structural component of CaMKII in the PSD that is important 
for sustaining LTP (Hell, 2014). This is partly due to the many CaMKII-associated proteins 
(CaMKAPs) present in the PSD including some structural scaffolding proteins like Densin-180, 
spinophillin, SAP-97, and α -actinin (Baucum et al., 2010; Jalan-Sakrikar et al., 2012; Jiao et al., 
2011; Nikandrova et al., 2010). 
The role of CaMKII in LTP has also been well-studied in its relationship to AMPA receptor 
signaling. LTP is dependent on the number and function of AMPA receptors within the synapse. 
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AMPA receptor subunits GluA1 and GluA2 heteromeric complexes constitute the majority of 
AMPA receptors in the synapse (Lu et al., 2009). CaMKII phosphorylation of GluA1 at Ser831 
enhances AMPAR conductance and has been shown to be increased after the induction of LTP 
(Barria et al., 1997; Benke et al., 1998; Derkach et al., 1999). Phosphoinhibitory Ser to Ala 
mutations at Ser831 and the PKC site Ser845 reduced LTP, LTD, and disrupted performance in 
learning and memory tasks (Lee et al., 2003). In agreement with this data, mice with a 
phosphomimetic mutation at residue 831 (Ser/Asp) showed increased channel conductance by 
improving channel efficiency (Kristensen et al., 2011).  
Other laboratories have questioned the importance of Ser831 in LTP because it was demonstrated 
that normal LTP could be established in neurons with an AMPAR that lacked the Ser831 harboring 
C-tail (Granger et al., 2013). Further, using a method that allows for the stoichiometric analysis of 
phosphorylation sites, it was shown that less than 1% of GluA1 subunits were phosphorylated at 
Ser831 in the hippocampus after LTP induction or learning (Hosokawa et al., 2015), but this was 
quickly refuted by other work showing that phosphorylated AMPARs represent 12-50% of 
receptors (Diering et al., 2016) . CaMKII phosphorylation of the auxiliary protein Stargazin is also 
necessary for these effects because it causes an increase in AMPAR retention in the PSD (Opazo 
et al., 2010; Sumioka et al., 2010). Because GluA1 phosphorylation has been largely investigated, 
but mutation or deletion of these residues has failed to completely inhibit the induction of LTP, 
new hypotheses that incorporate other mechanisms into LTP expression are being created and 
tested (Herring and Nicoll, 2016).  
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LTD 
Understanding the bidirectionality of synaptic plasticity was an important advance in the study of 
synaptic physiology. A form of LTD dependent on the activity of the NMDAR was reported in 
hippocampal CA1 pyramidal cells (Dudek and Bear, 1992). This supported the idea that memories 
and experiences can be encoded by the brain through the weight of synaptic strength and showed 
that neuronal activity is able to be downregulated in response to activity. NMDAR LTD was the 
first to be established but other forms of LTD exist. We will focus on the role of mGlu1/5 in 
plasticity in this section.  
Group I mGlu receptor LTD 
Although Group I mGlu receptors have been shown to facilitate both LTP and LTD, mGlu 
receptor-LTD of excitatory synapses is the most well characterized form of synaptic regulation by 
these receptors. Group I mGlu receptors can trigger LTD in a number of different brain regions 
including the hippocampus, cerebellum, and dorsal and ventral striatum (Bellone and Luscher, 
2005; Gladding et al., 2009; Grueter et al., 2006; Gubellini et al., 2001; Huang et al., 2011; Kano 
et al., 2008; Palmer et al., 1997; Sung et al., 2001). mGlu1 and mGlu5 have long been implicated 
in multiple forms of  LTD that require new protein synthesis (Huber et al., 2001a; Oliet et al., 
1997; Palmer et al., 1997) or increased endocannabinoid signaling (Luscher and Huber, 2010).  
mGlu1/5 receptor-mediated LTD was first characterized at parallel fiber-Purkinje cell synapses of 
the cerebellum (Aiba et al., 1994b; Linden et al., 1991; Shigemoto et al., 1994). mGlu1 is the 
primary Group I receptor expressed in cerebellar purkinje cells and is responsible for cerebellar 
mGlu receptor-LTD, (Kano et al., 2008). However, in other brain regions, deciphering the 
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individual impact of mGlu1/5 in LTD has proven difficult; however there have been some 
differences reported on the role of each individual receptor in synaptic plasticity. For instance, in 
hippocampus, mGlu1 increases the frequency of spontaneous inhibitory post-synaptic currents 
while mGlu5 potentiates NMDAR currents (Mannaioni et al., 2001). Additionally, antagonism of 
mGlu1 in the hippocampus results in a complete blockade of LTD initiation but not maintenance 
(Mannaioni et al., 2001). In contrast, blocking mGlu5 signaling blocked both LTD induction and 
the persistence of LTD. Positive modulation of mGlu5 can also potentiate mGlu receptor-LTD 
induced chemically or electrically (Ayala et al., 2009). It is not always easy to determine the 
individual roles of these receptors. For example, only the combination of an mGlu1and an mGlu5 
antagonist completely abolish LTD in the hippocampus (Volk et al., 2006).  
Mice lacking mGlu1 or mGlu5 have also been used to investigate the roles of these receptors 
individually. While mGlu5 KO mice show an absence of LTD, mGlu1 KO mice have reduced 
hippocampal LTD, suggesting both mGlu1 and mGlu5 play a role in this process (Huber et al., 
2001a; Volk et al., 2006). Because of their perisynaptic localization, mGlu1/5 are activated when 
excess glutamate spills out of the synaptic cleft. Electrical induction protocols can cause a fraction 
of synapses to express LTD, but many laboratories have used chemical induction methods to 
induce a more reliable form of chemically-induced LTD. Dihydroxyphenylglycine (DHPG) 
activates both mGlu1 and mGlu5 and has been a common drug used to investigate mGlu1/5 LTD. 
DHPG-LTD is thought involve similar expression mechanism to paired pulse lower frequency 
stimulation (PP-LFS) LTD electrically induced by 900 paired stimulations at 1 Hz ms, because the 
two forms of LTD occlude one another (Huber et al., 2001b). Pharmacological experiments and 
receptor KO mice indicate that DHPG-LTD depends principally on mGlu5 receptor activation, 
although the mGlu1 receptor may also have a role in LTD induction (Fitzjohn et al., 2001).  
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An important feature of hippocampal mGlu1/5 LTD is that is independent of NMDAR activation 
(Oliet et al., 1997). After the induction of NMDAR LTD, further synaptic depression can be 
induced with DHPG, suggesting two distinct mechanisms of induction (Fitzjohn et al., 1999). 
However, this is not true in all brain areas or across all age ranges. For instance both NMDAR and 
mGlu1/5 activation is required for LTD in the amygdala (Wang and Gean, 1999). In the 
hippocampus, a LFS-induced LTD that is absent in adults but is observed in animals less than 
postnatal day 21 (Kemp et al., 2000). PP-LFS LTD can be induced at all ages, although the role of  
NMDAR activation in this process only seems to be required in young animals, and unnecessary 
in adult animals (Kemp et al., 2000). A number of regulators including scaffolding proteins, 
kinases, and post-translational modifications regulate mGlu1/5 receptor control of synaptic 
strength. Differences in mGlu1/5 expression and signaling can lead to neuropathologies and effects 
on cognition.  
Post-synaptic expression of mGlu1/5-LTD requires rapid translation of proteins in many brain 
regions, including cerebellar Purkinje cells and the hippocampus (Costa-Mattioli et al., 2009; Hou 
and Klann, 2004; Huber et al., 2000; Kano et al., 2008; Yin et al., 2006). Translation of a number 
of different proteins ultimately lead to the internalization of post-synaptic AMPARs and a 
persistent reduction in synaptic strength (Bellone and Luscher, 2005; Snyder et al., 2001; Waung 
et al., 2008). This hippocampal DHPG-induced LTD has been shown to be Ca2+ independent 
(Fitzjohn et al., 2001) in some cases and to require Ca2+ in others (Holbro et al., 2009).  
mGlu1/5 receptor activation-dependent local mRNA translation became a major interest to many 
groups studying autism when it was shown that DHPG-induced LTD is enhanced in a mouse that 
lacks functional fragile X mental retardation protein (FMRP). The FMRP KO mouse is a genetic 
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model of Fragile-X syndrome (FXS), an X-linked form of mental retardation. FMRP works as a 
repressor of translation and has been hypothesized that the absence of FMRP leads to enhanced 
mGlu5 signaling, overactive protein translation, and enhancement of mGlu5-LTD (Dolen and Bear, 
2008). Increases in LTD lead to weaker synapses and more immature dendritic spines, which may 
play a role in the disease phenotypes.  
Understanding the production of new proteins at the synapse during LTD is key to understanding 
molecular mechanisms of this process in healthy individuals and during disease processes. The 
rapid synthesis of new proteins by the activation of mGlu5 receptors occurs locally and relies on a 
number of downstream mechanisms that lead to the internalization of postsynaptic AMPARs 
(Huber et al., 2000; Huber et al., 2001b; Snyder et al., 2001).  
One protein that has been shown to be important in this process is activity-regulated cytoskeleton-
associated protein (Arc/Arg3.1). mGlu receptor activation causes a rapid translation of Arc in 
dendrites and a genetic reduction of Arc blocks mGlu1/5-dependent LTD (Park et al., 2008; Waung 
et al., 2008). Arc increases AMPAR endocytosis through interactions with endocytic machinery 
(Chowdhury et al., 2006). Other proteins that are rapidly translated following Group I mGlu 
receptor activation have been shown to be important in this process. It has been shown that 
dephosphorylation of the AMPAR GluR2 is necessary for Group I mGlu receptor LTD (Moult et 
al., 2006). Striatal-enriched protein tyrosine phosphatase (STEP) was identified as the protein 
phosphatase linked to mGlu receptor-driven AMPAR endocytosis (Zhang et al., 2008). DHPG 
triggers translation of STEP, and inhibition of STEP activity blocks mGlu1/5-LTD (Zhang et al., 
2008). These two examples show that translation induced by mGlu receptor activity stimulates 
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protein expression important for AMPAR endocytosis required for the persistence of mGlu1/5-
LTD.   
The signaling mechanisms important to this process include the activation of the ERK1/2 pathway 
and the MAPK pathways. Activation of these pathways leads to the activation of transcription 
factors and the mTOR pathway (Ronesi and Huber, 2008a; Ronesi and Huber, 2008b; Waung et 
al., 2008). Highlighting the importance of this process,  mGlu receptor-LTD in the hippocampus 
requires both the ERK and PI3K-mTOR pathway (Gallagher et al., 2004; Hou and Klann, 2004). 
CaMKII in LTD 
Although CaMKII has been well studied in LTP, there is also evidence for the role of CaMKII in 
LTD. Both mGlu1/5- and NMDAR- dependent LTD induce CaMKII autophosphorylation at 
Thr286 (Marsden et al., 2010; Mockett et al., 2011). It was shown that autonomous CaMKII could 
cause both LTP or LTD depending on the phosphorylation status of the inhibitory CaMKII 
phosphorylation sites Thr305/306 (Pi et al., 2010). As discussed above, CaMKIIα translocates to 
excitatory synapses following NMDAR stimulation. Interestingly, it was shown that CaMKIIα 
translocates to inhibitory but not excitatory synapses in response to more moderate stimulus that 
enhances inhibitory transmission (Marsden et al., 2010). Stronger glutamatergic stimulation, 
coupled to AMPA receptor, insertion led to Thr286 autophosphorylation of CaMKII but 
accumulation of CaMKII at inhibitory synapses was prevented under these conditions by a 
phosphatase, PP2B/calcineurin (CaN). This preferential targeting of CaMKIIα directed by the 
strength of glutamatergic stimulation shows the dynamic capabilities of CaMKII to provide 
neurons with a mechanism to selectively potentiate excitation or inhibition (Marsden et al., 2010). 
The internalization of AMPARs necessary for some forms of LTD also seems to be a mechanism 
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that can be regulated by CaMKII. Phosphorylation of a CaMKII site on the first intracellular loop 
of GluA1 (Ser567) reduces localization of CaMKII to dendritic spines (Woolfrey et al., 2018).  
The autoregulatory mechanisms of CaMKII allow for tight control of CaMKII activity in neurons. 
CaMKII is capable of decoding frequencies into different levels of activation (Andy Hudmon and 
Howard, 2002; De Koninck and Schulman, 1998; Hanson et al., 1994; Romano et al., 2017). Some 
stimulations can bias activation of CaN over activation of CaMKII (Li et al., 2012). This type of 
regulation by Ca2+ frequencies is also decoded into specificity of gene expression (Dolmetsch et 
al., 1998). This type of regulation of protein activation by differing levels of Ca2+ influx is likely 
important to how CaMKII contributes to the induction of both LTP and LTD.  
Group I mGlu receptors in selected neurological disorders 
Group I mGlu receptors have been a major area of focus in neuronal disorders because of the many 
roles that they play. There has been evidence showing that abnormal expression, signaling and 
function of mGlu1/5 in the pathophysiology of a number of neuronal disorders. 
Group I mGlu receptors play an important role in neurogenesis and proper synaptic neuronal 
development (Castiglione et al., 2008; Catania et al., 2001; Copani et al., 1998; Di Giorgi Gerevini 
et al., 2004) and therefore mGlu5 dysregulation has been a target of study for developmental 
disorders such as autism spectrum disorders (D'Antoni et al., 2014). Studies have shown mutations 
of Group I mGlu receptors in schizophrenic patients and mGlu1-KO and mGlu5-KO mice exhibit 
schizophrenic behaviors (Ayala et al., 2009; Ayoub et al., 2012; Brody et al., 2003; Brody et al., 
2004; Cho et al., 2014). Because of the role of these receptors on synaptic plasticity, aberrant 
signaling can also lead to synaptic adaptations that underlie pathological behavioral changes such 
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as addiction. It seems that Group I mGlu receptors may also play a role in neuronal disorders 
associated with aging such as Parkinson’s disease, and Alzheimer’s disease, and Huntington’s 
disease (Kumar et al., 2015; Litim et al., 2017; Ribeiro et al., 2010).  
Here, I will discuss a few neurological disorders including Fragile X Syndrome, addiction, and 
Parkinson’s Disease in more detail. I felt that these three disorders exhibit the role of Group I mGlu 
receptors in mediating developmental disorders, dysregulation of synaptic plasticity, and a disease 
associated with the aging brain. There are many other disorders that I have not covered in detail 
including some that have been a major focus for many laboratories, such as schizophrenia, 
obsessive compulsive disorder, Alzheimer’s disease, and epilepsy (Kumar et al., 2015; Ngomba 
and van Luijtelaar, 2018; Stansley and Conn, 2018). 
Fragile X Syndrome 
Fragile X syndrome (FXS) is the most common inherited form of intellectual disability and autism 
spectrum disorder. FXS patients often present with severe phenotypes including hyperactivity, 
anxiety, and seizures. FXS is a X-linked disorder associated with trinucleotide repeat expansion in 
the Fragile X mental retardation 1 (FMR1) gene. This mutation leads to a silencing of Fragile X 
mental retardation protein (FMRP) (Bear, 2005). FMRP is a repressor of mRNA translation and a 
reduction of FMRP leads to excess protein synthesis. Many of the proteins regulated by FMRP are 
involved in the regulation of synaptic strength and signaling. Altered regulation of these processes 
are thought to cause many of the phenotypes associated with FXS.  
The Fmr1 KO mouse has been extensively used as an animal model of FXS. The role of Group I 
mGlu receptors in FXS was recognized because FMR1 KO mice show enhanced mGlu receptor-
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mediated LTD (DHPG-LTD) in the hippocampus (Huber et al., 2002). DHPG-LTD requires 
protein translation, and under normal conditions FMRP suppresses mRNAs implicated in this 
reduction in synaptic strength. Activation of Group I mGlu receptors typically leads to the 
degradation of FMRP (Nalavadi et al., 2012). This leads to increased local protein translation of 
proteins necessary for LTD (Niere et al., 2012). Excessive protein translation in the absence of 
FMRP, as in FXS, leads to higher levels of protein synthesis of mGlu1/5 regulated proteins and 
enhanced LTD.  
The evidence supporting the role of mGlu5 in FXS models is robust. Reducing mGlu5 expression 
or the use of mGlu5 antagonists/NAMs has been shown to reverse some of the behavioral and 
synaptic phenotypes of FMRP KO mice including improvements in learning deficits, normalizing 
DHPG-induced LTD, reductions in audiogenic seizures, corrections in aberrant dendritic spine 
density, and overactive ERK and mTOR signaling (Dolen et al., 2007; Michalon et al., 2014; 
Michalon et al., 2012; Thomas et al., 2012). Because of these data, the mGlu5 theory of FXS has 
been reviewed by multiple authors (Bear et al., 2004; Dolen and Bear, 2008; Ronesi and Huber, 
2008b; Scharf et al., 2015; Waung and Huber, 2009). 
Translating these findings to human trials has not been as successful as was expected considering 
the dramatic effects of mGlu5 antagonism in animal models of FXS (Ligsay and Hagerman, 2016). 
The failure of drugs targeting mGlu5 in clinical trials has raised questions about the validity of the 
Frm1 KO mouse model of FXS as well as the outcome of the clinical trials because of small patient 
populations, behavioral measurement protocols, and broad age-range of patients (Gomez-Mancilla 
et al., 2014). The production of new mGlu5 NAMs and the investigation of targets downstream of 
mGlu5 activation is ongoing for FXS treatment.  
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Addiction 
Addiction to different drugs of abuse is a chronic relapsing disorder that can lead to a number of 
deleterious effects on health. The reinforcing and rewarding effects associated with the initial onset 
of drug use drive further abuse of substances and chronic use despite negative consequences. 
Addiction research has led to the hypothesis that addictive drugs and the experience of their use 
induce synaptic adaptations that underlie behavioral changes. Addiction studies support that drug-
evoked changes in synaptic plasticity are driven by alteration of glutamatergic signaling in the 
mesocorticolimbic dopamine system. Addiction circuity and drug-evoked synaptic plasticity have 
been well-studied and summarized by a number of other groups (Cleva et al., 2010; Grueter et al., 
2012; Joffe et al., 2014; Luscher and Malenka, 2011; Nestler, 2004; Vranjkovic et al., 2017; Wolf, 
2016). Because of the data on the importance of Group I mGlu receptors in the addiction process, 
the production of allosteric modulators for these receptors have been a focus of study  (Caprioli et 
al., 2018).  
Both mGlu1 and mGlu5 have been implicated in addiction and have been shown to modulate 
addictive behavior in a number of ways with different drugs of abuse. Studies have used both 
pharmacological and genetic manipulations to study the role of these receptors. The role of mGlu5 
in addiction was realized when it was shown that mGlu5-KO mice do not self-administer cocaine 
and have no cocaine-induced increase in locomotor activity (Chiamulera et al., 2001). 
Additionally, Group I mGlu receptor-LTD is disrupted by cocaine administration (Grueter et al., 
2006) and mGlu5 null mice do not display cocaine-induced synaptic potentiation (Bird et al., 2010).  
Behavioral assays have been developed to determine the desire for drug seeking in animal models. 
Conditioned place preference (CPP) is a behavioral test used to measure the reinforcing properties 
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of drugs where a drug of abuse or a control is paired with a conditioned stimulus (context or 
location). After training to associate drug with the given context, the animal will demonstrate an 
increased amount of time spent with the conditioned stimulus. From this behavioral test, 
researchers can test the acquisition, expression, and reinstatement of CPP. Antagonism of mGlu5 
decreases cocaine self-administration and drug seeking behavior (Amato et al., 2013; Keck et al., 
2014; Kenny et al., 2003) and acquisition of a cocaine CPP in mice (McGeehan and Olive, 2003). 
Pharmacological inhibition of mGlu5 also reduced cocaine self-administration and reinstatement 
of drug seeking behavior in monkeys (Lee et al., 2005).  
In alcohol addiction studies, a selective mGlu1 antagonist decreased alcohol CPP and seizures 
associated with alcohol withdrawal (Kotlinska et al., 2011). Genetic deletion of mGlu5 resulted in 
reduced alcohol consumption and CPP, but exhibited increased sensitivity to alcohol (Bird et al., 
2008). Multiple studies have looked at the effect of blocking mGlu5 with specific antagonists, 
demonstrating that inhibition of mGlu5 has many desirable effects including reducing alcohol self-
administration, seeking, reinstatement, CPP to alcohol, seizures, and anxiety associated with 
alcohol withdrawal (Backstrom et al., 2004; Besheer et al., 2008; Blednov and Harris, 2008; 
Cowen et al., 2005; Hodge et al., 2006; Kotlinska and Bochenski, 2008; Kotlinska et al., 2011; 
Kumar et al., 2013; McMillen et al., 2005; Olive et al., 2005; Schroeder et al., 2005; Sinclair et al., 
2012). By altering the timing of mGlu5 antagonist administration it was reported that mGlu5 was 
important in the expression and reinstatement of alcohol CPP but not in alcohol CPP acquisition 
(Lee et al., 2016). Additionally, Group I LTD is absent in the hippocampus of chronic intermittent 
alcohol-exposed mice (Wills et al., 2017). Blocking Group I mGlu receptors may have positive 
effects on the addictive properties of alcohol by normalizing changes in synaptic plasticity 
developed during the development of dependence. A better understanding of the molecular 
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mechanisms and synaptic alterations that occur provide insight into how these drugs can overcome 
normal learning to produce harmful behavior and pathology. 
Parkinson’s Disease  
Parkinson’s Disease (PD) is a neurodegenerative disorder that results in a loss of dopaminergic 
neurons in the basal ganglia (BG). The BG network is important for the proper control of voluntary 
movements and other cognitive processes, but the imbalance of dopaminergic signaling and 
excessive activity of glutamatergic neurons contribute to the symptoms that are associated with 
PD including the characteristic motor complications (bradykinesia, rigidity, and tremor) and 
cognitive deficits and neuropsychiatric disorders such as depression, anxiety, and psychosis 
(Amalric, 2015; Chaudhuri et al., 2011). The classical treatment of PD to alleviate symptoms is l-
3,4-dihydroxyphenylalanine (l-DOPA), the precursor to dopamine, that provides beneficial 
treatment of motor deficits. Treatment with l-DOPA becomes less efficatious over time and leads 
to abnormal involuntary movements, termed l-DOPA-induced dyskinesias (LID) after 5–10 years 
of treatment. Because of the problems with targeting the dopaminergic network, many groups have 
studied treatments that could improve symptoms of PD patients by targeting the overactive 
glutamatergic system. The modulatory role of mGlu receptors on glutamatergic signaling and their 
expression in the BG made these receptors an attractive target for PD (Rouse et al., 2000).  
Research has focused on finding better and more long-term solutions for the treatment of PD.  
Animal models of PD have been used to study the loss of mid-brain dopamine neurons seen in 
human patients. A common experimental model is using 6-OH-dopamine as a neurotoxin to 
selectively target and kill dopamine neurons. This model is used in rodents and monkeys who 
display many of the motor phenotypes seen in human patients. Increases in mGlu5 expression are 
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also observed in the striatum of human PD patients and a model of PD monkeys  (Morin et al., 
2013; Ouattara et al., 2010; Ouattara et al., 2011). A number of recent reviews have summarized 
the work that has been done revolving around Group I metabotropic receptors in PD (Amalric, 
2015; Dickerson and Conn, 2012; Gasparini et al., 2013; Litim et al., 2017).  
The absence of Group I mGlu-LTD in the striatum of PD models also made Group I mGlu 
receptors an exciting target (Kreitzer and Malenka, 2007). Many different studies have found that 
blockade of mGlu5 in models of PD are helpful for a number of different phenotypes including 
restoration of proper synaptic plasticity, dopaminergic degradation, working memory and motor 
performance (Black et al., 2010; Chen et al., 2011; De Leonibus et al., 2009; Gregoire et al., 2011; 
Hsieh et al., 2012; Kreitzer and Malenka, 2007; Mela et al., 2007; Morin et al., 2013). Despite the 
preclinical promise of mGlu5 antagonists, the effectiveness of mGlu5 antagonists in human patients 
have yielded mixed results (Wang et al., 2018). More studies on this treatment need to be 
conducted because of a high degree of variation in the treatments and low statistical power 
currently reported in the literature. 
Regulation of Group I mGlu receptors by interacting partners 
The intracellular C-terminal domains (CTDs) of mGlu1 and mGlu5 have emerged as important loci 
for regulation by protein binding and phosphorylation (Enz, 2012; Mao et al., 2008b; Mao and 
Wang, 2016). While there are two splice variants of mGlu5 (mGlu5a and mGlu5b), most studies have 
focused on mGlu5a. The CTD of Group I mGlu receptors has been shown to be phosphorylated by 
kinases and bind to a number of different proteins to regulate cell surface localization, expression, 
and intracellular signaling of the receptor.  
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Figure 1.8 Known mGlu5-CTD binding partners. Sequence of the N-terminal region of the 
mGlu5a-CTD with marked protein binding regions. PKC phosphorylation sites are marked with 
purple text. CaM binding sites are marked in red. All other proteins are labeled with a bar 
corresponding to the color of the text above. A CaMKII binding site was identified in these studies 
(residues KRR 866-868). Not shown is Homer which binds to residues 1124-1127 or calcineurin 
(CaN) which for which a binding region has not been identified. Citations for these interactions 
are distributed throughout the text.  
 
Group I mGlu-CTDs contain binding sites for heterotrimeric G-proteins, kinases, and 
phosphatases, that can bind directly or indirectly to ion channels, receptors, and scaffolding 
proteins important for receptor signaling (Figure 1.8). Interacting proteins affect mGlu1/5 receptor 
characteristics including G protein-coupling, receptor localization, and modulation of multiple 
signaling pathways. Sometimes these proteins occupy overlapping binding domains, suggesting 
that there is a high degree of regulation of these binding sites. In some cases, proteins compete for 
binding to induce regulatory control of mGlu1/5 signaling.  
Group I mGlu receptor binding proteins 
Homer  
One of the first proteins that was reported to bind to Group I mGlu receptors was Homer 
(Brakeman et al., 1997). Homer has been a large focus of mGlu receptor regulation because of its 
importance in synaptic regulation (Fagni et al., 2002). Homer proteins are scaffolding proteins 
KPERNVRSAF TTSTVVRMHV GDGKSSSAAS RSSSLVNLWK RRGSSGETLS SNGKSVTWAQ NEKSTRGQHL WQRLSVHINK 
KENPNQTAVI KPFPKSTENR GPGAAAGGGS GPGVAGAGNA GCTATGGPEP PDAGPKALYD VAEAEESFPA AARPRSPSPI 
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present in the PSD and mainly localized at glutamatergic excitatory synapses. Synaptic scaffolding 
proteins like Homer are critical to proper synaptic function because they facilitate interactions by 
dynamically controlling the localization of important regulators of synaptic transmission (Saito et 
al., 2002). Improper assembly of mGlu receptor macro protein complexes can lead to impaired 
signal transduction and neurological disorders (Fagni, 2012).  
Homer is produced by 3 genes (Homer1, 2, and 3) that give rise to a number of different splice 
variants (Shiraishi-Yamaguchi and Furuichi, 2007). Much of the work with Group I receptors has 
focused on Homer1. The Homer1 gene gives rise to 3 major isoforms Homer1a, b, and c. Homer1b 
and Homer1c are longer isoforms that have a C-terminal coiled-coil domain that allows for these 
proteins to oligomerize. Homer1a serves as a dominant negative form that is incapable of forming 
oligomers (Xiao et al., 1998). The N-terminus of both short and long Homer isoforms interacts 
with a consensus binding motif (PPxxF) present on the cytosolic C-terminus of mGlu1 and mGlu5 
receptors. mGlu receptors bind indirectly to Shank and the  IP3 and ryanodine receptors through 
oligomeric Homer complexes to control intracellular Ca2+ release from the endoplasmic reticulum 
(Feng et al., 2002; Tu et al., 1999; Tu et al., 1998). Homer proteins therefore confine a number of 
proteins that control the release of Ca2+ from intracellular stores in close proximity to tightly 
control the intracellular Ca2+ release. Homer1a expression is upregulated in response to specific 
forms of synaptic activity, while other Homer isoforms are constitutively expressed (Brakeman et 
al., 1997). Because this immediate early gene form of Homer1 is unable to oligermerize, increases 
in expression of Homer1a disrupt the multi-protein postsynaptic complexes connected through the 
longer Homer isoforms (Kammermeier and Worley, 2007). Homer1a disruption of oligomerized 
Homer results in a reduction in mGlu5 coupling to postsynaptic signaling effectors (i.e. changing 
Ca2+ responses and activation of ERK1/2) without large changes in receptor distribution 
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(Kammermeier and Worley, 2007).  
In addition to being present on the CTD of mGlu1/5, IP3Rs, and ryanodine receptors, the Homer 
binding motif (PPxxF) is also present on a number of different proteins that can control 
intracellular Ca2+ signaling including the transient receptor-channels 1 and 4 (Yuan et al., 2003), 
the Cav2.1 subunit of voltage-gated Ca2+ channels (Worley et al., 2007), adrenergic receptor 
subtypes, dynamin 3 (Gray et al., 2003), and Shank (Tu et al., 1999). In this way, Homer facilitates 
proper localization and control of the synaptic localization of many Ca2+ effectors . mGlu1a, as well 
as both isoforms of mGlu5, show constitutive activity when expressed in heterologous cells, but 
this is not the case in neurons (Ango et al., 2001). It is hypothesized that the macro-complexes 
formed with Homer bound to mGlu receptors could create physical restrictions to the mGlu 
receptor CTDs to prevent agonist-independent activity of the receptor during basal activity (Chung 
and Kim, 2017). Different forms of Homer seem to play different roles tightly controlled by this 
synaptic scaffolding protein.  While this is a general overview of the function of Homer on Group 
I mGlu receptors, Homer binding to mGlu receptors does not affect mGlu receptor signaling 
uniformly across brain regions and cell-types.  
Calmodulin  
A critical distinction between mGlu1 and mGlu5 is that only mGlu5 is capable of binding 
calmodulin (CaM). This additional binding site on mGlu5 has revealed a molecular mechanism for 
functional differences in these two highly homologous receptors (Choi et al., 2011). CaM has been 
a very interesting mGlu5 regulator because of its Ca2+-dependence. CaM facilitates a number of 
Ca2+-dependent processes because it is a calcium-binding messenger protein activated by the 
presence of intracellular Ca2+. CaM binding to the mGlu5-CTD promotes mGlu5 surface expression 
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in heterologous cells. CaM competes with PKC phosphorylation of the receptor to regulate surface 
expression (Lee et al., 2008; Minakami et al., 1997). The binding site for CaM also overlaps with 
other regulators of mGlu5 surface expression, including CaMKII and the E3 ligase Siah-1a (Jin et 
al., 2013b; Ko et al., 2012). It seems that tight regulation of this portion of the mGlu5-CTD is 
important because of the multiple proteins that have been shown to bind in this region. It’s possible 
that CaM and other Ca2+ sensitive proteins like CaMKII can regulate the binding of other partners 
to mGlu5 to accurately control phosphorylation of the receptor.  
The importance of CaM in mGlu5 function was recently expanded when it was shown that CaM 
activity is required for mGlu5-mediated ERK1/2 activation, Arc expression, and LTD in the 
hippocampus (Sethna et al., 2016). mGlu5 is not the only mGlu receptor that has been shown to be 
regulated by CaM. A lot of work has also been done to study the role of CaM on the regulation of 
mGlu7 (Fagni et al., 2004; Nakajima et al., 1999). These studies may also further our insight into 
the role of CaM in the regulation of mGlu5.  
Norbin/neurochondrin  
Norbin/neurochondrin is another neuronal protein that was shown to bind to the mGlu5-CTD and 
coimmunoprecipitate with mGlu5 receptor from rat brain lysates. Norbin has been shown to be 
important for synaptic transmission because genetic deletion of the protein induced schizophrenia 
model-like behavior, reduced DHPG-induced LTD, and abolished the induction LTP in the 
hippocampus.  Defects in prepulse inhibition of startle (PPI) is due to abnormalities of 
sensorimotor gating and a behavioral phenotype of schizophrenia exhibited by mGlu5 KO and 
Norbin KO mice (Wang et al., 2009).  
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Optineurin 
Hungtington (Htt) is a large cytosolic protein (3144 amino acids) associated with Huntington’s 
disease. The function of WT Htt is unknown, but the abnormal expansion of a CAG tri-nucleotide 
repeat within exon 1 of the HTT gene causes aggregation of mutant Htt that produces dysfunction 
most well characterized in the medium spiny neurons of the striatum. Optineurin, is a Htt binding 
partner, that also directly binds the mGlu1a-CTD to promote formation of a complex with Htt 
(Anborgh et al., 2005).  
Optineurin competes with GRK2 for mGlu1a binding to desensitize receptor-induced activation of 
the PLC pathway and IP3 production. This is of great interest because group I mGlu receptors 
function is modified during the progression of Huntinton’s disease (Ribeiro et al., 2010).  
Group I mGlu receptor phosphorylation  
The role of kinases and phosphorylation on Group I mGlu receptors have been a major focus of 
early studies on Group I mGlu receptors. A number of different kinases are capable of 
phosphorylating Group I mGlu receptors and these have specific consequences in receptor 
regulation. These have been studied in heterologous cells and neurons to elucidate the role of 
phosphorylation on mGlu receptor signaling. My work has expanded our understanding of the role 
of kinases on mGlu5; therefore, I will discuss what is known about Group I mGlu receptor 
regulation by phosphorylation below.   
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PKC 
Protein Kinase C (PKC) was a large focus of early studies on Group I mGlu receptor signaling. A 
PKC phosphorylation site was identified on the CTD of mGlu5a at Thr840 following evidence that 
PKC was capable of phosphorylating mGlu1a (Alaluf et al., 1995; Kawabata et al., 1996). It was 
later reported that PKC phosphorylation of mGlu5 likely occurs at Ser839, but that Thr840 plays a 
permissive role in this phosphorylation (Kim et al., 2005). The site homologous to Thr840 in 
mGlu1a is an aspartate residue (D854). This T/D residue variation does not allow for PKC 
phosphorylation of the conserved serine in mGlu1a (Ser853) (Kim et al., 2005). This difference in 
PKC phosphorylation was one of the first reports to show differences between mGlu1 and mGlu5 
intracellular signaling. While activation of mGlu1a produced a single intracellular Ca2+ peak, 
mGlu5 activity elicited distinct oscillations in intracellular Ca2+. The discovery of this PKC 
phosphorylation site on mGlu5 provided a mechanism for the observed differences in the Ca2+ 
mobilization patterns of mGlu1 and mGlu5 in transfected heterologous cells (Kawabata et al., 
1996). Thr840 was shown to be critical to these mGlu5-specific Ca2+ oscillations because a 
Thr/Asp mutation at Thr840 (to mimic Asp854 in mGlu1) abolished mGlu5-dependent Ca2+ 
oscillations (Kawabata et al., 1996). While the exact mechanism of how PKC phosphorylation 
induces these Ca2+ oscillations is not understood, it is worth noting that Ser839 lies in the G 
protein-coupling region of the mGlu5-CTD. Regulation of mGlu5 Ca2+ oscillations by PKC was 
also investigated in cultured astrocytes where a PKC inhibitor turned oscillatory mGlu5 Ca2+ 
signals into single peaked responses.  In cultured astrocytes that solely express mGlu5, oscillatory 
responses of intracellular Ca2+ were converted to non-oscillatory responses by a PKC inhibitor and 
rises in Ca2+ were completely blocked by PKC activation (Nakahara et al., 1997). This 
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demonstrated for the first time that PKC phosphorylation controlled oscillatory patterns of mGlu5 
activation in astrocytes.  
PKC phosphorylation has also been shown to regulate receptor desensitization. This was initially 
shown pharmacologically because PKC inhibitors reduced Group I mGlu receptor desensitization 
in cultured neurons (Catania, 1991, Aronica, 1993). Multiple PKC consensus sites are present in 
mGlu1/5 and have led groups to determine the role of these sites in receptor function (Table 1.2). 
Mutagenesis studies revealed five residues in the 1st and 2nd intrcellular loops as well as the mGlu5-
CTD that were capable of reducing mGlu5 desensitization (Gereau and Heinemann, 1998) (Table 
1.2). Mutation of Thr840 had no effect on mGlu5 desensitization, but this result may have been 
misinterpreted since it is now believed that Ser839 is the main site of phosphorylation responsible 
for the generation of Ca2+ oscillations (Gereau and Heinemann, 1998; Kim et al., 2005) A single 
threonine residue seems to be the major PKC phosphorylation site responsible for this 
desensitization in mGlu1 (Francesconi and Duvoisin, 2000). These PKC phosphorylation sites of 
Group I mGlu receptors are thought to mediate their effects by disrupting G-protein coupling to 
the receptor, resulting in a reduction in the effectiveness of mGlu1/5 signaling.  
PKC phosphorylation is also a regulator of mGlu binding interactions. This has been well 
documented in the case of the interaction of mGlu5 with CaM (Lee et al., 2008; Minakami et al., 
1997). Phosphorylation of Ser890 affects mGlu5 binding to CaM and enhances mGlu5 
internalization in heterologous cells (Lee et al., 2008). Other GPCRs have also been shown to bind 
to CaM with phosphorylation-dependent regulation. This includes another mGlu receptor, mGlu7 
(Nakajima et al., 1999) and the 5-HT1A receptor (Turner et al., 2004). PKC activation selectively 
inhibits agonist-dependent stimulation of the IP3-production of mGlu1a by phosphorylation of a 
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threonine residue (Thr695) located in the G protein-interacting domain of the receptor disrupting 
mGlu1α–Gq/11 interaction (Francesconi and Duvoisin, 2000). PKC regulation in Group I mGlu 
receptor signaling has been shown to be important in synaptic plasticity (Bortolotto and 
Collingridge, 2000; Francesconi and Duvoisin, 2000; Gass and Olive, 2009; Malinow et al., 1989; 
Poisik et al., 2003; Schmidt et al., 2015; Skeberdis et al., 2001).  
GRK  
In addition to PKC, the G protein-coupled receptor kinase (GRK) family of kinases can also 
regulate mGlu receptor signaling. GRKs have been studied in their role in the desensitization and 
endocytosis of many GPCRs and GRKs have also been demonstrated in Group I mGlu receptor 
desensitization (Gainetdinov et al., 2004). 
The GRK family consists of GRK1-7 and it has been shown that GRK2, GRK4, and GRK5 may 
all phosphorylate mGlu1a to regulate mGlu receptor desensitization and endocytosis (Dale et al., 
2000; Dhami et al., 2002; Dhami et al., 2005; Dhami et al., 2004; Iacovelli et al., 2003; Mundell 
et al., 2003; Sallese et al., 2000). GRK2 mediated desensitization of mGlu1a occurs through direct 
binding of GRK2 to the receptor through its regulator of G protein signaling (RGS) homology 
domain. The RGS homology domain of GRK2 binds to the IL2 of mGlu1a at Lys691/Lys692 
(Lys677/678 in mGlu5a) (Dhami et al., 2005). It is thought that binding of GRK2 to IL2 may disrupt 
G protein-coupling and, consequently, reduce mGlu1 signaling. Although most studies have 
focused on mGlu1 regulation by GRKs, mGlu5 can also be regulated by a kinase activity dependent 
mechanism involving GRK2 (Sorensen and Conn, 2003). A kinase dead mutant of GRK2 
abolished the effects of GRK2 on mGlu5 desensitization, suggesting that, unlike mGlu1, the GRK2 
mediated effects on mGlu5 are activity (phosphorylation) dependent. Mutation of the Thr840 site 
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on mGlu5 reduced the effects of GRK2, so this site seems to be at least partially responsible for 
GRK2 regulation of mGlu5. GRKs, unlike many kinases, do not have a consensus sequences that 
makes phosphorylation predictable, therefore the sites of GRK phosphorylation have been difficult 
to study and have not yet been elucidated. 
 PKA  
Protein kinase A (PKA) is a kinase that is activated by increases in intracellular levels of cyclic 
AMP. In this way, PKA works as a regulator of synaptic signaling during times of increased cAMP 
production such as with activation of Gαs-coupled GPCRs. A recent study demonstrated PKA 
phosphorylation of mGlu5 and identified the phosphorylated residue (Ser870) (Uematsu et al., 
2015). This phosphorylation was identified in vitro and in mouse striatum with a phospho-specific 
antibody. DHPG-stimulated levels of phosphorylated ERK1/2 levels were prevented by an Ser/Ala 
mutation at residue 870 suggesting that PKA phosphorylation of the receptor is necessary for 
mGlu5-dependent ERK phosphorylation. The phospho-inhibitory Ser/Ala mutation at Ser870 also 
significantly reduced the number of mGlu5-transfected HEK cells that responded with Ca2+ 
oscillations and reduced the total number of Ca2+ oscillations per cell. 
 Distinct roles of PKA and PKC on mGlu1a signaling have also been demonstrated. While PKC 
activation selectively inhibits agonist-dependent stimulation of the IP3 pathway, PKA potentiated 
agonist-independent signaling by IP3 (Francesconi and Duvoisin, 2000). These data show how 
selective regulation of mGlu receptor signaling can be fine-tuned by local signaling machinery, 
such as kinases. This regulation may also differ based on brain region.  
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The importance of PKA in mGlu receptor signaling has been demonstrated in the globus pallidus 
in rat brain slices where it was found that inhibition or stimulation of PKA activity or D1 or D2 
dopamine receptors impacted the signaling properties of mGlu1 and mGlu5 (Poisik et al., 2003). It 
is possible that PKA regulation of Group I mGlu receptors can relay information between 
glutamatergic and dopaminergic signaling pathways in certain regions of the brain.  
CDK5 
 Cyclin-dependent kinase 5 (CDK5) is a proline-directed serine/threonine kinase involved in 
synaptic function and plasticity. In vitro kinase assays revealed that CDK5 could phosphorylate 
mGlu5 within the Homer binding domain of the CTD (Orlando et al., 2009). mGlu5 
phosphorylation by CDK5 increases the interaction between the mGlu5-CTD and Homer. Homer 
interactions with Group I mGlu receptors have been shown to regulate receptor surface expression 
and signaling. Phosphorylation of this region by CDK5 may be another way that to regulate the 
connection between Group I mGlu receptors and postsynaptic regulators of mGlu receptor 
trafficking, signaling, and localization.  
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Table 1.2. Reported phosphorylation sites and the effect of phosphorylation on mGlu1/5 
 
Protein Phosphatases  
Protein phosphorylation is bidirectionally adjusted by the presence of both protein kinases and 
protein phosphatases (PPs). The regulation of Group I mGlu receptors by PPs has been supported 
through a number of pharmacological and biochemical studies.  
Both catalytic γ-isoforms of protein phosphatase 1 (PP1γ1 and PP1γ2) bind to mGlu1a, 5a, and 5b 
in yeast cells and pull-down assays at a 5 amino acid residue stretch of the CTD (residues 
KSV[S/T]W 891-895 in mGlu5a and 880-884 in mGlu5b) that is necessary and sufficient for 
binding (Croci et al., 2003).  This binding site on mGlu5 contains a serine residue that can be 
phosphorylated by PKC (Ser881) that has been shown to be important for PKC dependent 
desensitization of the receptor.  
Kinase Phosphorylation site Effect Receptor Reference 
CDK5 T1164/S1167 Increases binding to homer mGlu5 Orlando et al., 2009
CaMKII T871 
Contributes to agonist-
induced desensitization.  mGlu1 Jin et al., 2013a 
GRK2
mGlu1a : K691/K692 
mGlu5a: K677/678 
 Activity independent 
binding disrupts G protein-
coupling at IL-2 mGlu1 Dhami et al., 2005
GRK2 Thr840 
Activity dependent 
desensitization of mGlu5 mGlu5 Sorensen and Conn, 2003
PKA S870
Regulates ERK activation 
and IP3-mediated Ca2+ 
release mGlu5 Uematsu et al., 2015
PKC S839
S839 disrupts G protein-
coupling  at the CTD mGlu5 Kawabata et al., 1996, Kim et al., 2005
PKC 
T606, S613, T665, S881, 
and S890
Mutation of all block PKC-
dependent desensitization mGlu5 Gereau and Heinemann, 1998
PKC T695
 Disrupts IL-2 G protein 
interaction mGlu1 Francesconi and Duvoisin, 2000
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In addition to PP1, an interaction was shown between mGlu5a and PP2A in neurons via a 
coimmunoprecipitation assay. Inhibition of PP2A mimicked the effects of an mGlu5 agonist in 
increasing phosphorylation of ERK1/2 (Mao et al., 2005). Further, activation of mGlu5 selectively 
inhibited PP2A and reduced mGlu5-PP2A binding (Mao et al., 2005). After agonist treatment, 
mGlu5 can be internalized and enter the recycling compartment before recycling back to the cell 
surface and it was reported that this process is dependent on PP2A and partially dependent on 
calcineurin (Mahato et al., 2015).  
One well studied effect of mGlu receptor activation is an enhancement of agonist-evoked currents 
through the NMDAR. Pharmacological evidence suggests that PPs are important in this process. 
NMDA induced a robust potentiation of IP3 production in cortical rat slices that could be blocked 
with inhibitors to CaN or mimicked with PKC inhibitors (Alagarsamy et al., 1999). A physical 
interaction and dephosphorylation of PKC sites have been demonstrated with purified CaN and 
the mGlu5-CTD (Alagarsamy et al., 2005). While CaN potentiated IP3 production of the WT 
receptor, the use of an mGlu5 construct in which a PKC phosphorylation site was mutated 
(Ser890Gly) lacked desensitization and the potentiating effect of NMDA (Alagarsamy et al., 
2005). Related to these effects, it was also shown that both mGlu1 and mGlu5 interact with the 
CaN inhibitor protein (CAIN) in heterologous cells and mouse brain lysates in the IL-2 to disrupt 
mGlu receptor/Gαq/11 interactions (Ferreira et al., 2009). This leads to the attenuation of mGlu 
receptor-stimulated IP3 production and agonist-stimulated endocytosis (Ferreira et al., 2009). This 
compilation of work suggests that Group I mGlu receptors may be found in a complex with PKC, 
CaN, CaM, and CAIN. The association of these Ca2+ dependent protein complexes is likely very 
important for spatial and temporal regulation of Group I mGlu receptor signaling in response to 
intracellular Ca2+ release.  
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CaMKII  
Interactions of CaMKII with CaMKII associated proteins (CaMKAPs) and roles of CaMKII in 
modulating ionotropic glutamate receptors and voltage gated ion channels have been studied 
intensively, but the role of CaMKII in GPCR regulation is less well understood.  
 CaMKII has been shown to phosphorylate the CTD of mGlu1 at a threonine site (Thr871) and 
CaMKII activity in the striatum contributes to agonist-induced mGlu1 desensitization  (Jin et al., 
2013a). We have evidence that CaMKII can also phosphorylate the CTD of mGlu5 (Chapter V). 
Because CaMKII is activated by the presence of Ca2+, CaMKII works to decode synaptic activity 
conveyed through local Ca2+ release. CaMKII has a consensus sequence for phosphorylation sites 
(RXX(S/T), and many examples of this can be found in the CTDs of mGlu1 and mGlu5. Although 
no phosphorylation site has been reported for mGlu5, groups have reported that CaMKII can bind 
to the CTD and IL-2 of both mGlu1 and mGlu5 (Jin et al., 2013b; Raka et al., 2015).  
Before binding and phosphorylation sites of CaMKII were defined, pharmacological studies 
provided evidence that mGlu5 and CaMKII are linked functionally in heterologous cells and in 
neurons. Internalization of mGlu1a was shown to be dependent on CaMKII and PKC in 
heterologous cells by increasing the association between mGlu1 and GRK2 (Mundell et al., 2004). 
mGlu5 agonist-induced internalization and ERK1/2 activation are also modulated by CaMKII in 
heterologous cells (Raka et al., 2015).  
In the initial characterization of the CaMKII binding site on mGlu5, it was determined that, like 
PKC, CaMKII competes with CaM binding to the CTD of the receptor (Jin et al., 2013b). This 
will be a very interesting topic of study in the future because precise control of mGlu5 signaling is 
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likely conveyed through these three Ca2+ sensitive proteins competing for a small region of the 
mGlu5-CTD. Cultured striatal neurons were used to show that mGlu5 activation leads to increased 
CaMKII binding and phosphorylation of a CaMKII sensitive site on NMDAR GluN2B subunits 
(Jin et al., 2013b). As discussed above, mGlu5 potentiation of NMDAR activity has been well 
studied. mGlu5 activation was also shown to enhance GluN1 and GluN2B subunit expression on 
the surface of neurons in a CaMKII-dependent process (Jin et al., 2015). The phosphorylation and 
binding of mGlu5 and CaMKII have larger implications in synaptic plasticity that I will continue 
to discuss in the next section.  
Support for the mGlu5-CaMKII interaction in synaptic signaling 
The focus of this dissertation will be the tie between CaMKII and mGlu5 signaling; therefore, I 
will now discuss linkages in CaMKII and mGlu5 in synaptic plasticity. The role of CaMKII and 
mGlu5 interaction in modulating synaptic activity has been shown in many different brain regions. 
For instance, acute inhibition of CaMKII with KN62 inhibited the induction of hippocampal 
DHPG-induced LTD through Group I mGlu receptors. In support of this role, CaMKII Thr286 
autophosphorylation was increased after DHPG application and necessary for mGlu receptor- 
mediated protein synthesis required for LTD (Mockett et al., 2011). This finding was specific to 
CaMKII because this reduction in LTD and protein synthesis was not seen by blocking PKC or 
PLC (Mockett et al., 2011). This role of CaMKII in mGlu1/5-LTD was later confirmed using a 
more specific inhibitor of CaMKII (Bernard et al., 2014).  
CaMKIIα is essential for LTD at cerebellar parallel fiber–Purkinje cell synapses (Hansel et al., 
2006). This is interesting because the CaMKIIα-KO mice do not have deficits in LTP at Purkinje 
cell synapses, suggesting a specific role of CaMKII in mGlu receptor-dependent LTD in this brain 
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region. Furthermore, in mouse nucleus accumbens (NAc) slices, electrically-evoked Group I mGlu 
receptor LTD was enhanced by antagonism of NMDAR or CaMKII during but not after electrical 
stimulation and increased the interaction of mGlu5 with the scaffolding protein Homer1b/c. These 
results were not replicated by DHPG-induced LTD, suggesting that glutamate release can activate 
NMDAR and Group I mGlu receptors in NAc neurons and impair the interaction between mGlu5 
and Homer1b/c to attenuate LTD induction. mGlu and NMDARs are closely clustered in 
postsynaptic membranes and there is evidence that these receptors interact to control excitatory 
synaptic transmission. DHPG application to striatal neurons concentration-dependently increased 
surface expression of the NMDARs GluN1 and GluN2B, enhanced CaMKIIα activity, and 
elevated GluN2B phosphorylation by CaMKII at Ser1303. This effect was blocked by antagonism 
of mGlu5 or CaMKII (Jin et al., 2015).  
Our lab has demonstrated that CaMKII plays a role in endocannabinoid-mediated plasticity in the 
striatum where activation of Group I mGlu receptors produces endocannabinoids through 
activation of diacylglycerol lipase α (DGLα).  Deletion of DGLα results in anxiety phenotypes and 
depletion of the DGLα product 2-arachidonoylglycerol increases susceptibility to stress (Bluett et 
al., 2017; Shonesy et al., 2014a). CaMKIIα activity attenuates DGLα synthesis of 2-AG and causes 
a tonic reduction of endocannabinoid short-term depression (Shonesy et al., 2013). This is a finding 
counter-intuitive since it seems like DHPG induces both CaMKII activation and increased 
endocannabinoid production. I have data that show that the genetic deletion of mGlu5 results in 
large increases in Thr286 phosphorylated CaMKII in multiple brain regions including the 
hippocampus and the striatum (Chapter VII), which may lead to further insights into the 
bidirectional signaling between these two important regulators of synaptic transmission.  
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Other proteins involved in CaMKII or mGlu5 localization and signaling have also shed light on 
the interaction between these two proteins. For example, densin-180 is a scaffolding CaMKAP in 
the PSD that forms a high-affinity complex with α-actinin (Jiao et al., 2011). Densin knock-out 
mice displayed ASD and schizophrenia-like phenotypes and a selective loss of synaptic mGlu5 
(Carlisle et al., 2011). This loss of mGlu5 was accompanied by impairment of both Group I mGlu 
and NMDAR-dependent LTD. While CaMKII localization and expression seemed to be 
unchanged, basal levels of Thr286 autophosphorylation were reduced by 25% and activity-driven 
activation of Thr286 CaMKII was two-fold higher in densin-180 knock-out neurons (Carlisle et 
al., 2011).  
It was recently shown that calcium influx via L-type voltage gated calcium channels (VGCCs) is 
a necessary aspect of mGlu-LTD induction (Bernard et al., 2014). This is interesting because our 
lab recently published work showing CaMKII regulation in the control of the LTCC CaV1.3 to 
initiate long-range signaling to the nucleus to control cellular excitation-transcription coupling. 
(Wang et al., 2017). L-type calcium channels were hypothesized by Bernard et al. to mediate 
calcium accumulations that stimulate CaMKII to mediate mGluR-LTD induction (Bernard et al., 
2014). Their findings also suggest that persistent phosphorylation of CaMKII substrates may 
reduce the need for CaMKII and L-type VGCC activation at the time of mGluR-LTD induction in 
neurological disorders such as early life seizures and Fragile-X syndrome. This study shows the 
wide range of CaMKII effects on mGlu5 that are likely regulated by brain region specific protein 
complexes and local signaling molecules.  
From the studies above linking mGlu5 and CaMKII signaling, it seems that both proper expression, 
localization, and activation levels of both of these proteins have large effects on proper control of 
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synaptic strength. A greater understanding of the interaction between mGlu5 and CaMKII signaling 
is necessary to increase our understanding of these complex protein interactions and signaling 
pathways.  
Overview of work presented in this thesis 
As described above, there are a number of studies linking mGlu5 and CaMKII signaling in synaptic 
function in normal and disease physiology. This project is conceptually innovative because little 
is known about the direct effect of CaMKII binding and phosphorylation on mGlu5 function. 
Therefore, we hypothesized that CaMKII binding or phosphorylation of mGlu5 could regulate 
receptor function and signaling. Because mGlu5 activation results in intracellular Ca2+ release and 
CaMKII activation is dependent on rises in intracellular Ca2+, we also hypothesized that mGlu5 
activity could work as a feedback regulator of CaMKII activation and synaptic function (Figure 
1.9). To test this hypothesis, I generated two aims as follows:  
	56	
 
Figure 1.9. Schematic representation of the aims outlined in this dissertation. Aim 1 examines the role of 
CaMKII in modulating downstream mGlu5 signaling by first characterizing the CaMKII interaction and 
phosphorylation of the mGlu5-CTD then showing the effect of this interaction on mGlu5 surface expression, 
intracellular Ca2+ release, and activation of ERK1/2. Aim 2 examines the role of the mGlu5-CaMKII 
interaction and the feedback of mGlu5-activation in regulating CaMKII activation and synaptic function. 
 
Aim 1: To determine the role of CaMKII in modulating downstream mGlu5 signaling.  
I tested the hypothesis that CaMKII modulates signaling via an interaction with mGlu5 through 
binding or phosphorylation of the receptor. First, I further characterized the CaMKII interaction 
with the mGlu5a-CTD and showed that CaMKII binding to the mGlu5a-CTD in vitro is largely 
increased by CaMKIIα. I show that the interaction between mGlu5 and activated CaMKII can be 
disrupted by the presence of Ca2+/CaM and that this interaction requires three basic residues 
(Lys866-Arg867-Arg868) on the mGlu5-CTD. I show the CaMKII effect on mGlu5a surface 
mGluR5
IP3R%
PLC
IP3
CaMKII
Gq
P!
IP3R
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expression and Ca2+ signaling in heterologous cells, demonstrating that CaMKIIα can increase cell 
surface expression of mGlu5a and effect mGlu5a-dependent Ca2+ mobilization. All of these effects 
are prevented by the triple Ala substitution for Lys866-Arg867-Arg868 in the CTD.  
Moreover, I provide data showing that CaMKII can phosphorylate both mGlu5a and mGlu5b. 
Importantly, CaMKII binding to Lys866-Arg867-Arg868 in the CTD also disrupts CaMKII 
phosphorylation of mGlu5. Using mass spectroscopy, I was able to identify a number of possible 
phosphorylation sites on both mGlu5a and mGlu5b. Phosphorylation of both mGlu5 isoforms by 
CaMKII can be inhibited by the presence of Ca2+/CaM with different potencies.  
In addition to characterizing the binding and phosphorylation of mGlu5 by CaMKII, I also 
investigated the role of CaMKII in regulating neuronal Ca2+ signaling. In order to do this, we have 
examined the role of CaMKII in intracellular increases in Ca2+ through activation of different 
sources, including LTCCs and mGlu1/5. We developed techniques to examine the responses from 
specific Ca2+ inputs in the presence or absence of CaMKII using shRNA-knockdown in 
hippocampal neuronal cultures. We expanded this work to examine the role of Shank-3, an 
important PSD scaffolding protein, in responses to LTCC and mGlu5 activation uncovering the 
importance of the proper PSD composition for proper Ca2+-influx from multiple sources.    
Aim 2: To determine the role of mGlu5 in regulating CaMKII activation and synaptic 
function.  
To begin studying how mGlu5 activity could work as a feedback regulator of CaMKII activation 
and synaptic function, I examined the autophosphorylation of CaMKII in mGlu5 knock-out mice 
to show that the absence of mGlu5 causes aberrant CaMKII activation. Using slice pharmacology 
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experiments, we also showed that activation of Group I mGlu receptors could reduce CaMKII 
autophosphorylation in the hippocampus and striatum of mice. I used in vitro binding studies with 
GST-mGlu5a-CTD and purified CaMKII to show that the mGlu5-CTD enhances the apparent 
cooperativity for CaMKII activation by Ca2+/CaM in vitro, causing it to be activated in a more 
switch-like manner.  
I undertook these studies because understanding the interplay between mGlu5 and CaMKII will 
provide mechanistic insights into the modulation of synaptic transmission physiologically, and in 
neuropsychiatric diseases. The work done on these aims is separated into chapters characterizing 
the mGlu5-CaMKII interaction, study of the mGlu5-CaMKII interaction on mGlu5 signaling, 
CaMKII phosphorylation of the mGlu5-CTD, the role of CaMKII in neuronal Ca2+ signals, and 
finally preliminary work understanding the role of mGlu5 on CaMKII activation.  
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Chapter II 
 
Materials and methods 
 
Molecular Biology  
DNA constructs 
The GST-mGlu5a-CTD and the GST-mGlu5b-CTD expression constructs were created by PCR 
amplification of the region encoding residues 827-964 of mGlu5a using primers 
5’CTGGAAGTTCTGTTCCAGGGGCCCGGATCCAAACCGGAGAGAAAT 3’ (Forward) and 
5’ GCCGCAAGCTTGTCGACGGAGCTCGAATTCTTAGGTCCCAAAGCGCTT 3’ (Reverse) 
and inserting the product into BamHI/EcoR1 sites of pGEX6P using a sequence and ligation 
independent cloning (SLIC) cloning protocol (Li and Elledge, 2012).  
The pCGN plasmid to express WT mGlu5a with an N-terminal HA-tag was made by amplifying 
the entire rat mGlu5a coding sequence (forward primer: 
5’TGACGTGCCTGACTATGCCTCTAGAATGGTCCTTCTGTTGATCCT3’; reverse primer: 
5’ ACTCACCCTGAAGTTCTCAGGATCCTCACAACGATGAAGAACTCT3’) and inserting 
the fragment into XbaI and BamHI restriction sites of the empty pCGN plasmid  (a gift from Dr. 
Winship Herr, Université de Lausanne, Switzerland, Addgene plasmid ID 53308).  
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Table 2.1. Primers used in generating mGlu5 truncations and mutagenesis 
 
Mutagenesis of K866RR868 and SS870/871 to alanine mutation in mGlu5a and S887 to alanine in mGlu5b 
were generated by site-directed mutagenesis of the pGEX6P or pCGN constructs (see above) using 
a Quick Change protocol (Agilent). The mGlu5a-truncation constructs were created from the GST-
mGlu5a-CTD construct. The mutagenesis and truncation primers are listed in Table 2.1.   
 
 
Primer  5' Sequence 3'  
mGlu5 827-964 
Forward  CTGGAAGTTCTGTTCCAGGGGCCCGGATCCAAACCGGAGAGAAAT  
mGlu5 827-964 
Reverse GCCGCAAGCTTGTCGACGGAGCTCGAATTCTTAGGTCCCAAAGCGCTT 
T1 mGlu5 827-
873 Forward  GCCCCTGGGATCCCCGGAATTCAAACCGGAGAGAAATGTGCG 
T1 mGlu5.827-
873 Reverse  GTCAGTCACGATGCGGCCGCttaAGAGGAGCCCCTCCTCTTCC 
T2 mGlu5.853-
899 Forward  GCCCCTGGGATCCCCGGAATTCTCATCGTCCGCTGCCAGCAG 
T2 mGlu5.853-
899 Reverse  GTCAGTCACGATGCGGCCGCttaCCACAAATGTTGCCCCCGGG 
T3 mGlu5.879-
925 Forward  GCCCCTGGGATCCCCGGAATTCTCCAACGGAAAATCTGTGAC 
T3 mGlu5.879-
925 Reverse  GTCAGTCACGATGCGGCCGCttaTGTGCTCTTGGGAAAGGGTT 
T4 mGlu5.905-
964 Forward  GCCCCTGGGATCCCCGGAATTCCACATCAACAAGAAGGAGAA 
T4 mGlu5.905-
964 Reverse  GTCAGTCACGATGCGGCCGCttaGTCAGTCACGATGCGGCCGC 
K866RR868 to AAA 
Forward GGGTTTCCCCAGAGGAGCCGGCGGCGGCCCACAGGTTGACTAGGCTGCT 
K866RR868 to AAA 
Reverse  AGCAGCCTAGTCAACCTGTGGGCCGCCGCCGGCTCCTCTGGGGAAACCC 
SS870/1 to AA 
Forward  GGAAGAGGAGGGGCGCCGCCGGGGAAACCCTAAG 
SS870/1 to AA 
Reverse   CTTAGGGTTTCCCCGGCGGCGCCCCTCCTCTTCC 
S887 mGlu5b to A 
Forward  GTGAAACACTCTATTTCGGCCTTGTGCTGGGCCAGTC 
S887 mGlu5b to A 
Reverse  GACTGGCCCAGCACAAGGCCGAAATAGAGTGTTTCAC 
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We used pcDNA3.1 constructs to express untagged and mApple-tagged WT-CaMKIIα, a 
constitutively active T286D/T305A/T306A triple mutant of CaMKIIα (CA-CaMKIIα), and a 
catalytically dead kinase mutant K42R (KD-CaMKIIα) as previously described (Jalan-Sakrikar et 
al., 2012; Jiao et al., 2008; Stephenson et al., 2017). In the CA-CaMKIIα, the phospho-mimetic 
T286D mutation results in constitutive CaMKIIα activity and the phospho-null T305A/T306A 
mutations prevent CaMKIIα phosphorylation at these sites, which interferes with binding of 
Ca2+/CaM and α-actinin (Jalan-Sakrikar et al., 2012). 
CaMKII shRNA constructs for neuronal Ca2+ imaging were expressed with mApple using a pLL3.7 
plasmid (a gift from Luk Van Parijs lab, Massachusetts Institute of Technology, Cambridge, 
Massachusetts) as described in (Wang et al., 2017). The shRNA-targeted sequence in the mouse 
CaMKIIIα cDNA contains two mismatches from the corresponding rat sequence, rendering it resistant 
to the shRNA. Knockdown and shRNA-resistance were confirmed by western blot and 
immunostaining. All constructs were confirmed by DNA sequencing. 
Shank-3 shRNA was designed by Tyler Perfitt and targets exon 21 of mouse and rat Shank3b residues 
1881-11933. The sequence of this construct is as follows:  
Shank3 shRNA: 5’-GGAAGTCACCAGAGGACAAGA-3’ 
Shank3 shRNA control: 5’-GAAAAAGCCCGGAGGACAAGA-3’   
Recombinant protein purification 
Expression and purification of recombinant mouse CaMKIIα has been described before (McNeill 
and Colbran, 1995). To express GST-tagged proteins, pGEX6P-1 plasmids were transformed into 
BL21(DE3) bacteria cells. Cells were grown in LB media at 37°C to reach OD~0.6. Cells were 
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cooled to room temperature and IPTG (0.2 mM) was then added to induce protein expression for 
12-16 hours. Inducing protein expression at room temperature substantially reduced protein 
degradation seen when proteins were expressed at 37°C. Expressed proteins were purified using 
Pierce Glutathione Agarose beads (Cat. #16101) following manufacture’s instruction. Eluted 
proteins were then dialyzed in 10 mM HEPES pH 7.5, 25 µM PMSF, 62.5 µM Benzamidine, 62.5 
µM EDTA, 0.1% Triton X-100 overnight with one buffer change.  
CaMKIIα autophosphorylation  
Purified mouse CaMKIIα was autophosphorylated under two different conditions. Typically, 
CaMKIIα was incubated with 50 mM HEPES, pH 7.5, 10 mM Mg(CH3-COO)2, 0.5 mM CaCl2, 2 
µM CaM, 40 µM ATP on ice for 90 s before addition of EDTA and EGTA (20 mM final) to 
terminate phosphorylation by chelation of Mg2+ and Ca2+. Similar conditions were previously 
shown to result in the selectively autophosphorylation of Thr286 (McNeill and Colbran, 1995). 
Where indicated, identical autophosphorylation reactions were incubated for 10 minutes at 30°C 
to perform a more extensive phosphorylation at several additional sites (Baucum et al., 2015).  
GST pulldown and CaM binding competition 
Purified GST-mGlu5-CTD (1 µM) and CaMKIIα (62.5 nM; pre-autophosphorylated as indicated 
in figure legends) were incubated at 4°C in GST-pulldown buffer (50 mM Tris-HCl pH 7.5; 150 
mM NaCl; 1% (v/v) Triton X-100) with either 2 mM EGTA or 2.5 mM CaCl2 plus 10 µM 
calmodulin, as indicated. An aliquot (5%) of each incubation was saved as an input sample. After 
1 h, pre-washed glutathione agarose beads (Pierce Cat. #16101) (15 µl of a 50:50 slurry) were 
added and incubation was continued at 4°C for an additional 1 h. The beads were then separated 
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by centrifugation (2000 x g, 30 s), and washed three times with GST-pulldown buffer containing 
either 2 mM EGTA or 2.5 mM CaCl2, respectively. Beads were then incubated at 4°C with GST 
pulldown buffer containing 20 mM glutathione, adjusted to pH 8.0, for 10 min. After 
centrifugation, eluted proteins were transferred to a new tube, mixed with 4X SDS-PAGE buffer 
and heated for 10 minutes at 90°C prior to SDS-PAGE and Western Blot analysis.  
In Vitro Phosphorylation Assay 
CaMKII was pre-autophosphorylated by incubation with 50 mM HEPES, pH 7.5, 10 mM Mg(CH3-
COO)2, 0.5 mM CaCl2, 2 µM CaM, 40 µM ATP on ice for 90 s before addition of EDTA and 
EGTA (20 mM final) to terminate phosphorylation by chelation of Mg2+ and Ca2+. Phosphorylation 
of purified GST-tagged mGlu5a or mGlu5b CTDs (1 µg) were incubated with a final concentration 
of 10 nM in 50 mM HEPES, pH 7.5, 10 mM magnesium acetate, 0.5 mM CaCl2, 1 mg/mL bovine 
serum albumin, 1 mM DTT, and 0.4 mM [γ-32P] ATP (~500 cpm/pmol) with indicated 
concentrations of CaM at 30°C for 10 minutes before being stopped by 1x Laemmli buffer. 
Samples were then resolved on a SDS-PAGE gel which was dried to complete autoradiography. 
For cooperativity studies CaMKII was preincubated with GST-mGlu5a-CTD or GST for 30 
minutes on ice. Reactions were started by addition of indicated concentrations of CaM, along with 
2mM Ca2+, 0.4 mM [γ-32P] ATP, and 0.2 mM syntide-2. After 10 minutes at 30°C.  
To count 32P incorporation the same procedure was carried out in reactions involving GST-mGlu5 
and CaMKII, except that 15 µl aliquots of the reactions were stopped on P82 Whatman paper. The 
papers were then washed and phosphorylation stoichiometries were determined by quantifying 32P 
incorporation using a scintillation counter.  
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CaMKII phosphorylation for mass spectrometry was performed the same way as above except that 
nonradioactive ATP was used. Samples were resolved on a SDS-PAGE gel and stained with 
Colloidal Blue (Thermo Fisher Scientific, Cat. #LC6025) for three hours and washed with 
deionized water overnight. The band that corresponds to full-length proteins was then excised for 
mass spectrometry analysis at the proteomics core facility of Vanderbilt University. 
Immunoblotting and semi-quantitative analysis 
Since heating samples results in aggregation of full-length mGlu5 protein, all samples that were 
blotted for the full-length receptor were eluted in SDS sample buffer containing 150 mM DTT for 
10 minutes at room temperature before SDS-PAGE. SDS-polyacrylamide gels were transferred to 
nylon-backed nitrocellulose membranes in 10 mM CAPS buffer. After blocking in TTBS (50 mm 
Tris-HCl, pH 7.5, 0.1% (v/v) Tween 20, 150 mm NaCl) containing 5% nonfat milk, membranes 
were incubated for either 2 h at room temperature for purified protein studies or overnight at 4 °C 
in HEK293A and brain lysate samples with primary antibodies diluted in TTBS with 5% milk. 
Membranes were washed 5 times in TTBS and incubated for 1 h at room temperature with 
secondary antibodies conjugated to horseradish peroxidase (Promega or Santa Cruz 
Biotechnology), or infrared dyes (LiCor Biosciences, Lincoln, NE) diluted in TTBS with 5% milk. 
Antibody signals were visualized via enzyme-linked chemiluminescence using the Western 
Lightening Plus-ECL, enhanced chemiluminescent substrate (PerkinElmer) and visualized using 
Premium X-ray Film (Phenix Research Products). Images were quantified using ImageJ software. 
Secondary antibodies conjugated to infrared dyes (LI-COR Biosciences) were used for 
development with an Odyssey system (LI-COR Biosciences). 
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Antibodies 
The following antibodies were used for immunoblotting at the indicated dilutions: Total CaMKIIα 
(Thermo Catalog # MA1-048 1:5000) and p-Thr286 CaMKIIα (Santa Cruz Biotechnology Catalog 
# sc-12886-R, 1:3000), mGlu5–specific antibody (Millipore, Catalog # AB5675, 1:3000), rabbit 
anti-HA (Santa Cruz, Catalog #sc805, 5 µL for immunoprecipitation), goat-GST antibody (Abcam 
Catalog # ab181652, 1:10,000).  
Secondary antibodies: HRP-conjugated anti-rabbit (Promega catalog #W4011, 1:3000), HRP-
conjugated anti-mouse (Promega catalog #W4021, 1:3000), and HRP-conjugated anti-goat (Santa 
Cruz Biotechnology catalog #sc-2056, 1:3000), IR dye-conjugated donkey anti-rabbit 800CW (LI-
COR Biosciences catalog #926–32213, 1:10,000), and IR dye-conjugated donkey anti-mouse 
680LT (LI-COR Biosciences catalog #926–68022, 1:10,000). 
Heterologous Cell Experiments  
Cell culture, transfection and immunoprecipitation 
HEK293A cells (Invitrogen Catalog #R70507) were maintained in complete DMEM 
supplemented with 5% FBS, 2 mM L-glutamine, 20 mM HEPES, 0.1 mM Non-Essential Amino 
Acids, 1 mM sodium pyruvate, at 37 °C in a humidified incubator containing 5% CO2 and 95% 
O2. Vectors encoding mApple-CaMKIIα (WT or CA) and mGlu5a (3 µg DNA each) or empty 
vector controls (3 µg) were co-tranfected into one 10-cm dish of 60-70% confluent HEK293A 
cells using 3 µl of Fugene 6 (Promega Catalog # E2691) per µg of DNA. About 48 hours later, 
cells were lysed in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM 
DTT, 0.5% NP-40 (v/v), 0.5% deoxycholate (v/v), 0.2 mm PMSF, 1 mm benzamidine, 10 µg/ml 
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leupeptin, 10 µm pepstatin, and 1 µm microcystin. Cell lysates were cleared by centrifugation (10 
min at 12,000 x g), and a 30 µL sample of the input was saved for SDS-PAGE. The remaining 
supernatant was incubated at 4°C for 1 hour with rabbit anti-HA antibodies and 20 µl prewashed 
Dynabeads Protein A (Thermo-Fisher, Cat. #10001D, 50% v/v). Beads were isolated magnetically, 
washed three times using lysis buffer and eluted using 2X Laemmli sample buffer for 10 minutes 
at room temperature prior to SDS-PAGE and Western Blotting.  
ERK activation experiments 
For ERK activation experiments we used HEK293A cells stably expressing low amounts of the 
rat mGlu5a receptor (293A-5aLOW cells) as previously described (Gregory et al., 2012; Hammond 
et al., 2010; Noetzel et al., 2012). The cells were maintained at 37°C in complete DMEM 
supplemented with 10% fetal bovine serum, 2 mM l-glutamine, 20 mM HEPES pH 7.5, 0.1 mM 
nonessential amino acids, 1 mM sodium pyruvate, antibiotic/antimycotic solution (Invitrogen), 
and 500 µg/ml G418, in a humidified incubator containing 5% CO2/95% O2. For experiments, 10 
cm dishes were transfected with 3 µg of mApple control vector (mApp), 3 µg mApp-CaMKIIα 
(wild type, KD, or CA; see above). The following day, the media was replaced with DMEM 
containing 10% dialyzed FBS, 20 mM HEPES, 1 mM sodium pyruvate, and incubated overnight 
at 37°C in 5% CO2. Approximately 24 hours later, medium was manually removed and replaced 
with fresh DMEM containing 10% dialyzed FBS, 20 mM HEPES, 1 mM sodium pyruvate for 1 
hour. After incubation for 1 hour at 37°C in 5% CO2, cells were treated with direct addition of 
glutamate to the plate for a final concentration of 100 µM glutamate for 5 minutes. The reaction 
was stopped by putting the plate on ice and addition of 2X Lamelli Sample Buffer containing 150 
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mM DTT directly to the cells. The cells were scraped down, transferred to 1.5 mL tubes and 
sonicated before immunoblotting for ERK/pERK, mGlu5, and CaMKII.  
Biotinylation and cell surface expression 
Transfected HEK293A cells (see above) were placed on ice, the media was gently removed and 
the cells were immediately washed two times using ice cold PBS. Cells were then scraped into ice-
cold PBS, transferred to a 1.5 mL tube, centrifuged at 4°C (500 x g; 3 min), and gently resuspended 
in 1 mL of cold PBS containing 2 mg of EZ-Link Sulfo-NHS-SS-Biotin. After gently rocking for 
1 hour, excess reagent was quenched by addition of 50 mM Tris HCl pH 8.0, and cells were 
centrifuged and washed again in 1 mL of 50 mM Tris HCl. Cells were then suspended in 1 mL of 
ice-cold lysis buffer (25 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate containing 0.2 mm PMSF, 1 mm benzamidine, 10 µg/ml leupeptin, and 10 µm 
pepstatin), and incubated on ice for 30 min. Insoluble material was removed by centrifugation 
(16,000 x g; 10 min, 4°C) and a 30 µL aliquot of the supernatant was saved for an input sample 
for SDS-PAGE (Cho et al., 2014). The remaining supernatants were mixed for 1 hour at 4°C with 
magnetic NeutrAvidin beads (30 µL; 50% slurry). The beads were separated magnetically and 
washed three times with lysis buffer. Biotinylated proteins were dissociated from the beads in SDS 
sample buffer containing 150 mM DTT for 10 minutes at room temperature. The biotinylated and 
total protein samples were analyzed by Western blotting for mGlu5. 
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Ca2+ Imaging Experiments  
Ca2+ Imaging in 96-well Plates 
A FlexStation II liquid handler/plate reader (Molecular Devices) was used for intracellular Ca2+ 
measurements in HEK293A cells stably expressing low amounts of the rat mGlu5a receptor (293A-
5aLOW cells) as previously described (Gregory et al., 2012; Hammond et al., 2010; Noetzel et al., 
2012). The cells were maintained at 37°C in complete DMEM supplemented with 10% fetal bovine 
serum, 2 mM l-glutamine, 20 mM HEPES pH 7.5, 0.1 mM nonessential amino acids, 1 mM sodium 
pyruvate, antibiotic/antimycotic solution (Invitrogen), and 500 µg/ml G418, in a humidified 
incubator containing 5% CO2/95% O2. For experiments, 10 cm dishes were transfected with 3 µg 
of mApple control vector (mApp) or 3 µg mApp-CaMKIIα (wild type or CA; see above). The 
following day, cells were transferred to clear-bottomed, black-walled, poly(d-lysine)-coated 96-
well plates (BD BioCoat, Bedford, MA) (3 × 104 cells per well) in DMEM containing 10% 
dialyzed FBS, 20 mM HEPES, 1 mM sodium pyruvate, and incubated overnight at 37°C in 5% 
CO2. Approximately 24 hours later, medium was manually removed and replaced with Hanks' 
balanced salt solution containing 20 mM HEPES, 2.5 mM probenecid, and 2 µM Fluo-
4/acetoxymethyl ester dye, pH 7.4, and plates were incubated for 30 min (37°C, 5% CO2). This 
medium was manually removed and replaced with 40 µl of calcium assay buffer (Hanks' balanced 
salt solution, 20 mM HEPES, and 2.5 mM probenecid, pH 7.4). Glutamate additions were 
performed after a 30 s baseline to construct concentration-response curves (CRCs) and plates were 
monitored for a total of 120 sec using an excitation wavelength of 488 nm, an emission wavelength 
of 525 nm, and a cutoff wavelength of 515 nm. Data were collected with SoftMax Pro (Molecular 
Devices) then transformed and agonist concentration-response curves were fitted to a four-
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parameter logistic equation with GraphPad Prism. For area under the curve measurements, time 
parameters were set to measure the area under the curve between the timepoints of 10-60 seconds 
to capture the initial Ca2+ peak. Raw values were generated by SoftMax Pro and normalized to the 
max response of control cells.  
Single Cell Ca2+ Imaging  
HEK293A cells were transiently transfected to express full-length mGlu5a (WT or AAA: 0.3µg 
DNA) and either mApple or mApple-CA-CaMKIIα (3 µg DNA). The following day, transfected 
cells were plated in clear glass-bottomed, poly(D-lysine)-coated 29 mM dishes (Cellvis D29-10-
1.5-N) (5 × 104 cells) in DMEM containing 10% dialyzed FBS, 20 mM HEPES, 1 mM sodium 
pyruvate, and 1% Pennicillin/Streptomycin (Gibco) and incubated overnight at 37°C in 5% CO2. 
The day of the experiment, cells were incubated in media supplemented with 2 µM Fura-2 
acetoxymethyl ester (Molecular Probes) for 20 minutes at 37°C in 5% CO2, and then transferred 
to Ca2+ imaging solution (150 mM NaCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM glucose 
and 10 mM HEPES pH 7.5 (~313 mOsm)). After incubation for 20 minutes at 37°C in 5% CO2, 
fluorescence imaging was performed using a Nikon Eclipse TE2000-U microscope equipped with 
an epifluorescence illuminator (Sutter, Inc), a CCD camera (HQ2; Photometrics Inc), and Nikon 
Elements software. Cells were perfused at 37°C at a flow of 2 mL/min with Ca2+ imaging solution. 
First, the field of view was imaged using 568 nm excitation to detect cells expressing either 
mApple-CA-CaMKII or mApp-PCDNA3.1 control. Then, ratios of emitted fluorescence (at 510 
nm) from mApple positive cells were measured following excitation at 340 nm and 380 nm 
(F340/F380); ratios were measured every 3 seconds for a 1 min baseline period.  Thn the cells 
were treated with 100 µM glutamate (added to the Ca2+ imaging solution) for 10 min during which 
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the Fura-2 F340/F380 ratios were collected every 3 s. Relative changes in Ca2+ of the mApple 
expressing cells were analyzed using Nikon Elements software. The F340/F380 ratios of each cell 
were normalized to the first F340/F380 ratio acquired for that cell during the baseline period (F/F0 
= (340/380 value)/(baseline 340/380 value)) and then analyzed using Clampfit software 
(Molecular Devices, Sunnyvale, California). Peak Ca2+ responses for all cells were aligned (at 45 
seconds), a ROUT test was first used to identify outliers in the maximal DF/F0 values for all cells 
within each experimental group, and then DF/F0 values for each time point were averaged together 
for each dish of cells. The maximal Ca2+ response (Max Peak) was defined as the average of all 
the peak DF/F0 values on an experimental day. An average trace for each day of experiments was 
generated to calculate the half-life of each condition. To compare half-lives of the Ca2+ signals the 
decline of the average DF/F0 values in each dish were normalized to the average max peak in that 
dish, and then fitted to a non-linear one phase exponential decay fit constrained to y0 = 1 using 
Graphpad Prism software (version 6.0).  We determined DF/F0 and half lives in 5 independent 
experiments (transfections) on separate days (19-124 cells per condition per day) and tested for 
differences using a Student’s T-Test. All values are presented as the mean ± SEM.  
Neuronal Ca2+ imaging  
Dissociated rat hippocampal neurons from rat E18 were prepared as previously described (Wang 
et al., 2017) and cultured in coated 29-mm glass bottom dishes (Cellvis, catalog no. D29-10-1.5-
N) for CaMKII KD experiments, cells were transfected with a total of 2 µg of DNA/dish after 8 
DIV. All neurons were imaged on DIV 13–14. CaMKII shRNA constructs lacking the CaMKII 
promoter and GFP were co-expressed with mApple to label transfected cells. Cells were incubated 
at 37 °C for 20 min in culture medium (neural basal medium with 2% B27, 0.25% glutamax, and 
1% penicillin-streptomycin) supplemented with 2 µm Fura-2 acetoxymethyl ester (Fura-2AM) 
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(Thermo Fisher Scientific, catalog no. F1221), washed twice with 5K Tyrode's solution, and then 
incubated at 37 °C for 20 min in 5K Tyrode's solution with 1 µM TTX, 10 µM APV 50 µM NBQX, 
10 µM VU-50, and 10 µM MPEP as indicated in each figure. For nimodipine-treated groups, this 
medium was replaced with 5K Tyrode's solution containing 10 µm nimodipine (in addition to TTX, 
APV, and NBQX) ∼5 min before imaging. All except ~100 µl of the 5K Tyrode’s solution was 
removed immediately prior to imaging. At this point a 30 sec. baseline was recorded followed by 
addition of 1 mL of 40K Tyrode’s solution or 5K Tyrode’s solution containing 100 µM DHPG in 
addition to the inhibitors included in the preincubation.  
For experiments including Shank-3 KD and DHPG treatment, cells were transfected at ~14 DIV 
2.5 µl Lipofectamine 2000 for 2-3 hours with 2 µg soluble mApple or 2 µg Shank shRNA for 
imaging at DIV 21. Cells were incubated at 37 °C for 20 min in culture medium supplemented 
with 2 µm Fura-2AM (Thermo Fisher Scientific, catalog no. F1221), washed twice with 5K 
Tyrode's solution, and then incubated at 37 °C for 25 min in 5K Tyrode's solution with TTX, APV, 
VU-50 and NBQX. 
For 40K treatment conditions, cells were transfected at 8 DIV with 1.8 µg Shank3 shRNA, 0.2 µg 
mApple, or 1.8 µg shRNA and 0.2 µg of mApple tagged Shank3 resistant shRNA.  
For all experiments, Fura-2 fluorescence images were collected using a Nikon Eclipse TE2000-U 
microscope equipped with an epifluorescence illuminator (Sutter Instrument Co.) and an HQ2 
CCD camera (PhotoMetrics Inc.). Cell somas were selected as regions of interest using Nikon 
Elements software; transfected neurons were selected based on mApple fluorescence. The ratios 
of emitted fluorescence (505 nm) intensities at excitation wavelengths of 340 and 380 nm 
(F340/F380) were measured every 3 sec. Responses of individual cells at each time point were 
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quantified as the change in fluorescence ratio above baseline (ΔF = (340/380 value)/(baseline 
340/380 value)). The peak change in fluorescence ratio was used to compare responses between 
cells within each group (ΔF = (maximum 340/380 value)/(baseline 340/380 value)), and outlier 
cells were excluded based on a ROUT outliers test (Q = 1%).  
Mouse work  
Mice 
CaMKII-KO mice were generated in the Vanderbilt Transgenic Mouse Core as a by-product of 
published CRISPR/Cas9 mediated experiments directed at creating a knock-in E183V mutation of 
CaMKIIα (Stephenson et al., 2017). We selected a founder containing a deletion of 11-base pairs 
(TGCTGAGGAAG) from exon 8, leading to a frame shift and early translational termination. The 
knockout of CaMKIIα was confirmed by Western Blot. Primers used to genotype the CaMKIIα 
knockout mice are: (Forward) 5’GATACCTCTCCCCAGAAGGAC3’, (Reverse) 
5’TGCAGTGGTAAGGAGTGGTG3’ for wild-type and (Forward) 
5’GGACAGTACAACCCCAGCTT3’ and (Reverse) 5’CCCGTACGGGTCCTTCCTCA3’ for 
knockout generating a 206bp band for WT, 351bp band for KO, and 557bp band for all mice and 
the CaMKIIα-KO was confirmed by immunoblotting brain lysates.  
mGlu5 KO mice were a generous gift from Dr. Danny Winder and are from Jackson Laboratory 
stock number 003121. I developed and confirmed a new genotyping PCR for these mice that 
allowed for me to perform genotyping in a single reaction. The primers for this reaction are:  
mGlu5 Fwd: CAC ATG CCA GGT GAC ATT AT 
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mGlu5 Rev: CCA TGC TAG TTG CAG AGT AA 
Jax 2060: CAC GAG ACT AGT GAG ACG TG 
For future reference I will also include the PCR reaction details because this is a new mouse line 
to our lab in Table 2.2 and Table 2.3 below.    
 
Reagent Volume	(µL)	
Std Taq Buffer 2.5	
10mM dNTp 2	
mG5 F 3	
mG5 R  1	
Jax Primer  2	
Std Taq 0.3	
H2O 13.2	
DNA 1 
Table 2.2 mGlu5-KO genotyping PCR reaction 
 
Cycling        
Step # Temp °C Time Note 
1 95 3 min  - 
2 95 30  - 
3 61 30 sec   
4 68 45 sec 2-4 X 38 cycles 
   -  -   
5 68 5 min  - 
6 25 hold  - 
Table 2.3. mGlu5-KO genotyping PCR cycle details 
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All mice were on a mixed B6D2 (C57BL/6J (B6) x DBA/2J (D2)) background and were housed 
(2–5 per cage) on a 12 h light-dark cycle with food and water ad libitum. Wild-type and knockout 
experimental mice (littermates) were generated using a HETXHET breeding strategy. All animal 
procedures were approved by the Vanderbilt University Institutional Animal Care and Use 
Committee in accordance with the National Institutes of Health Guide for the care and use of 
laboratory animals. 
Mouse brain tissue preparation and immunoprecipitation 
Both male and female mice were anesthetized with isofluorane, decapitated, and forebrains were 
quickly dissected. Half of a forebrain (cut along the mid-line) was homogenized using at least 20 
strokes with a Dounce homogenizer in 1.5 mL of an isotonic buffer containing 150 mM KCl, 50 
mM Tris-HCl, 1 mm DTT, 1% (v/v) Triton X-100, 1% sodium deoxycholate, 0.2 mM PMSF, 1 
mM benzamidine, 10 µg/ml leupeptin, 10 µM pepstatin, and 1 µM microcystin. The homogenate 
was rotated end-over-end at 4°C for 30 min and then centrifuged at 10,000 × g for 30 min to 
remove insoluble material. A 30µL input sample was saved before CaMKIIα (MA1-048) antibody 
and 20µL magnetic Protein G beads (Invitrogen Catalog #10003D) was added to 1 mL of 
homogenate and rotated end over end for 3-4 hours. Beads were separated magnetically and 
washed three times with homogenization buffer. Immunoprecipitated complexes were eluted using 
2X Lamelli Sample Buffer containing 150 mM DTT for 10 minutes at room temperature. CaMKII 
and mGlu5 immunoprecipitation was analyzed by immunoblot analysis. 
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Acute slice preparation and slice pharmacology 
Mice were anesthetized using isofluorane and then decapitated. Brains were removed, cut into left 
and right hemispheres, and then 300 µm coronal slices were made at 1-4°C in oxygenated (95% 
v/v O2, 5% v/v CO2) dissecting solution (208 mM sucrose, 2.5 mM KCl, 1 mM CaCl2, 4 mM 
MgCl2, 4 mM MgSO4, 1.6 mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose, and 3 mM Na-
pyruvate) using a Vibratome 3000 (The Vibratome Company). Slices including the hippocampus 
and the striatum were collected for analysis. Slices were allowed to recover on a nylon mesh for 1 
h at 30°C in oxygenated ACSF (113 mM NaCl, 2.5-5 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 
1 mM NaH2PO4, 26 mM NaHCO3, 20 mM glucose, and 3 mM Na-pyruvate) followed by addition 
of picrotoxin (50 µM) for 30 min. Slices were then transferred to oxygenated 30°C ACSF solutions 
supplemented with vehicle or 100 µM DHPG for 10 min. Punches (2 mm diameter) of 
hippocampus or dorsal striatum, were collected from slices on ice after incubation. Total lysates 
were prepared by immediately homogenizing striatal tissue punches in lysis buffer (2% SDS, 2 
mM EGTA, 0.2 mM PMSF, 1 mM benzamidine, 10 µg/ml leupeptin, 10 µM pepstatin, and 1 µM 
microcystin). Protein concentrations in total striatal lysates were determined by BCA assay 
(Thermo Scientific), using a bovine serum albumin standard. 
Fractionation  
Mice were decapitated and the hippocampus and striatum of mice ~P30-P60 were microdissected 
Tissue was homogenized in isotonic buffer (IB) without detergents (150 mM KCl, 50 mM Tris-
HCl pH 7.5, 1 mM DTT, 0.2 mM PMSF, 1 mM Benzamidine, 1 µM Pepstatin, 10 mg/l Leupeptin, 
1 µM microcystin). Protein concentrations were measured by BCA assay and all samples were 
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100,000 × g for 1 h. The supernatant (S1 fraction, “cytosolic”) was saved, and the pellet was 
resuspended in IB containing 1% (v/v) Triton X-100 and then incubated at 4°C with rocking for 
30 min. This lysate was then centrifuged at 18,403 × g, and the resulting supernatant (S2 fraction, 
“Extrasynaptic membrane”) was saved. The pellet was resuspended in 1/3 of the original volume 
of isotonic buffer containing 1% Triton X-100 and 1% deoxycholate and sonicated (S3 fraction, 
“Synaptic”). 4X Lamelli Sample Buffer containing 150 mM DTT was added to the samples before 
SDS-PAGE and immunoblotting. Subcellular fractionation efficiency was confirmed by 
evaluating the distribution of a cysolic S1 protein GAPDH, S2 protein IP3R, and a synaptic S3 
proteins PSD-95.  
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Chapter III 
 
The CaMKII interaction with mGlu5 
 
Introduction 
The mGlu5-CTD is a highly regulated portion of the receptor that is modulated by phosphorylation 
and protein binding. CaMKII activation is necessary for interaction with many proteins and less is 
known about proteins that interact with inactive kinase. After an interaction was shown between 
CaMKII and mGlu1, the interaction between mGlu5 and CaMKII was also described (Jin et al., 
2013a; Jin et al., 2013b). It was reported that CaMKII activation increased the interaction between 
CaMKII and mGlu1 (Jin et al., 2013a). The interaction between mGlu5 and CaMKII was reported 
to be reduced by kinase autophosphorylation (Jin et al., 2013b).  
After an initial confirmation that mGlu5 and CaMKII bind in mouse forebrains using co-
immunoprecipitation studies, I began to more closely investigate the interaction between CaMKII 
and mGlu5 using purified GST-tagged protein constructs. In an attempt to replicate the previously 
reported results, I found that inactive CaMKII bound weakly to mGlu5. Therefore, I more carefully 
characterized the interaction using different autophosphorylation protocols for CaMKII and was 
able to show that active CaMKII can bind more strongly to the mGlu5-CTD depending on the 
autophosphorylation conditions. This was true for binding with purified protein constructs and in 
heterologous cells.  I was also able to identify a tri-basic residue that disrupted CaMKII binding to 
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both purified CTD constructs of mGlu5 and full-length receptor. This work allowed for the study 
of the consequences of CaMKII binding to mGlu5 on receptor signaling discussed in the following 
chapter. The work in this chapter, with the exclusion of Figure 3.1, was published in Molecular 
Pharmacology (Marks et al., 2018).  
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Figure 3.1 Overview of work performed in Chapter 3. A. Initial confirmation that mGlu5 and 
CaMKII bind in mouse forebrains using co-immunoprecipitation studies. B. Creation of a GST-
fusion protein of the membrane-proximal region of the mGlu5-CTD (residues 827-964) allowed 
for in vitro binding assays to show that activation of CaMKII increases CaMKII binding to the 
mGlu5-CTD in vitro and in full-length mGlu5 constructs. Additional characterization revealed a 
tri-basic residue cluster at residues Lys866-Arg867-Arg868 necessary for CaMKII binding to this 
portion of the receptor. Triple alanine mutation of these residues or addition of CaM to the binding 
reaction resulted in a loss of CaMKII binding in vitro and a reduction in CaMKII binding to full-
length mGlu5.  
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Mouse forebrain lysates contain CaMKIIα-mGlu5 complexes  
In order to confirm that mGlu5 specifically associates with CaMKII in the brain, we incubated 
forebrain lysates from WT or CaMKIIα-KO mice with a CaMKIIα-specific monoclonal antibody 
or a control IgG. The resulting immune complexes were isolated and then immunoblotted for 
mGlu5 and CaMKIIα. Note that the mGlu5 antibody used for these studies recognizes an epitope 
that is shared by the two known mGlu5 splice variants, mGlu5a and mGlu5b, which are differentially 
expressed during development (Minakami et al., 1995; Romano et al., 1996). Input samples from 
WT and CaMKIIα-KO tissue prepared in parallel contain similar levels of the monomeric and 
dimeric forms of mGlu5 (Figure 3.2), although the ratio of monomeric and dimeric species varied 
between independent experiments (not shown). CaMKIIα complexes isolated from WT mouse 
forebrain contained both monomeric and dimeric forms of mGlu5, with the ratio of these forms 
reflecting variability in the ratio detected in the inputs. However, very little mGlu5 could be 
detected in IgG control complexes isolated from WT tissue, or in CaMKIIα complexes isolated 
from CaMKIIα-KO tissue (Figure 3.2). Thus, mGlu5 is a component of the CaMKIIα complexes 
present in mouse brain lysates.  
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Figure 3.2. Co-immunoprecipitation of mGlu5 with mouse forebrain CaMKIIα. Solubilized 
fractions from WT or CaMKIIα-KO mouse forebrain were immunoprecipitated using CaMKIIα-
specific (α) or control (IgG) antibodies, as indicated. Inputs and immune complexes were analyzed 
by immunoblotting: mGlu5 was detected only in immune complexes isolated from WT tissue using 
the CaMKIIα antibody. Open and closed arrowheads indicate dimeric and monomeric species of 
mGlu5. Representative of 3 similar experiments. 
 
CaMKIIα directly binds to the mGlu5 C-terminal domain  
Like most prior studies, we chose to use the mGlu5a splice variant for our binding studies. It was 
previously reported that residues 827-964 of the mGlu5a-CTD bind to inactive CaMKIIα, but that 
CaMKII autophosphorylation disrupted the interaction (Jin et al., 2013b). In order to confirm this 
finding, we generated a GST-tagged mGlu5a-CTD construct containing residues 827-964 (GST-
mGlu5a-CTD) for use in glutathione agarose co-sedimentation experiments (Figure 3.3). Initial 
studies detected weak binding of inactive CaMKIIα to GST-mGlu5a-CTD that was not consistently 
Figure 1
  WT WT KO 
Input 
CaMKIIα 
mGlu5 
IP        mGlu5 
–150
–116
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–116
– 66
– 45
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above background binding to a GST negative control (data not shown). Therefore, we 
systematically tested interactions of GST-mGlu5a-CTD with CaMKIIα in various activation states.  
Purified CaMKIIα was autophosphorylated in the presence of Ca2+/CaM in vitro at either 4°C or 
at 30°C. Similar total levels of Thr286 autophosphorylation were detected by immunoblotting 
following incubation at either 4°C or at 30°C (Figure 3.3A), but the 30°C autophosphorylation 
reduced the electrophoretic mobility of CaMKIIα. These observations are consistent with prior 
studies showing that incubation at 4°C results in selective Thr286 autophosphorylation (McNeill 
and Colbran, 1995), whereas incubation at 30°C allows for extensive autophosphorylation at 
several other sites (Baucum et al., 2015).  
We then performed glutathione-agarose cosedimentation experiments to test the interaction of 
GST-mGlu5-CTD with CaMKIIα in these different activation states (after terminating the 
autophosphorylation reactions by chelating metal ions with excess EGTA and EDTA). The 
selective Thr286-autophosphorylation (4°C) protocol resulted in a robust enhancement of 
CaMKIIα binding to GST-mGlu5-CTD relative to the non-phosphorylated kinase, but this 
interaction was substantially reduced following more extensive in vitro phosphorylation at 30°C 
(Figure 3.3B). The short exposure times used for development of these immunoblots failed to 
detect weak binding of inactive CaMKIIα to GST-mGlu5-CTD. In combination, these data show 
that while activation and Thr286 autophosphorylation of CaMKIIα strongly enhances binding to 
the mGlu5a-CTD, the interaction can be weakened by autophosphorylation at additional non-
Thr286 sites. Although we largely focused on the interaction between mGlu5a and CaMKIIα, I also 
generated data showing that the mGlu5b-CTD (residues 827-996), and full-length receptor are 
capable of binding to CaMKIIα in vitro and in HEK293 cells, respectively.  
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Figure 3.3. CaMKII autophosphorylation at Thr286 enhances binding to the mGlu5 C-terminal 
domain. A. Autophosphorylation of purified CaMKIIα. Purified CaMKIIα was incubated with 
Mg(C2H3O2)2, CaCl2, CaM, and ATP for either 90 s at 4°C or 10 min at 30°C and samples were 
immunoblotted for total or phospho-Thr286 CaMKII. While quantitative analysis (right) indicated 
that there was a similarly robust Thr286 autophosphorylation using these two conditions, the 10 
min/30°C incubation resulted in a substantial reduction in electrophoretic mobility due to 
phosphorylation at additional unidentified sites. Data are plotted as the mean ± SEM (n = 3) and 
analyzed using a one-way ANOVA (p = 0.0167, F = 8.746, R square = 0.7446) with Sidak’s post-
hoc test for multiplicity adjusted p values: Control vs. 4°C, p = 0.031. Control vs. 30°C, p = 0.035. 
4°C vs. 30°C, p = 1.00 B. The GST-mGlu5a-CTD binds CaMKIIα following selective 
autophosphorylation at Thr286.  GST-mGlu5a-CTD was incubated with purified CaMKIIα that 
had been preincubated as in panel A, and complexes were isolated using glutathione agarose. 
Immunoblot analyses revealed that CaMKIIα binding to the CTD was strongly enhanced by 
selective Thr286 autophosphorylation at 4°C, but that the autophosphorylation of additional sites 
on CaMKII at 30°C substantially reduced binding. Data are plotted as the mean ± SEM (n = 3) 
and were analyzed using a one-way ANOVA (p = 0.005, F = 2.477, R square = 0.829) with Sidak’s 
post-hoc test for multiplicity adjusted p values: Control vs. 4°C, p = 0.009. 4°C vs. 30°C, p = 
0.011. Control vs. 30°C, p = 1.00. Data are plotted as the mean ± SEM 
 
Binding of activated CaMKIIα to the GST-mGlu5a-CTD is disrupted by Ca2+/CaM 
Ca2+/CaM binds to residues 889-917 within the CTD of mGlu5a with important functional 
consequences (Choi et al., 2011; Lee et al., 2008; Minakami et al., 1997). Moreover, it was 
previously reported that excess Ca2+/CaM disrupts the binding of inactive CaMKIIα to the mGlu5a-
CTD (Jin et al., 2013b). Therefore, we tested whether excess Ca2+/CaM also disrupts the binding 
of activated CaMKIIα to GST-mGlu5a-CTD. Thr286-autophosphorylated CaMKIIα (4°C protocol) 
robustly binds to GST-mGlu5a-CTD, as noted above, but this interaction was essentially eliminated 
by inclusion of excess Ca2+/CaM in the binding assay (Figure 3.4). Thus, binding of activated 
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CaMKIIα to the mGlu5a-CTD is also blocked by Ca2+/CaM, suggesting that multiple Ca2+ sensitive 
proteins are involved in the regulation of mGlu5 signaling. 
 
 
Figure 3.4 Binding of activated CaMKIIα to GST-mGlu5a-CTD is disrupted by Ca2+/CaM. Purified 
CaMKIIα was autophosphorylated for 90 s at 4°C and then incubated with GST-mGlu5a-CTD in 
the absence or presence of excess Ca2+/CaM. Complexes were isolated using glutathione-agarose 
and then immunoblotted as indicated. Data are plotted as the mean ± SEM; excess Ca2+/CaM 
significantly reduced CaMKIIα binding (p < 0.0001 relative to theoretical value of 1.00 by one-
sample t-test; n = 4). 
 
Identification of a CaMKIIα-binding determinant in the mGlu5-CTD  
As an initial approach to identify key CaMKIIα binding determinants in the mGlu5a-CTD, we 
compared residues 827-964 of mGlu5 with CaMKIIα-binding domains that have been previously 
identified in other proteins. Our lab recently showed that activated CaMKIIα binds to the N-
terminal domains of CaV1.2 and CaV1.3 L-type voltage gated Ca2+ channels, and that this 
interaction is disrupted by mutation of three basic residues (Arg83-Lys-Arg85) to alanine (Wang et 
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al., 2017). Similar tri-basic residue motifs are also present within CaMKIIα binding domains that 
have been previously identified in the intracellular loops of the D2 and D3 dopamine receptor (Liu 
et al., 2009; Zhang et al., 2014), and the mGlu1-CTD (Jin et al., 2013a). Notably, the CaMKIIα-
binding fragment of the mGlu5a-CTD also contains a tribasic residue motif (residues Lys866-Arg867-
Arg868) (Figure 3.5A). We found that substituting alanines for Lys866-Arg867-Arg868 in the mGlu5a-
CTD essentially abolished the binding of activated CaMKIIα to GST-mGlu5-CTD in vitro (Figure 
3.5b). These data identify a key determinant for CaMKII-binding to the CTD of mGlu5a.  
 
 
Figure 3.5 Identification of CaMKII-binding determinants in the mGlu5a-CTD. A. Alignment of 
part of the mGlu5a-CTD with amino acid sequences surrounding known CaMKII-binding domains. 
Tribasic residue motifs (highlighted) were identified within CaMKII-binding domains from other 
proteins, as well as within the CaMKII binding fragment in the CTD of mGlu5a. Mutation of 
R83K84R85 to AAA in the CaV1.3 N-terminal domain (NTD) disrupts the binding of CaMKII (Wang 
et al., 2017). The red and blue fonts indicate residues in each domain that are identical and 
homologous, respectively, with residues in the mGlu5a sequence. Underlined residues in the 
mGlu1-CTD and the D2 dopamine receptor (IL3: third intracellular loop) demark the sequences of 
synthetic peptides that were shown to compete for CaMKII binding (Jin et al., 2013a; Zhang et al., 
2014). B. Mutation of the tribasic residue motif in the mGlu5a-CTD disrupts CaMKII binding. 
Thr286 autophosphorylated CaMKIIα (90 s/4°C protocol) was incubated with GST-mGlu5a-CTD 
(WT or with a K866R867R868 to AAA mutation) and complexes were analyzed as in Fig. 1. The 
K866R867R868/AAA mutation essentially abolishes CaMKII binding Data are plotted as the mean ± 
SEM (p = 0.003 by a one sample t-test; n = 4). 
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CaMKIIα activation increases CaMKIIα-mGlu5a association in heterologous cells 
In order to better understand the interaction of CaMKIIα with full-length mGlu5a we conducted 
co-immunoprecipitation experiments from lysates of transfected HEK293A cells. We first tested 
the hypothesis that CaMKIIα activation would increase the association with full-length mGlu5a, as 
with in vitro binding of CaMKIIα to GST-mGlu5a-CTD. We expressed mApple-tagged WT 
CaMKIIα in the absence or presence of mGlu5a with an N-terminal HA-epitope tag in HEK293A 
cells. Prior to HA immunoprecipitation, the cell lysates were split into two aliquots and pre-
incubated with either excess EGTA and EDTA or with Ca2+/CaM, Mg2+, ATP, and phosphatase 
inhibitors to stimulate CaMKIIα autophosphorylation. CaMKII activation in the lysates resulted 
in a robust increase in autophosphorylation at Thr286, without the large shift in electrophoretic 
mobility that was observed following autophosphorylation of purified CaMKIIα at 30°C (Figure 
3.6). HA-immununoprecipitation from the two preincubated lysates yielded similar amounts of the 
monomeric and dimeric species of HA-mGlu5a, but CaMKIIα activation resulted in a statistically 
significant ~3-fold increase in the amount of co-immunoprecipitated CaMKIIα (Figure 3.6). These 
data show that full-length mGlu5a preferentially interacts with activated WT CaMKIIα.  
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Figure 3.6 CaMKII activation enhances interaction with full length mGlu5.  Solubilized fractions 
of HEK293A cells expressing HA-tagged mGlu5a and/or mApple-tagged WT CaMKIIα (as 
indicated above lanes) were pre-incubated with Ca2+/CaM, MgAc2, and ATP in the presence or 
absence of excess EDTA (–/+ activation, respectively) and then immunoprecipitated using 
antibodies to the HA epitope. Lysates and immune complexes were analyzed by immunoblotting, 
as indicated. CaMKIIα activation results in robust Thr-286 autophosphorylation, which increases 
CaMKIIα association with HA-mGlu5a Data are plotted as the mean ± SEM (p = 0.043; one-sample 
t-test; n = 4). Open and closed arrowheads indicate dimeric and monomeric species of mGlu5a. 
 
Association of activated CaMKIIα with full-length mGlu5a requires Lys866-Arg867-Arg868 
We next investigated whether the association of activated CaMKIIα with full-length mGlu5a 
involves the CTD. In order to avoid complications that might arise from preincubating cell lystates 
to activate WT-CaMKIIα, we used an mApple-tagged constitutively active T286D/T305A/T306A 
triple mutant of CaMKIIα (mApple-CA-CaMKIIα); the phospho-mimetic T286D mutation results 
in constitutive CaMKIIα activity and the phospho-null T305A/T306A mutations prevent CaMKIIα 
phosphorylation at these sites, which interferes with binding of Ca2+/CaM and α-actinin (Jalan-
Sakrikar et al., 2012). The mApple-CA-CaMKIIα was expressed alone, or co-expressed with either 
HA-mGlu5a or HA-mGlu5a-AAA (with Lys866-Arg867-Arg868 mutated to alanines). HA-
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immunoprecipitation from cell lysates confirmed a robust association of mApple-CA-CaMKIIα 
with WT mGlu5a that was partially (~50%) reduced by the triple alanine mutation in the CTD 
(Figure 3.7). These data demonstrate that the Lys866-Arg867-Arg868 residues in the mGlu5a-CTD 
play an important role in the association of activated CaMKIIα with the full-length mGlu5 receptor. 
 
Figure 3.7 CaMKII association with full-length mGlu5a is disrupted by mutation of the CTD 
tribasic residue motif. Solubilized fractions of HEK293A cells expressing HA-mGlu5 (WT or with 
the K866R867R868/AAA mutation) and mApple-tagged CA-CaMKIIα were immunoprecipitated 
using antibodies to the HA epitope. Lysates and the immune complexes were analyzed by 
immunoblotting, as indicated.  The K866R867R868/AAA mutation reduced the association of CA-
CaMKIIα with HA-mGlu5 Data are plotted as the mean ± SEM (p = 0.028; one sample t-test; n = 
4). 
 
Discussion 
In a previous report, the membrane proximal region of the mGlu5a-CTD was shown to bind inactive 
CaMKII (Jin et al., 2013b). Here we extend these findings by further characterizing the physical 
and functional relationship between these key regulators of synaptic transmission. We confirmed 
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that CaMKIIα and mGlu5 specifically interact in mouse brain. However, our data show that 
mGlu5a-CTD residues 827-964 bind more strongly to CaMKIIα in an active, Thr286-
autophosphorylated conformation, but that this interaction is disrupted by excess Ca2+/CaM or by 
robust CaMKII autophosphorylation at additional undefined sites.  
There is a growing appreciation that specific physiological actions of CaMKII are modulated in 
part through dynamically-regulated interactions with CaMKAPs. Several CaMKAPs 
preferentially interact with activated conformations of CaMKII; these CaMKAPs can be sub-
classified based on differences between the amino acid sequences of their CaMKII-binding 
domains. CaMKII-binding domains in the NMDAR GluN2B subunits and calcium channel β1 and 
β2 subunits resemble the CaMKII regulatory domain (Grueter et al., 2008; Jiao et al., 2008; Strack 
et al., 2000). In contrast, the amino acid sequence of a CaMKII-binding domain in densin has 
similarity with a naturally occurring CaMKII inhibitor protein (CaMKIIN) (Jiao 2011). Here, we 
show here that the binding domain for activated CaMKII in the mGlu5a-CTD does not resemble 
these CaMKAPs. Rather, this novel interaction requires three basic residues (Lys866-Arg867-
Arg868), similar to the recently identified interaction of activated CaMKII with the N-terminal 
domains of L-type voltage-gated Ca2+ channels (Wang et al., 2017). Interestingly, triple basic 
residue motifs can also be identified in CaMKII-binding domains of other GPCRs, including 
intracellular loops of the Gαi-coupled D2 and D3 dopamine receptors (Zhang et al., 2014; Liu et 
al., 2009), and the CTD of the mGlu1 receptor (Jin et al., 2013a; Jin et al., 2013b), which also 
couples to Gαq/11 (Figure 3). Thus, it will be interesting to investigate the role of these triple basic 
residue motifs in CaMKII binding to additional GPCRs.  
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One unusual aspect of CaMKII binding to the mGlu5a-CTD is that, while the in vitro interaction 
requires CaMKIIα activation and Thr286 autophosphorylation, additional autophosphorylation at 
non-Thr286 sites following incubation at 30°C reduces the binding. Our recent proteomics 
analyses of purified CaMKIIα autophosphorylated in vitro using a similar 30°C protocol detected 
17 autophosphorylation sites, in addition to Thr-286 (Baucum et al., 2015). Presumably the 
autophosphorylation at one or more of these non-Thr286 sites interferes with in vitro CaMKIIα 
binding to mGlu5a. While this is a potentially interesting finding, parallel proteomics analyses of 
CaMKII isolated from mouse brain failed to detect phosphorylation at many of these in vitro sites 
(Baucum et al., 2015). However, it is possible that this observation explains why Jin and colleagues 
found that autophosphorylated CaMKII did not bind to mGlu5a in vitro (Jin et al., 2013b) because 
their autophosphorylation reactions were incubated at 30°C. 
Our data show that CaMKIIα activation enhances the association with full-length mGlu5a, and that 
this interaction involves the Lys866-Arg867-Arg868 motif in the CTD. However, triple alanine 
substitution of CTD residues 866-868 reduced the interaction by only ~50%, suggesting that 
CaMKII may interact with additional regions in mGlu5a or bind to the receptor through an indirect 
interaction. Indeed, a CaMKII interaction with the second intracellular loop of mGlu5 has been 
previously reported (Raka et al., 2015). In order to determine the effect of CaMKII binding to the 
mGlu5-CTD we used the tools generated in this chapter to study the role of CaMKII on mGlu5 
signaling.  
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Chapter IV 
 
 
Consequences of CaMKII-mGlu5 binding on mGlu5 receptor localization and signaling 
 
 
 
Figure 4.1 Overview of work presented in Chapter IV. Schematic representation of mGlu5-
dependent downstream signaling that include activation of PLC and Ca2+ release from intracellular 
stores and activation of a Src/ERK-cascade. In this chapter I examine the effect of CaMKII on 
three readouts of mGlu5 function including (1) surface expression, (2) ERK1/2 activation, and (3) 
Ca2+ release from intracellular stores in a heterologous cell system.   
 
Introduction 
Work to characterize the CaMKII binding domain in the mGlu5-CTD made it possible to determine 
the effect of CaMKII binding on receptor localization and signaling in a heterologous cell system. 
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mGlu5 activation has many downstream effects that can be controlled in a number of different 
ways including surface expression, protein binding, and phosphorylation. Here, I examined the 
role of CaMKII in three readouts of mGlu5 activation including the CaMKII effect on surface 
expression, ERK1/2 activation, and Ca2+ release from intracellular stores (Figure 4.1). CaMKII 
had significant effects on all three of these readouts including an increase in basal mGlu5 surface 
expression disrupted by mutation of the CaMKII binding site on the mGlu5-CTD, an increase in 
ERK1/2 activation, and a reduction in the initial peak Ca2+ amplitude but prolonged mGlu5-
mediated Ca2+ signals. These results were published in the same manuscript as the results shown 
in Chapter III (Marks et al., 2018). All figures in this chapter with the exception of Figure 4.1 and 
Figure 4.3 were published in this manuscript 
CaMKIIα increases basal mGlu5a surface expression 
Since the CTD is known to modulate mGlu5 cell surface expression and consequently mGlu5 
signaling, we investigated the effect of CaMKIIα on the cell-surface expression of full-length 
mGlu5a. Intact HEK293A cells expressing mGlu5 with or without mApple-CA-CaMKIIα were 
incubated with Sulfo-NHS-SS-Biotin to biotinylate all surface-expressed proteins. Streptavidin-
conjugated magnetic beads were then used to isolate cell-surface proteins from cell lysates. 
Immunoblototting of total cell lysates and isolated cell-surface proteins revealed that the co-
expression of mApple-CA-CaMKIIα increased the proportion of mGlu5a expressed on the cell-
surface by 3.0±0.7-fold (SEM) under basal conditions (p = 0.036; one-sample t-test vs. 
hypothetical value of 1) (Figure 4.2). In order to determine whether CaMKIIα interaction with the 
mGlu5a-CTD is important for this effect we examined the cell surface expression of mGlu5a-AAA, 
in which Lys866-Arg867-Arg868 in the CTD were replaced with alanines. In the absence of co-
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expressed CaMKII, the surface expression of mGlu5a-AAA was not significantly different from 
those of WT mGlu5a (1.6±0.6-fold (SEM); n = 5; p = 0.35; one-sample t-test vs. hypothetical value 
of 1). Moreover, the co-expression of mApple-CA-CaMKIIα had no effect on cell-surface 
expression of mGlu5a-AAA. These data demonstrate that interaction with the mGlu5a-CTD is 
necessary for CaMKIIα-mediated increases in mGlu5a cell-surface expression.  
 
 
Figure 4.2 CaMKII enhances the cell-surface expression of mGlu5a via interaction with the CTD. 
Cell-surface biotinylation analyses of HEK293A cells expressing mGlu5a (WT or with 
K866R867R868/AAA mutation in the CTD) with either mApple or mApple-tagged CA-CaMKIIα. 
The co-expression of CA-CaMKIIα increased steady-state surface expression levels of WT mGlu5a 
(p = 0.036; one sample t-test; n = 6), but not of the K866R867R868/AAA mutant. Data are plotted as 
the mean ± SEM (p = 0.569; one sample t-test; n = 5). 
 
CA-CaMKIIα increases glutamate stimulated ERK activation 
To investigate the effect of CaMKIIα on mGlu5a signaling through the activation of the ERK-
cascade we measured glutamate-induced ERK activation (phosphorylation) in populations of 
293A-5aLOW cells that stably express mGlu5a and were transiently transfected to co-express 
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mApple or mApple-tagged CaMKIIα (WT, kinase dead (K42R), or CA (T286D/305/306AA). 
Cells were glutamate starved then treated with 100 µM glutamate for 5 minutes. The reaction was 
stopped and the cell lysates were probed for CaMKII, and total and phosphorylated levels of ERK 
to look for ERK activation. The glutamate response was unaffected by co-expression of m-Apple, 
mApple-WT-CaMKIIα, mApple-KD-CaMKIIα, but the co-expression of mApple-CA-CaMKIIα 
increased glutamate-stimulated ERK activation (Figure 4.3). I attempted to replicate these studies 
in transiently-transfected cells, which would allow us to determine the role of the CaMKII-CTD 
interaction. However, despite extensive efforts to optimize my procedure, my analyses were 
frustrated by considerable variability in basal levels of ERK activation and glutamate-induced 
ERK activation levels, likely reflecting variability in the transfection and expression of the WT 
and mutated receptor.   
 
 
 
 
 
	95	
	
Figure 4.3 CA-CaMKII enhances mGlu5 ERK1/2 activation. Stable cells expressing low amounts 
of mGlu5 (293A-5aLOW cells) were transfected with an empty vector (Mock), WT, kinase dead 
(KD-CaMKII with catalytic mutation K42R) or CA-CaMKII (T286D/AA) and treated with 100 
µM glutamate for 5 min. Cell lysates were immunoblotted for total and p-ERK1/2. Only the 
presence of CA-CaMKII had a statistically effect to enhance glutamate-stimulated ERK1/2 
activation by mGlu5 Two-way repeated measures ANOVA with Sidak’s multiple comparisons test 
n = 6 Source of variation ERK1/2 p = 0.7393, transfection p = 0.0002, ERK1: Mock vs WT p = 
0.95, mock vs. K42R p = 0.99, mock vs. T286D/AA p = 0.01, ERK2: Mock vs WT p = 0.9309, 
Mock vs K42R p = 0.7591, mock vs T286D/AA p = 0.03. 
 
CaMKIIα reduces mGlu5a-stimulated peak Ca2+ mobilization  
To investigate the effect of CaMKIIα on mGlu5a signaling, we measured glutamate-induced Ca2+ 
mobilization in populations of 293A-5aLOW cells that stably express mGlu5a and were transiently 
transfected to co-express mApple or mApple-tagged CaMKIIα (either WT or CA). A similar 
fraction of the total cells expressed detectable levels of mApple-tagged WT- or CA-CaMKIIα in 
each transfection (typically ~60%). After loading glutamate-starved cells with fluo-4-AM, a 
fluorescent Ca2+ indicator, we measured fluorescence responses of total cell populations to 
increasing glutamate concentrations (0.01-100 µM) (Figure 4.4A). An overlay of raw traces from 
cells expressing mApple, mApple-WT-CaMKIIα, or mApple-CA-CaMKIIα in a representative 
experiment is shown in Figure 4.4B. Peak Ca2+ responses (increased fluorescence) at each 
glutamate concentration were expressed as a ratio to the maximum response to a saturating 
concentration of glutamate (100 µM) in mApple-expressing control cells for each individual 
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experiment, and then data were averaged across 5 independent experiments. Glutamate increased 
the peak fluorescence in a concentration-dependent manner, with an apparent EC50 of 0.38±0.03 
µM in control cells, similar to previous analyses (Hammond et al., 2010; Schoepp et al., 1999). 
The glutamate response was unaffected by co-expression of mApple-WT-CaMKIIα, but the co-
expression of mApple-CA-CaMKIIα reduced peak Ca2+ responses at the highest concentrations of 
glutamate by approximately 20%, without affecting the apparent EC50 (Figure 4.4C). As an 
alternative measure of Ca2+ responses, we determined the area under the curve of the initial Ca2+ 
peak at the highest glutamate concentration. There was no difference in area under the curve 
between cells expressing mApple or mApple-CaMKIIα-WT, but the co-expression of mApple-
CA-CaMKIIα significantly reduced the area under the curve (Control, 109.2±2.7; WT, 101.3±7.4; 
CA, 82.6±4.1. One-way ANOVA, p = 0.011, F=6.280. Sidak’s post hoc test for multiplicity 
adjusted p values: WT vs. control, p = 0.51, CA vs. control, p = 0.0073) (data not shown). Since 
mApple-CA-CaMKIIα is expressed in only a fraction of the cell population in each well, the 
measured reductions in maximal Ca2+ responses presumably under-estimate the actual impact of 
expressing CA-CaMKIIα in each cell. However, these data cannot differentiate whether this effect 
reflects decreased Ca2+ mobilization within each cell or a decrease in the fraction of responsive 
cells. Nevertheless, the data indicate that the co-expression of CA-CaMKIIα but not WT-CaMKIIα 
can reduce mGlu5a-stimulated peak Ca2+ mobilization. 
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Figure 4.4 CaMKIIα regulates mGlu5a-stimulated Ca2+ mobilization in 293A-5aLOW cells. Time 
courses of intracellular Ca2+ responses to glutamate were measured by changes in Fluo-4 
fluorescence in stable 293A-5aLOW cells in 96 well plates. A. Time courses of Ca2+ responses. 
Example of calcium responses to increasing glutamate concentrations collected in a row of 8-wells. 
B. Overlay of individual Ca2+ responses to increasing concentrations of glutamate (labeled by 
colors in Panel A) from 293A-5aLOW cells transiently transfected to express mApple control, 
mApple-CaMKIIα-WT or mApple-CA-CaMKIIα from a representative experiment. C. 
Concentration response curves. Initial peak Ca2+ responses (ΔF/F0) at each concentration were 
normalized to the maximal glutamate-stimulated response in control (mApple-transfected) cells 
within each experiment. Normalized Ca2+ responses are plotted as the mean ± SEM (n = 5 
experiments) as a function of glutamate concentration. The expression of CaMKIIα-WT had no 
impact on the Ca2+ response curve but the expression of CA-CaMKIIα reduced peak Ca2+ 
responses (multiple comparisons two-way ANOVA: Sources of Variation: CaMKII p < 0.0001, 
Interaction p = 0.029. Tukey’s post hoc test for multiplicity adjusted p values: mApple vs. WT, p 
= 0.926, mApple vs. CA-CaMKIIα, p < 0.0001. WT vs. CA-CaMKIIα, p = 0.0002). The inset table 
shows the maximum response (Max), EC50 (µM), and Hill coefficient (± SEM) obtained by fitting 
the data in GraphPad Prism. 
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CaMKIIα prolongs mGlu5a-mediated Ca2+ signaling  
To address caveats associated with studies investigating the effects of mApple-CA-CaMKIIα on 
Ca2+ mobilization in 293A-5aLOW cells, we also examined Ca2+ mobilization in single HEK293A 
cells transfected to express full-length mGlu5a with either mApple alone (control) or mApple-CA-
CaMKIIα. After loading all cells with Fura-2-AM, a ratiometric Ca2+ indicator, single cells were 
selected for analysis based on the presence of mApple as a marker of transfection. Application of 
100 µM glutamate to cells co-expressing soluble mApple or mApple-CA-CaMKIIα with WT 
mGlu5a produced an initial peak of Fura-2 fluorescence followed by highly variable changes of 
fluorescence over the next 10 min (Figure 4.5A).  
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Figure 4.5. CaMKIIα binding to the CTD is required for modulation of mGlu5a-stimulated Ca2+ 
mobilization. HEK293A cells were transiently transfected to express mGlu5a (WT or 
K866RR868/AAA) with either mApple or mApple-CA-CaMKIIα for single-cell Fura-2 Ca2+ 
imaging (see Methods). A, D. Representative data from a single experiment. Averaged normalized 
changes in fluorescence from 58-114 cells (ΔF/F0: mean ± SEM) expressing mGlu5a-WT (A) or 
mGlu5-K866R867R868/AAA (D) in the presence (blue lines) or absence (red lines) of mApple-CA-
CaMKIIα. The inset graphs show line-fits for time courses of the decline of Ca2+ signals from the 
peak ΔF/F0 under each condition. B, C, E, F. Summary data. The bar graphs depict mean ± SEM 
values for peak Ca2+ signals (ΔF/F0) (B, E) and half-lives for the decline in Ca2+ signals (C, F) 
with super-imposed data points from each experiment (n = 5). Expression of constitutively-active 
mApple-CA-CaMKII decreases the peak Ca2+ signal but increases the half-life of the Ca2+ signal 
with mGlu5a-WT (B, p = 0.009. C, p = 0.001), but has no significant effect on the mGlu5a-
K866R867R868/AAA mutant that disrupts CaMKII binding to the CTD (E, p = 0.155. F, p = 0.415). 
Paired Student’s t-tests were used for statistical comparisons in each panel. 
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returned to baseline between oscillations (10-21%) or were super-imposed on a more sustained 
Ca2+ elevation (18-25%) (Figure 4.6A-B). 
However, the percentage of WT mGlu5a cells exhibiting Ca2+ oscillations was unaffected by the 
co-expression of mApple-CA-CaMKIIα (Figure 4.6C). Since it is unclear whether oscillating and 
non-oscillating cells have different physiological effects, we developed an approach to analyze the 
responses of all cells (both oscillating and non-oscillating) across 5 independent experiments, 
revealing that the initial peak fluorescence was significantly reduced (p = 0.009) in cells expressing 
mApple-CA-CaMKIIα vs. cells expressing mApple alone (Figure 4.5A), consistent with data from 
stably transfected cell populations (Figure 4.4).  Moreover, the Ca2+ signal was relatively 
prolonged in cells expressing mApple-CA-CaMKIIα vs. cells expressing mApple alone, as 
reflected by a statistically-significant increase in the half-life of the fluorescence signal (Figure 
4.5C).  We also analyzed responses in subsets of the cells within each population that exhibited at 
least three baseline Ca2+ oscillations (Figure 4.7).  
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Figure 4.6 Variability of glutamate-induced mGlu5 Ca2+ responses in transfected HEK293A cells. 
Data reported is from data summarized in Fig. 7. Responses of individual cells could be divided 
into two main categories: A. Non-oscillators: An initial peak of Ca2+ that is sustained or returns to 
baseline over time (blue), in some cases with second shoulder (red), with no clear oscillations. B. 
Oscillating cells:  The initial Ca2+ peak decays in an oscillatory pattern (up to ~25 oscillations in 
10 min) that may (blue) or may not (red) return to baseline between successive oscillations. C. 
Distribution of responding cells between non-oscillating or oscillating categories for each 
transfection condition. The ratio of non-oscillating to oscillating HEK293A cells was not affected 
by co-expression of mApple-CA-CaMKIIα with WT mGlu5a (p = 0.28 by Fisher’s exact test) or 
by mutation of Lys866-Arg867-Arg868 in the CTD to alanines in mGlu5a-AAA (p = 0.62).  
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There was no statistically significant difference in the total number of mGlu5a-mediated Ca2+ 
oscillations between transfection conditions (Figure 4.7B). However, co-expression of mApple-
CA-CaMKIIα reduced the relative rate of decay of peak Ca2+ signals in successive oscillations 
(Figure 4.7C). Co-expression of mApple-CA-CaMKIIα also increased the frequency of Ca2+ 
oscillations, as reflected by a reduction of the inter-event intervals (Figure 4.7D). In combination, 
these data indicate that CaMKIIα can reduce the amplitude of initial mGlu5a-dependent Ca2+ 
mobilization while extending the relative duration of Ca2+ signals and increasing the frequency of 
oscillations when they are present. 
To test the hypothesis that CaMKIIα binding to the mGlu5a-CTD is necessary for the modulation 
of Ca2+ mobilization, we examined the effect of co-expressing mApple-CA-CaMKIIα with 
mGlu5a-AAA, in which Lys866-Arg867-Arg868 in the CTD were replaced with Ala (Figure 7D). This 
CTD mutation had little effect on glutamate-stimulated Ca2+ mobilization in cells expressing 
mApple. Moreover, the co-expression of mApple-CA-CaMKIIα with mGlu5a-AAA had no 
statistically significant effect on either the initial peak (Figure 4.5E) or the duration (Figure 4.5F) 
of the glutamate-stimulated Ca2+ signal relative to control cells expressing mApple alone. 
Furthermore, the CTD mutation had no statistically significant effect on the responses of cells 
displaying baseline Ca2+ oscillations (Figure 4.6D), but abrogated the CaMKII-dependent 
modulation, as reflected by a lack of effect on the peak height decay of successive Ca2+ oscillations 
(Figure 4.7C) and the Ca2+ oscillation frequency (Figure 4.7D). These data indicate that binding 
to the mGlu5a-CTD is important for both the increase of initial peak Ca2+ signals and for the 
prolonged Ca2+ signaling induced by co-expression of CA-CaMKIIα. 
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Figure 4.7. Ca2+ responses in baseline-oscillating HEK293A cells. Expressing mGlu5-WT or 
mGlu5-AAA with either mApple or  mApple-CA-CaMKII A. Overlays of ten representative Ca2+ 
responses for each transfection condition from cells selected for ≥3 baseline oscillations. B. There 
were no statistically significant differences in the total number of oscillations recorded over 10 
min between transfection conditions (total numbers of baseline-oscillating cells: mGlu5-WT, 78; 
mGlu5-WT+CKII, 62; mGlu5-AAA, 38; mGlu5-AAA+CKII, 21. One-way ANOVA: p = 0.08). 
The error bars depict the range between the minimum (3) and maximum number of oscillations, 
boxes indicate the 25-75th percentile, lines within each box indicate the median, and the “+” sign 
within each box indicates the mean. C. Peak responses for the first 5 oscillations were normalized 
to the first Ca2+ peak and plotted as the mean ± SEM for each transfection condition. Co-expression 
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of mApple-CA-CaMKII significantly slows the rate of decay of successive peak Ca2+ responses in 
cells expressing mGlu5a-WT, but has no effect in cells expressing mGlu5a-AAA (2-way repeated 
measures ANOVA . CaMKII effect, p<0.0001, Sidak’s test for multiplicity adjusted p values: 
mGlu5a vs mGlu5a-WT+CaMKII p = 0.0003, mGlu5a vs. mGlu5a-AAA p>0.999, mGlu5a-AAA vs 
mGlu5a-AAA + CaMKII p>0.999). D. Cumulative probability curves for mean inter-event 
intervals in baseline-oscillating cells. Co-expression of mApple-CA-CaMKII significantly 
decreases inter-event intervals between Ca2+-oscillations in cells expressing mGlu5a-WT but not 
mGlu5a-AAA (Kruskal Wallis test p = 0.006, Dunn’s test for multiplicity adjusted p values: WT-
mGlu5a vs WT-mGlu5a + CaMKII p = 0.003, WT-mGlu5a vs mGlu5a-AAA p>0.999, mGlu5a-AAA 
vs mGlu5a-AAA + CKII p>0.999). 
 
Discussion 
The data in this chapter indicate that CaMKII binding to the CTD exerts complex effects on mGlu5a 
surface expression and downstream Ca2+ mobilization.  Our analyses in heterologous cells indicate 
that CaMKIIα interaction with the CTD is critical for several novel functional effects of CaMKII 
on mGlu5a signaling. First, we show here that CaMKIIα can increase cell surface expression of 
mGlu5a. Second, we found that CaMKIIα has complex effects on mGlu5a-dependent Ca2+ 
mobilization. As noted previously, mGlu5 activation can induce temporally-diverse intracellular 
Ca2+ responses in heterologous cells and in neurons (Flint et al., 1999; Jong and O'Malley, 2017; 
Kim et al., 2005; Mao and Wang, 2003; Uematsu et al., 2015). The co-expression of CaMKII had 
little effect on the proportion of cells exhibiting different oscillatory or non-oscillatory response 
patterns. However, we found that the co-expression of CA-CaMKIIα reduces the amplitude of the 
initial peak Ca2+ signals (Figure 4.4C, Figure 4.5B), but prolongs the duration of the Ca2+ signals 
(Figure 4.5C, Figure 4.7C) in both the total responding cell population or only in cells that exhibit 
baseline Ca2+ oscillations. The co-expression of CA-CaMKIIα also increases the frequency of 
baseline Ca2+ oscillations (Figure 4.7D). All of these effects are prevented by the triple alanine 
substitution for Lys866-Arg867-Arg868 in the CTD (Figure 4.5 D-F, Figure 4.7C,D). 
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Presumably, the effect of CaMKIIα to increase basal cell-surface expression contributes to the 
prolongation of Ca2+ signaling, but the mechanisms underlying the reduced initial peak Ca2+ signal, 
observed in both stable 293A-5aLOW cell populations and in single transiently-transfected cells, 
remains unclear. Taken together, our data show that binding of CaMKIIα can play an important 
role in modulating cellular responses to mGlu5a activation. Further examination into the 
contribution of these mechanisms in synaptic plasticity and neuronal Ca2+ signaling are warranted 
in future studies. 
Interestingly, cell surface expression of mGlu5a is also modulated by direct binding of Ca2+/CaM 
to the CTD and prolongs mGlu5-mediated Ca2+ signaling (Lee et al., 2008), similar to the effects 
of CaMKIIα binding to the CTD reported herein. The Ca2+/CaM binding domain involved in 
mediating these effects is located 30-40 residues C-terminal to the tribasic residue motif that is 
critical for CaMKII binding. Nevertheless, we found that Ca2+/CaM competes for binding of 
activated CaMKII to the mGlu5a-CTD in vitro (Figure 4.3C). Taken together, our data suggest an 
intriguing model in which the binding of CaM might confer a relatively transient Ca2+-dependent 
modulation of mGlu5a surface expression and signaling, but that increased CaMKIIα 
autophosphorylation at Thr286 would result in sustained binding to the CTD and longer-term 
modulation of mGlu5a surface expression and Ca2+ mobilization. Since Thr286 
autophosphorylation of CaMKII is sensitive to changes in the source, duration, or frequency of 
Ca2+ signals originating from multiple channels (Pasek et al., 2015), such as those occurring during 
synaptic plasticity, as well as to the regulated activities of protein phosphatases, this may provide 
a mechanism for cross-talk with other signaling pathways. 
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As noted above, CaMKII has also been shown to interact with a membrane proximal region in the 
CTDs of mGlu1 (Jin et al., 2013a), and the CaMKII-binding domain in mGlu1 contains a tri-basic 
residue motif, similar to the motif we have here identified as being critical for CaMKII binding to 
the mGlu5a-CTD.  However, CaMKII was shown to desensitize mGlu1 signaling whereas we found 
that CaMKII prolongs mGlu5 signaling. This apparently differential modulation of mGlu1 and 
mGlu5 by CaMKII may contribute to their distinct neuronal roles (Mannaioni et al., 2001; Valenti 
et al., 2002; Volk et al., 2006). Interestingly, the effects of CaMKII on mGlu1 signaling are 
mediated in part by phosphorylation at Thr871, which lies near the CaMKII-binding domain. 
Therefore, it will be interesting to investigate whether phosphorylation is required for the effects 
of CaMKII on mGlu5 signaling, as well as the physical interaction demonstrated here. 
The effects of CaMKIIα on mGlu5a must also interface with the known modulation of mGlu5 
signaling by other mechanisms. Prior studies have shown that several protein kinases modulate 
mGlu5 via the CTD. PKC phosphorylates Ser901 in the mGlu5a-CTD to inhibit Ca2+/CaM binding 
and antagonize the aforementioned modulation by Ca2+/CaM (Lee et al., 2008). In addition, PKA 
phosphorylates Ser870 in mGlu5a, prolonging Ca2+ mobilization, similar to the effects of CaMKII 
reported here, and enhancing ERK activation (Uematsu et al., 2015). However, it was previously 
reported that CaMKII reduces mGlu5-stimulated ERK1/2 activation and increases agonist-induced 
mGlu5 internalization (Raka et al., 2015). It is possible that the enhanced agonist-induced 
internalization in part results from the increased basal surface expression reported here (Figure 
4.6). Although the mechanistic relationships between these different modes of mGlu5 regulation 
remain to be more clearly established, the convergence of Ca2+/CaM, CaMKII, PKA and PKC 
actions within an ~60 amino acid region in the long CTD (345 amino acids) suggests that the 
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actions of mGlu5 are tightly controlled across different time frames, presumably fine-tuning 
neuronal responses such as different forms of synaptic plasticity. 
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CHAPTER V 
 
CaMKII phosphorylation of the mGlu5-CTD 
 
Introduction 
As reviewed in Chapter I, regulation of mGlu5 signaling by phosphorylation has been well studied 
and phosphorylation of the mGlu5-CTD has been defined by a number of kinases including PKA 
and PKC. These phosphorylation sites have broad physiological consequences for mGlu5 
signaling, including modulation of Ca2+ oscillations, surface expression, and ERK activation. It 
was previously reported that residues 827-964 of the mGlu5a-CTD bind to CaMKII, and, as 
reported in Chapter III, we identified a mutation that could disrupt this binding. To date, no reports 
have presented evidence on the ability of CaMKII to phosphorylate mGlu5. Therefore, we began 
to research if CaMKII was capable of phosphorylating the CTD of mGlu5 using biochemical and 
proteomic approaches. Here, I report evidence that CaMKII phosphorylates both mGlu5a and 
mGlu5b isoforms of mGlu5 in vitro. In addition to abolishing CaMKII binding to the CTD of mGlu5, 
the triple-alanine mutation at residues 866-868 also disrupts CaMKII phosphorylation of the 
mGlu5-CTD. Similar to binding, phosphorylation of mGlu5 by CaMKII can be blocked by the 
presence of Ca2+/CaM in both isoforms, although with different potencies. Using a proteomic 
approach, I identified putative sites of phosphorylation and began to confirm these sites in vitro.  
These studies are important because they establish that CaMKII is capable of phosphorylating 
mGlu5. Few studies have examined both mGlu5a and mGlu5b and there is little evidence supporting 
differences between these two receptor isoforms. We have identified a mGlu5b-specific 
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phosphorylation site and shown differences in the potency of CaM required to inhibit CaMKII 
phosphorylation. These findings may lead to a better understanding of mGlu5a and mGlu5b 
regulation across development.  
CaMKII phosphorylates purified mGlu5a and mGlu5b in vitro 
To determine if CaMKII is capable of phosphorylating the mGlu5-CTD, we used GST-fusion 
constructs of both mGlu5a and mGlu5b in the presence of pre-autophosphorylated CaMKII and 
radio-labeled [γ-32P] ATP. I was able to demonstrate that both isoforms of mGlu5 can be 
phosphorylated by CaMKII in vitro (Figure 5.1B). I also wanted to determine if the binding site 
identified in Chapter III was necessary for CaMKII to phosphorylate the mGlu5a-CTD. We found 
that substituting alanines for Lys866-Arg867-Arg868 in the mGlu5a-CTD essentially abolished the in 
vitro phosphorylation of GST-mGlu5-CTD by CaMKII (Figure 4.1C).   
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Figure 5.1 CaMKII phosphorylates the CTD of mGlu5a and mGlu5b A. Schematic representation 
of GST-fusion proteins of the mGlu5a and mGlu5b CTD. These constructs are identical except for 
a 32 amino acid insert that is specific to mGlu5b denoted in yellow. B. In vitro phosphorylation of 
the GST-fusion constructs of the mGlu5a-CTD and mGlu5b-CTD with pre-autophosphorylated 
CaMKII show that CaMKII can phosphorylate both mGlu5a and mGlu5b. Full length GST-fusion 
constructs are denoted with red and yellow arrows, respectively. C. A representative protein stain 
and autoradiograph from an in vitro CaMKII phosphorylation assay where triple alanine mutation 
of the tribasic residues Lys866-Arg867-Arg868 previously shown to disrupt CaMKII binding to the 
mGlu5-CTD also disrupts CaMKII phosphorylation of the mGlu5-CTD. Representative of three 
independent experiments.  
 
CaM inhibits CaMKII phosphorylation of mGlu5a and mGlu5b 
Because the presence of Ca2+/CaM is capable of breaking the binding interaction between mGlu5a 
and CaMKII, we also decided to test if this was true for CaMKII phosphorylation of the mGlu5-
CTD. Using the GST fusion constructs for mGlu5a and mGlu5b, we performed an in vitro 
phosphorylation assay with increasing concentrations of CaM (Figure 5.2). The presence of CaM 
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was capable of inhibiting phosphorylation of both mGlu5a and mGlu5b, but the CaM concentration 
dependence of this effect was different between mGlu5a and mGlu5b. Inhibition of phosphorylation 
on mGlu5a was much more sensitive to CaM than mGlu5b. This presents an interesting difference 
between mGlu5a and mGlu5b that was previously unknown. This may be due to the additional 32-
amino acid insert specific to mGlu5b. 
 
 
Figure 5.2 CaM inhibits CaMKII phosphorylation of the mGlu5a/b-CTD with different potencies. 
Phosphorylation of GST-mGlu5a-CTD and GST-mGlu5b-CTD in vitro by CaMKII alone, in the 
presence of Ca2+, or with increasing concentrations of CaM. The phosphorylation of both mGlu5-
CTD constructs were largely reduced by the presence of CaM. The left panel shows the protein 
stain and autoradiograph from a single experiment. The 32P incorporation was measured by 
autoradiograph signals normalized to the phosphorylation of the GST-fusion construct in the –
Ca2+/CaM condition. Normalized phosphorylation responses are plotted as the mean ± SEM in the 
right panel (n = 3 experiments). CaM had a significant effect on the phosphorylation of both 
mGlu5a and mGlu5b-CTDs, The CaM-dependent inhibition of mGlu5-CTD constructs were also 
significantly different. (multiple comparisons two-way ANOVA: Sources of Variation: CaM 
p<0.0001, GST-mGlu5a-CTD vs. GST-mGlu5b-CTD, p = 0.0226, Interaction p = 0.0973.) 
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Identifying the region of CaMKII phosphorylation on mGlu5a 
To determine which portion of the mGlu5a-CTD was being phosphorylated, I generated 
overlapping truncations of the GST-tagged mGlu5a-CTD constructs designated C1-C4 containing 
residues 827-873, 853-899, 879-925, and 905-964, respectively (Figure 5.3A). We saw that in vitro 
CaMKII phosphorylated C1, C2, and C3 constructs, suggesting CaMKII can phosphorylate 
multiple residues on the mGlu5-CTD, at least in vitro because there are regions within C1 and C3 
that do not overlap. C1 and C2 were the most strongly phosphorylated of the constructs. C4, the 
most C-terminal truncation did not contain detectable phosphorylation. From this study we 
deduced that phosphorylation occurs at residues between 827-905.   
 
 
Figure 5.3 CaMKII phosphorylation of mGlu5-CTD truncations. A. Schematic showing the four 
overlapping truncations of the GST-tagged mGlu5a-CTD constructs designated C1-C4 containing 
the residues denoted. B. A representative protein stain and autoradiograph from an in vitro CaMKII 
phosphorylation assay of GST, GST-mGlu5-827-964, and C1-C4 using preautophosphorylated 
CaMKII. CaMKII can phosphorylate C1, C2, and C3. Respresentative of three independent 
experiments.  
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Proteomic analysis of CaMKII phosphorylation sites on the mGlu5-CTD 
We submitted mGlu5a and mGlu5b fragments phosphorylated using nonradioactive ATP for 
proteomics analysis to identify detectable phosphorylation sites. Tryptic digestion was performed 
prior to mass spectral analysis. In Figure 5.5A the expected tryptic digestion of the mGlu5a-CTD 
is diagrammed. We identified several sites of phosphorylation by CaMKII denoted in red in Figure 
5.5A.  
 
 
Figure 5.4 Identification of putative phosphorylation sites by mass spectroscopy A. The sequence 
of the mGlu5a-CTD region of interest with tryptic digestion sites denoted with arrows. All residues 
that were detected as phosphorylated are highlighted in red in both panels B. Using a crude 
quantitative assessment made from the relative number of times a peptide is identified in its 
phosphorylated vs non-phosphorylated state we detected three peptides identified about 5% of the 
time as phosphorylated, but the peptide containing residues 868-880 was detected more than 60% 
in a phosphorylated state. For this reason, we targeted residues on this peptide for phospho-null 
mutations and in vitro phosphorylation assays.  
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In agreement with the in vitro radiolabeled phosphorylation assay, no phosphorylation was 
detected after amino acid 905. We identified four peptides that contained phosphorylation sites 
after incubation with CaMKII (Figure 5.5b). Using a crude quantitative assessment made from the 
relative number of times a peptide is identified in its phosphorylated vs non-phosphorylated state, 
we determined that three of these peptides were identified about 5% of the time as phosphorylated, 
but more than 60% of the peptide containing amino acids 868-880 was identified in a 
phosphorylated state. This suggests that the major CaMKII site of phosphorylation lies within this 
region of the mGlu5a-CTD.  
Verifying CaMKII phosphorylation sites on the mGlu5-CTD 
We examined the proteomics data and found the most commonly identified phosphorylation site 
on the 868-880 peptide was Ser871. We were able to confirm Ser871 phosphorylation in the mass 
spectral data by identifying characteristic fragmentation patterns of the phosphorylated peptide 
(Figure 5.6B).  In order to test whether this was a major site of CaMKII phosphorylation we 
generated a serine to alanine phosphoinhibitory mutation of Ser870 and Ser871. We decided to 
proceed initially with a double alanine mutation because CaMKII can phosphorylate a neighboring 
site in single point mutation experiments. We followed our mass spectral analysis with an in vitro 
phosphorylation of the mGlu5-CTD-Ser-870/871-Ala construct. We were able to demonstrate that 
mutation of these sites reduced CaMKII phosphorylation of the mGlu5-CTD by about 65% in three 
independent experiments (Figure 5.6 C,D). This suggests that Ser870/Ser871 (one or both 
residues) are site(s) of phosphorylation by CaMKII in vitro. As is visible in figure 5.6C, one caveat 
to this study is that the Ser-870/871-Ala construct was largely degraded in these experiments, and 
much more degraded than the WT samples. Because of this, this study needs to be repeated in 
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proteins that have been re-purified to produce more intact constructs with comparable degradation. 
However, because of the agreement of the proteomic and biochemical data, Ser871 is a great target 
for future studies of CaMKII regulation of mGlu5 by CaMKII.  
 
 
Figure 5.5 Verification of mass spectroscopy identified phosphorylation sites on the mGlu5-CTD 
A. Alignment of the mGlu5a and mGlu5b peptide sequences. spanning the phosphorylated residues 
detected in mass spectroscopy experiments. As noted in Figure 5.5 we detected the following sites 
in mGlu5a: S834 T837 T838 S839 T840 S860 S870 S871 S876 S877 S881 T883 The mGlu5b 
specific sequence is highlighted in blue. In mGlu5b we did not detect all of the same sites as we 
identified in mGlu5a including S834, T837, S870, S871, S877. We also identified a site within the 
mGlu5b specific sequence as a potential CaMKII phosphorylation site S887 denoted with a blue 
arrow. The tribasic residue sequence shown in Chapter III to disrupt CaMKII binding to mGlu5a 
and disrupt CaMKII phosphorylation of mGlu5 in Chapter IV is denoted in green. B. A spectrum 
from the LC-MS/MS showing the phosphorylation of Ser871 of the mGlu5a-CTD Purified GST-
R G  S  s  G  E  T  L  S  S  N G K 
 b11
 y2 y4 y6 y7
 b9 b7  b8
[M+2H -H  PO   ]
 y8 y10 y11
 b6 b5 b4 b3 b2
 y9
 b12 b10
 y3
 
200 300 400 500 600 700 800 900 1000
m/z
0
5
10
15
20
25
30
35
40
45
50
R
el
at
iv
e 
A
bu
nd
an
ce
631.5440
622.5201
671.5145
679.6019 892.4785850.4484 937.4758
 y5
 4 3
 2+
 y2
204.11 214.23
 b2
301.18
 b4-H3PO4  
  370.26  y4 
405.34
 b3  y5 
492.15
 y11-H3PO4  
  524.91
 y1
B. 
0 5 10 15 20
0
50
100
Time (min) 
Ph
os
ph
or
ly
at
io
n 
(N
or
m
al
ize
d) mGlu5a-CTD 
mGlu5a 870/1AA
–45
GST-mGlu5a-CTD 
WT SS870/1AA
–45
Protein
Stain  
Auto-
radiograph
E. C. 
mGlu5b 887A
Protein Stain 
Autoradiograph –45
–45
D. 
–45
GST-mGlu5a-CTD 
WT SS870/1AA
–45
Protein
Stain  
Auto-
radiograph
–45
GST-mGlu5a-CTD 
WT SS870/1AA
–45
Protein
Stain  
Auto-
radiograph
A. 
KPERNVRSAF TTSTVVRMHV GDGKSSSAAS RSSSLVNLWK RRGSSGETL*
********** ********** ********** *SSNGKSVTW
KPERNVRSAF TTSTVVRMHV GDGKSSSAAS RSSSLVNLWK RRGSSGETLR 
YKDRRLAQHK SEIECFTPKG SMGNGGRATM SSSNGKSVTW
827
827
884
906
mGlu5a
mGlu5b
887
875
876
876
877
mGlu5a
mGlu5b
870-871
	116	
tagged mGlu5a-CTD was incubated with 10 nM purified mouse CaMKII 30oC for 20 minutes with 
nonradioactive ATP. Samples were then resolved by SDS-PAGE and the gel was stained by 
colloidal blue. Bands corresponding to the full-length proteins were excised and submitted for 
mass spectrometry analysis. Data in panel B were annotated by Christian Marks and verified by 
Kristie Rose, Ph.D. C. Protein stain and autoradiograph showing simultaneous mutation of the 
identified phosphorylation sites Ser870/1 to alanine largely reduces CaMKII phosphorylation. A 
representative protein stain and autoradiograph is shown from three independent experiments. D. 
Time course data showing the normalized 32P incorporation into GST-mGlu5a-CTD or GST-
mGlu5a-CTD with a Ser870/1 to alanine mutation. The time course of 32P incorporation into 
mGlu5a vs. mGlu5a870/1AA were significantly different (Two-way ANOVA: Sources of Variation: 
mGlu5a vs mGlu5a 870/1AA p = 0.0008, Time p<0.0001, Interaction p<0.0001) E. Mutation of the 
mGlu5b specific phosphorylation site S887 to a phosphoinhibitory alanine reduced mGlu5b 
phosphorylation by an average of 40% in two independent experiments. 
 
During our proteomic analyses we also investigated the phosphorylation of the mGlu5b construct 
by CaMKII. Interestingly, not all of the phosphorylation sites identified in the analysis of mGlu5a 
were identified in mGlu5b (Figure 5.6A.). These include residue Ser871, the most commonly 
detected phosphorylation site on mGlu5a-CTD construct. In addition to this, we identified 
phosphorylation of a serine residue present in a CTD sequence unique to mGlu5b. This residue, 
Ser887, caught our attention because there are very few differences that have been shown between 
the mGlu5a/b isoforms. In order to test if Ser887 was a site of CaMKII phosphorylation in vitro we 
generated a mGlu5b-CTD-Ser887/Ala phosphoinhibitory mutation. When we tested this construct 
for phosphorylation we saw that in two experiments that mGlu5b-CTD-Ser887/Ala reduced mGlu5b 
phosphorylation by ~40% in two independent experiments (Figure 5.6E).  
While mass spectroscopy is a great tool for identifying phosphorylation sites, the absence of the 
detection of phosphorylation is not enough to remove the possibility that other sites not detected 
are being phosphorylated. Sites can be missed because of poor peptide detection or fragmentation 
during analysis.  
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Discussion 
Phosphorylation of Group I mGlu receptors has been studied for a number of different kinases 
including PKC and PKA. PKC phosphorylation at Ser839 has been reported as the site responsible 
for mGlu5 Ca2+ oscillations and also plays a role in receptor desensitization (Kawabata et al., 1996; 
Nakahara et al., 1997). The role of PKC phosphorylation of mGlu5 is an example of a 
phosphorylation site dynamically regulated by the presence of CaM on the mGlu5-CTD (Lee et 
al., 2008; Minakami et al., 1997). The binding site for CaM also overlaps with other regulators of 
mGlu5 surface expression including CaMKII and the E3 ligase Siah-1a (Jin et al., 2013b; Ko et al., 
2012). The importance of CaM on mGlu5 has been demonstrated including the finding that CaM 
activity is required for mGlu5-mediated ERK1/2 activation, Arc expression, and LTD in the 
hippocampus (Sethna et al., 2016). It seems that tight regulation of this portion of the mGlu5-CTD 
is important because of the multiple proteins that have been shown to bind in this region. It seems 
that CaM and other Ca2+ sensitive proteins like CaMKII can regulate the binding of other partners 
to mGlu5 to accurately control phosphorylation of the receptor.  
In this chapter, I demonstrate that CaMKII is capable of phosphorylating both mGlu5a and mGlu5b, 
at least in vitro. The finding that triple alanine mutation of Lys866-Arg867-Arg868 disrupts 
phosphorylation of CaMKII leaves unanswered questions about work done in the previous 
chapters of this thesis, and opens the door to determine the roles of both CaMKII binding and 
phosphorylation. It will be important to establish if the effects that we saw from disrupting CaMKII 
binding are a result of CaMKII phosphorylation of the mGlu5-CTD. Future studies should be able 
to create a phosphoinhibitory mGlu5 construct that is still capable of binding to CaMKII to tease 
apart the roles of CaMKII binding and phosphorylation on receptor function. 
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Our proteomics study identified a number of potential phosphorylation sites on the mGlu5-CTD 
and we identified Ser871 as a likely candidate for phosphorylation on mGlu5a. A recent study 
identified PKA phosphorylation of mGlu5 and identified at the neighboring residue Ser870 
(Uematsu et al., 2015). The phosphoinhibitory alanine mutation at Ser870 also significantly 
reduced the number of mGlu5-transfected HEK cells that responded with Ca2+ oscillations and 
reduced total number of Ca2+ oscillations per cell. This is distinct from what we see with CaMKII, 
but interesting considering that we suspect that the neighboring Ser871 may be a major site of 
CaMKII phosphorylation. There are some issues with the experiment showing the effect of the 
phosphoinhibitory mutation of Ser870-871 presented in this dissertation because of extensive 
GST-fusion protein degradation. This experiment needs to be repeated to determine if mGlu5 
degradation effects phosphorylation of the mGlu5 construct. If we are able to verify this finding, 
phosphorylation of this site poses the possibility of an exciting project to look at the linkage 
between mGlu5 phosphorylation by CaMKII and PKA. The literature suggests that while CaMKII 
seems to promote mGlu5 Ca2+ signaling, that PKA seems to have the opposite effect. 
Phosphorylation by these kinases at these neighboring sites may cause major differences in mGlu5 
activity during neuronal activation. 
We also identified a CaMKII phosphorylation site that is specific to mGlu5b. This is exciting 
because there is little known about the differences between two mGlu5 isoforms. The 
developmental regulation of mGlu5 isoform expression suggests that there are important to 
receptor function.  
The finding that CaM is capable of blocking both phosphorylation and binding of mGlu5 is also of 
interest because it confirms that CaM can compete for CaMKII binding to the mGlu5-CTD. If the 
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major site of phosphorylation on mGlu5a is Ser871 and CaMKII phosphorylation is blocked by the 
presence of CaM, it is likely that PKA phosphorylation at Ser870 can also be affected by the 
presence of CaM. This could suggest that a small section of the mGlu5-CTD presents a system 
within where CaM, CaMKII, PKA and PKC can all compete for binding, but the CaM effect on 
CaMKII phosphorylation is much less potent on mGlu5b. This leads me to hypothesize that mGlu5b 
is less sensitive to the competing effects of CaM and CaMKII. We were also unable to detect 
phosphorylation of Ser871 in our mass spectroscopy analysis of mGlu5b. The presence of the 32-
amino acid insert in the CTD lies close to the residues necessary for CaMKII binding and Ser871. 
This insert may change the way that CaMKII binds to the receptor or disrupt phosphorylation of 
Ser871. I would hypothesize that the mGlu5b-specific residues reduce the effect of CaM binding 
on mGlu5 regulation and allow for CaMKII-mediated modulation of the receptor even in the 
presence of CaM. This might make mGlu5b more accessible to modulation by CaMKII. 
Additionally, it is possible if CaM can block phosphorylation of both PKC and PKA, that mGlu5b 
receptor regulation by CaMKII would be preferred during intracellular Ca2+ influx. Further 
understanding of this difference may shed light on the developmental changes that we see in 
synaptic plasticity.   
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Chapter VI 
 
Regulation of Neuronal Ca2+ Signaling 
 
Introduction  
Long-term changes in synaptic function require changes in synaptic proteins. Some proteins play 
direct roles in synaptic transmission while others serve as structural scaffolds within the synapse.  
Functional changes require shifts in the availability, distribution, and post-translational 
modifications of the PSD proteins. Accordingly, functions related to the protein composition of 
the PSD underlies synaptic physiology and malfunction can cause neuronal diseases. 
 In my studies I decided to focus on the role of some of these synaptic regulators in controlling 
intracellular changes in neuronal Ca2+. First, I have examined the role of CaMKII in intracellular 
increases in Ca2+ through activation of different sources. Here we chose to focus on Ca2+ increases 
dependent on known CaMKII binding partners including mGlu1/5 and LTCCs.  
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Figure 6.1. CaMKII-associated macro-molecular protein complex composition. The macro-
molecular complexes formed with CaMKII are tightly regulated and important to proper synaptic 
signaling. Levels of Ca2+ influx through the signaling of ion channels within this complex are 
important for proper control of CaMKII activity and other Ca2+ regulated mGlu5 binding partners 
like CaM and CaN. Multiple proteins in this complex can be regulated by CaMKII binding and 
phosphorylation including LTCCs, SHANK, a-actinin, NMDARs, and AMPARs. These proteins 
also indirectly connect mGlu5 to modulators of intracellular Ca2+ like the NMDAR and IP3R.  
 
 CaMKII has many binding partners in the PSD, including some structural scaffolding proteins 
(Figure 6.1). Our lab has unpublished evidence that CaMKII is capable of binding and 
phosphorylating SHANK-3, an important PSD scaffolding protein. There is evidence that 
SHANK-3 is important in the regulation of dendritic spine morphology and synaptic plasticity 
(Durand et al., 2012) and has been linked to autistic phenotypes. Group I mGlu receptors directly 
bind the scaffolding protein Homer to form indirect binding interactions with Shank and the IP3 
and ryanodine receptors to control intracellular Ca2+ release from the endoplasmic reticulum (Feng 
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et al., 2002; Tu et al., 1999; Tu et al., 1998). The LTCC CaV1.3 also has a SHANK binding domain 
that is important for Ca2+-dependent long-range signaling to the nucleus (Zhang et al., 2005). 
CaMKII, Shank-3, Homer, mGlu5 and the LTCC CaV1.3 form a complex. We hypothesized that 
disruption of this complex would have effects on Ca2+ signals generated through both LTCCs or 
mGlu5. To study this, we measured Ca2+ signals in cells expressing endogenous SHANK-3 or 
shRNA knockdown of Shank-3. These studies show that CaMKII can differentially regulate 
neuronal Ca2+ signals in hippocampal neurons depending on the source of neuronal excitation. 
Additionally, we have begun to gather evidence to show that SHANK-3 is important for proper 
Ca2+ influx. 
Characterizing mGlu1/5 mediated Ca2+ responses in hippocampal neurons  
In order to study the role of mGlu5 in generating Ca2+ responses in our hippocampal culture system, 
I began to characterize neuronal Ca2+ responses in the presence of the Group I mGlu receptor 
agonist DHPG by measuring somatic changes in Fura-2 fluorescence. The neurons were imaged 
in 5 mM K+ Tyrode’s solution with DHPG alone, or with different receptor and channel inhibitors. 
In the presence of DHPG alone, most neurons exhibited a single Ca2+ spike that was reduced to 
levels below the baseline in about 150 seconds (Figure 6.2A). Only two of twenty-six imaged 
neurons responded with a sustained response (Figure 6.2A, orange trace). To look more 
specifically at Group I mGlu receptor-mediated responses, we incubated neurons in 5 mM K+ 
Tyrode’s solution APV and CNQX to block the activation of NMDA- and AMPA-type glutamate 
receptors, and with tetrodotoxin (TTX) to inhibit voltage-dependent sodium channels before 
stimulation with DHPG. In this condition, application of DHPG should activate both mGlu1 and 
mGlu5 receptors. Inhibition of NMDARs, AMPARs, and voltage-dependent sodium channels 
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resulted in a prolonged Ca2+ signal with a larger area under the curve than with DHPG alone 
(Figure 6.2B). To show that this response was specific to Group I mGlu receptors, we proceeded 
to simultaneously inhibit mGlu1 and mGlu5. In the presence of the mGlu5 specific antagonist 
MPEP and mGlu1 NAM VU0469650 (VU50), DHPG cause no increase in intracellular Ca2+ as 
expected (Figure 6.2C).  
When we inhibited mGlu5 with MPEP to exhibit a mGlu1-specific response, we saw no increases 
in intracellular Ca2+ throughout the 10-minute experiment (Figure 6.2D). Inhibition of mGlu1 alone 
(to exhibit mGlu5-mediated responses) produced two types of neuronal responses. About half of 
the cells exhibited larger single-peaked Ca2+ responses (14/30 cells) that returned to baseline 
(Figure 6.2E) and the half of the cells responded with smaller sustained Ca2+ responses (Figure 
6.2F) (16/30 cells). This data suggests that DHPG-mediated Ca2+ responses in our primary 
hippocampal neuron system require the activation of mGlu5 to produce intracellular Ca2+ release. 
After this initial characterization we performed all DHPG neuronal Ca2+ imaging experiments in 
the presence of APV, CNQX, TTX and VU50 to elicit mGlu5-specific responses. All of the traces 
in Figure 6.2 came from one day’s experiments. I am reporting them in this dissertation because I 
think they pose valuable information in the future of this project, but these studies do need to be 
repeated in order to more formally report these results.   
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Figure 6.2 Characterizing Group I mGlu receptor Ca2+ responses in primary hippocampal 
cultures. Ca2+ imaging experiments in primary hippocampal neuronal cultures (DIV 14). Neurons 
were incubated with Tyrode’s solution for 30 seconds and switched to Tyrode’s solution 
containing 100 uM DHPG for 10 minutes and the Ca2+ responses were measured in the presence 
of A. DHPG alone resulting in a single-spiked increase in intracellular Ca2+. 2/26 neurons 
responded with a sustained response (i.e., orange trace). All other conditions (B-F) were pre-
incuabted in Tyrode’s solution with the inhibitors CNQX, AP-5, and TTX in the presence or 
absence of the indicated mGlu receptor specific inhibition and stimulation with DHPG. B. 
Blockade of AMPA, NMDARs and voltage-dependent sodium channels shifted Ca2+ influx from 
a single peaked increase to a more sustained Ca2+ signal.  C. The presence of VU50 and MPEP to 
block both mGlu1 and mGlu5 completely abolished DHPG-mediated intracellular Ca2+ increases 
D. MPEP alone had a similar effect and eliminated DHPG-mediated Ca2+ responses E,F. VU50 
produced two types of Ca2+ responses. E. 14/30 cells exhibited larger single-peaked Ca2+ responses 
F. The other half of cells responded with smaller sustained Ca2+ responses (16/30). Example traces 
from a single experiment are plotted.  
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CaMKII-KD reduces mGlu5-mediated Ca2+ responses in hippocampal neurons  
To understand the role of CaMKII in neuronal mGlu5-mediated Ca2+ responses, we used a CaMKII 
knock-down and rescue strategy. In our earlier HEK-293 experiments we saw that the presence of 
CaMKII reduced peak mGlu5 Ca2+ amplitudes and prolonged mGlu5 signals (Chapter IV); 
therefore, we hypothesized that CaMKII-KD would enhance mGlu5 Ca2+ amplitudes and lead to 
faster termination of Ca2+ signals in CaMKII-KD neurons.  
Neurons were transfected with control shRNA or shRNAs to knockdown CaMKIIa and CaMKIIb 
expression. In cells transfected with control-ShRNA, DHPG produced a fast, sustained increase in 
intracellular Ca2+. This response was specific to mGlu5, because addition of MPEP at the end of 
the experiment quickly reduced intracellular Ca2+ levels back to baseline. Knockdown of CaMKII 
and CaMKII expression significantly reduced mGlu5-dependent somatic peak Ca2+ amplitudes in 
response to DHPG. Moreover, the re-expression of shRNA-resistant constitutively active 
CaMKIIa (CA-CaMKIIaR) rescued the reduction in peak amplitude seen with CaMKIIa/b 
knockdown. 
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Figure 6.3 CaMKII-KD reduces neuronal mGlu5-mediated Ca2+ responses. Neurons were 
transfected with control shRNA, CaMKII shRNA, or CaMKII shRNA and CA-CaMKII rescue. 
Neurons were preincubated in Tyrode’s solution containing CNQX, APV, and VU-50 before 
imaging. Neurons were imaged for 30 seconds in Tyrode’s solution with inhibitors to elicit mGlu5 
specific responses and switched to Tyrode’s solution containing DHPG and the Ca2+ responses 
were measured. To show the mGlu5 specificity of this response, MPEP was added to the plate at 
the end of the experiment. Average traces from 3 independent experiments are plotted as the 
change in fluorescence over baseline fluorescence.  
 
This is not the result that we would have expected based on our HEK-293 data. Neurons are a 
much more complicated system than HEK293 cells, and mGlu5 signaling is supported by proper 
formation of the complex macro-molecular structures of the PSD (Figure 6.1).  We suspect that 
CaMKII-KD may have effects on other proteins present in synaptic signaling. To determine the 
specificity of this result we followed by testing the effect of CaMKII-KD in LTCC-mediated 
responses. 
The role of CaMKII in somatic LTCC-mediated Ca2+ influx  
In collaboration with Xiaohan Wang, a former graduate student in the Colbran lab, I began to study 
the role of CaMKII in LTCC dependent Ca2+ signaling. This work was published in the Jounal of 
Biological Chemistry (Wang et al., 2017). To study the effect of CaMKII on LTCC somatic Ca2+ 
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responses, we used a stimulation paradigm to induce LTCC-dependent increases of Ca2+ 
concentrations. Neurons were pre-incubated in 5 mM K+ Tyrode’s solution containing APV and 
CNQX to block the activation of NMDA- and AMPA-type glutamate receptors, and with TTX to 
inhibit voltage-dependent sodium channels before stimulation. Neuronal depolarization was 
induced by replacing the solution with 40 mM K+ Tyrode’s solution in the presence of APV, 
CNQX and TTX. The addition of 40 mM K+ induced a significant increase in intracellular 
(somatic) Ca2+, which is largely blocked by 10 µM nimodipine, a highly selective LTCC antagonist 
(Figure 6.3). Transfection of shRNAs to knockdown CaMKIIa and CaMKIIb expression had had 
no significant effect on LTCC-dependent somatic Ca2+ responses to stimulation with 40 mM K+ 
Tyrode’s solution. The re-expression of shRNA-resistant wild-type CaMKIIa (WT-CaMKIIaR) 
also had no effect (Figure 6.3). LTCC channel activation can induce new mRNA transcription, a 
phenomenon called excitation-transcription (E-T) coupling often measured by the phosphorylation 
of the transcription factor CREB. Although we saw no effect on somatic Ca2+ levels in response 
to 40 mM K+, we did see significant deficits in LTCC-mediated activation of CREB (Wang et al., 
2017). This suggests that, even though total Ca2+ levels were not changed under these conditions, 
smaller changes in the LTCC nanodomain are important for the proper control of Ca2+ signaling 
to mediate the proper downstream effects.  
While CaMKII-KD had no effect on LTCC-specific influxes, we see a reduction in mGlu5-
dependent signaling in the absence of CaMKII. These finding show that there are unique effects 
of CaMKII on Ca2+ sources when measured by changes in somatic Ca2+ influx.  
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Figure 6.4 CaMKII-KD does not affect somatic LTCC-mediated Ca2+ influx A. Ca2+ imaging 
showing that nimodipine largely prevents the high K+-induced increase of somatic Ca2+. Neurons 
were incubated with Tyrode’s solution containing 5 mM KCl (5K) for 30 seconds and switched to 
Tyrode’s solution containing 40 mM KCl for 2 minutes in the absence (40K control, n = 193) or 
presence (40K+NIM, n = 215) of 10 mM nimodipine. The black arrow indicates the buffer switch. 
A total of 5 dishes from two independent cultures were analyzed per group. B. CaMKIIa/b 
knockdown or re-expression/rescue has no effect on high K+-induced increases of somatic Ca2+. 
Cultured hippocampal neurons were transfected with mApple only (n = 17), mApple with 
CaMKIIa/b shRNA (n = 23), or mApple/CaMKIIa/b shRNA with shRNA-resistant CaMKIIaR-
WT (n = 26) There was no significant difference between conditions by Two-way ANOVA. 
Sources of variation are as follows Interaction p = 0.40 Transfection p = 0.582 time p < 0.0001. 
All data were plotted as mean ± S.E.M. Figures were adapted from Wang et. al, 2017 
 
Shank-3 Knockdown Reduces LTCC- and mGlu5-mediated Ca2+ Responses  
We thought it might be possible that the reductions in somatic mGlu5 Ca2+ responses and changes 
in LTCC E-T coupling (Wang et al., 2017) that we saw in response to CaMKII-KD might involve 
mechanisms other than the direct regulation of mGlu5 and LTCCs.  Because CaMKII, mGlu5, 
LTCC are part of a bigger PSD molecular complex, we decided to study another protein that was 
identified by our lab as a major component of CaMKII complexes by mass-spectroscopy (Baucum 
et al., 2015). Shank-3, an important synaptic scaffolding protein, can bind to both LTCC and 
indirectly to mGlu5 to regulate PSD composition. Our lab has also confirmed a direct interaction 
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between CaMKII and Shank-3 (Tyler Perfitt, unpublished results). Therefore, we decided to 
investigate the role of Shank-3 in both mGlu5- and LTCC- mediated Ca2+ responses.  
For these experiments, we measured somatic changes in Fura-2 fluorescence in hippocampal 
neurons with control shRNA or shRNA-KD of Shank-3 in response to LTCC-mediated 
depolarization and mGlu5-mediated responses to DHPG. Unlike knockdown of CaMKII, 
knockdown of Shank-3 caused significant reduction in both LTCC- and mGlu5-mediated somatic 
Ca2+ responses (Figure 6.3). When cells were transfected with Shank-3 shRNA, 40 mM K+ 
treatment resulted in a significant reduction in Ca2+ influx (Figure 6.3 A,B). This was also the case 
for neurons treated with DHPG (Figure 6.3 C,D). These results emphasize the result that the PSD 
macromolecular complexes are important for proper control of intracellular Ca2+ influx.  
 
 
	130	
 
Figure 6.5 Shank-3 KD affects both LTCC- and mGlu5-mediated Ca2+ responses Somatic levels 
of high potassium concentrations (A., B.) or DHPG-induced (C.,D.) transfected with a control 
shRNA or with shRNA to knock-down Shank-3 protein levels. A. Depolarization induced Ca2+ 
entry was measured by Fura-2 fluorescence in hippocampal neurons from three independent 
cultures (Control n = 41, Shank3-KD n = 22) pre-incubated with 5K Tyrode’s solution containing 
APV, CNQX, and TTX. The black arrow indicated the buffer switch to 40K Tyrodes. Shank-KD 
caused a significant reduction in the 40K Ca2+ response by Two-way ANOVA Source of Variation 
Interaction p < 0.0001 Time p < 0.0001  Shank-KD p = 0194 B. Peak Ca2+ signals for each cell 
were normalized to the day of the experiment and plotted. Shank-3 KD caused a significant 
reduction in LTCC Ca2+ responses. In an unpaired t test p = 0.001. C. To measure the effect of 
Shank-3 expression on mGlu5 responses and Ca2+ signals DHPG-induced Ca2+ entry was measured 
by Fura-2 fluorescence in hippocampal in one experimental day (Control n = 17, Shank3-KD n = 
16) pre-incubated with 5K Tyrode’s solution containing APV, CNQX, TTX, and VU-50. The 
black arrow indicates the buffer switch. Shank-3 KD also reduced mGlu5-mediated Ca2+ influx 
(Two-way ANOVA Interaction p < 0.0001 Time p < 0.0001 Shank-3-KD, p = 0.010). D. Peak 
Ca2+ signals for each cell were normalized to the control and plotted.  Shank-3 KD reduced peak 
DHPG-induced Ca2+ levels by an unpaired T-test (p = 0.0059). All data were plotted as mean ± 
S.E.M. 
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Discussion 
Ca2+influx into neurons through channels or by activation of receptors plays an important role in 
proper synaptic function. Understanding the molecular mechanisms that underlie the specificity of 
signaling downstream of these channels and receptors is critical to understanding their biological 
roles.  
Here, we show the effect of CaMKII on regulating Ca2+ release from different sources in neurons. 
In Chapters III-V I discuss the role of CaMKII on mGlu5 in vitro and in a heterologous cell system, 
but it is important to understand the role of CaMKII in a neuronal context. The macro-molecular 
complexes formed between CaMKII, mGlu5, Homer, SHANK-3, and other Ca2+ regulating 
proteins within the synapse increases the complexity of the system and introduces a number of 
unknown variables within these experiments (Figure 6.1).  
In order to study the role of CaMKII in these processes, I first focused on Group I mGlu receptors. 
I began to characterize Group I mGlu receptor responses in the presence of a number of inhibitors. 
I was also able to execute an experimental paradigm to study mGlu5 specific responses. In data 
collected from heterologous cells, we reported that CaMKII was capable of reducing mGlu5-
mediated intracellular Ca2+ signals while prolonging the relative Ca2+ signal. From these data we 
hypothesized that knockdown of CaMKII in neurons would produce larger mGlu5-mediated 
signals than control cells. Instead, we saw significant deficits in the Ca2+ response to mGlu5-
specific activation in neurons when CaMKII was knocked down. Reducing CaMKII in this 
neuronal system is likely to have many effects because of the large number of CaMKII interacting 
proteins. The importance of CaMKII in synaptic regulation has been demonstrated and therefore I 
propose using KD and re-expression of WT mGlu5 or mGlu5 866-868AAA (Chapter III-IV) to 
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reduce CaMKII binding to mGlu5. In this way we could use an experimental design that would 
preserve the interaction of CaMKII with other binding partners and eliminate a number of 
unknown variables introduced by long-term knockdown of CaMKII. We did not examine mGlu5-
mediated activation of transcription in the absence of CaMKII, but future studies should examine 
if CaMKII knockdown can also impair mGlu5-mediated transcriptional activation. I would 
hypothesize that CREB activation would be impaired by CaMKII-KD similar to what we saw in 
LTCC experiments.  
To study the effect of CaMKII on LTCC responses we began by measuring LTCC-specific 
responses by stimulating neurons with 40 mM K+ in the presence of AMPAR and NMDAR 
antagonists. Knock-down of CaMKII had no effect on LTCC-mediated Ca2+ responses measured 
in the soma of neurons, but there was an impairment of long-range signaling to the nucleus as 
measured by the activation of E-T coupling (Wang et al., 2017). LTCC mediated E-T coupling 
seems to be independent of increases in nuclear Ca2+ concentrations, but seems to depend on Ca2+ 
signals within the LTCC nanodomain. Examining Ca2+ within neuronal spines may reveal 
differences when CaMKII is knocked down, but these changes were undetectable using our 
methods. Using more targeted Ca2+ imaging should help us to determine if there are smaller 
changes in LTCC nano-domain Ca2+ that can explain the E-T coupling deficits that we see with 
the CaMKII knockdown. I propose imaging dendritic spines for these experiments with GCaMP-
X-tagged receptors described recently (Yang et al., 2018). These findings emphasize that local 
LTCC signaling is important to mediate the proper downstream effects of LTCC activation even 
when global changes are not detectable.  
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Lastly, we studied the role of SHANK-3 in LTCC-mediated depolarization and mGlu5-mediated 
Ca2+ responses. The presence of Shank-binding motifs in CaV1.3 sequence is both necessary and 
sufficient for synaptic clustering of CaV1.3 L-type Ca2+ channels and important to LTCC E-T 
coupling (Zhang et al., 2005). Knockdown of Shank3 has also been shown to reduce mGlu5 surface 
expression, CREB phosphorylation, and synaptic plasticity (Verpelli et al., 2011). This evidence 
led us to hypothesize that disruption of this synaptic scaffolding protein by shRNA-KD of Shank-
3 would cause reductions in LTCC and mGlu5 Ca2+ signals. Unlike knockdown of CaMKII, 
knockdown of Shank-3 caused significant reduction in both LTCC- and mGlu5-mediated somatic 
Ca2+ responses. These data suggest that the experimental procedures we describe to measure Ca2+ 
responses in our primary hippocampal neurons are a good model to study LTCC- and mGlu5-
specific Ca2+ responses. We saw specific changes with CaMKII knockdown where global Ca2+ 
was not changed after activation of LTCCs, but was impaired in mGlu5-signaling. Additionally, 
Shank-3 is an important component of proper LTCC- and mGlu5-mediated Ca2+ release. The 
complex macro-molecular structures of the PSD are important to proper signaling within the cell. 
Future studies may be able to determine more carefully dissect the role of CaMKII on mGlu5-
specific signaling in neurons by using the mGlu5 construct that we identified that is capable of 
reducing CaMKII binding and phosphorylation of mGlu5.   
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Chapter VII 
 
The effect of mGlu5 on CaMKII signaling 
 
Introduction 
Most of the work in this dissertation has surrounded focused on understanding the role of CaMKII 
in modulating mGlu5. In this chapter I investigate questions surrounding the second aim of this 
project to understand the role of mGlu5 on regulating CaMKII. CaMKII activation is necessary for 
its interaction with many proteins. Because CaMKII is a critical regulator of numerous synaptic 
processes, mGlu5-dependent modulation of CaMKII in vivo might have important implications for 
synaptic regulation. Because mGlu5 activation leads to intracellular Ca2+ release, I hypothesized 
that mGlu5 activation could work as a feedback regulator of CaMKII activation in neurons. mGlu5-
induced Ca2+ responses are modulated by a number of different mGlu5 binding proteins including 
the Ca2+ sensitive CaM and CaMKII, but the effect of mGlu5 on CaMKII activity and function is 
not well understood.  
This work began the initial steps necessary to determine how activation of these two proteins are 
linked in normal physiology. First, we looked for basal differences in CaMKII activation in WT 
or mGlu5-KO mice.  
To determine the CaMKII response to mGlu5 activation, we generated data showing the effect of 
DHPG treatment on CaMKII activation in acutely isolated brain slices. Lastly, we used in vitro 
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tools to understand the role of the mGlu5-CaMKII interaction on CaMKII activation.  
Changes in CaMKII activation in mGlu5-KO mice  
CaMKII and mGlu5 have both been shown to regulate synaptic function in the hippocampus and 
the striatum. Distinct physiological stimuli are required for bidirectional synaptic plasticity in these 
brain regions, but differences in the underlying signaling mechanisms are poorly understood. To 
begin to understand how mGlu5 might be regulating CaMKII activity in the brain, we compared 
CaMKII phosphorylation in micro-dissected striatum and hippocampus from WT mice and mice 
lacking mGlu5 (mGlu5-KO). We used a fractionation protocol to separate subcellular fractions 
containing cytosolic (S1), extrasynaptic (S2), and PSD (S3) proteins to probe brain lysate for levels 
of total and activated CaMKII.  
We probed these samples for total CaMKII and pThr-286 to measure the level of CaMKII 
autophosphorylation as a measurement of CaMKII activation. In WT mice, the levels of basal 
CaMKII autophosphorylation are relatively low, but the absence of mGlu5 in the mGlu5-KO mice 
resulted in significant increases in CaMKII autophosphorylation at Thr286 in all of the synaptic 
fractions in both brain regions (Figure 7.1) 
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Figure 7.1 Subcellular fractionation from WT or mGlu5 knockout mice forebrains. The 
hippocampus and striatum were microdissected from WT, and mGlu5-KO mice and fractionated 
to isolate S1 (cytosolic), S2 (membrane-associated), and S3 (PSD-associated) proteins. All three 
fractions were then immunoblotted with a CaMKII and phospho-Thr286 antibody. The WT 
average Thr286/Total CaMKII was taken and used to normalize all values of Thr286/total CaMKII 
signals. A. Immunoblot showing p-Thr286 and total CaMKII levels in S1, S2, an S3 of WT (n = 
4) and KO mice (n = 5) hippocampi showing that CaMKII autophosphorylation at Thr286 is 
increased in all three fractions. B. Quantification of the immunoblots where mGlu5-KO 
significantly increased the autophosphorylation of CamKII by Two-way ANOVA (Interaction p = 
0.0065, Fraction p = 0.0065, Genotype p = 0.0052) B. Representative data of striatal extracts where 
CaMKII autophosphorylation in also increased in the striatum of mGlu5 KO mice. By Two-way 
Anova Interaction p = 0.2789, Fraction p = 0.2789, Genotype p = 0.0014. Each individual data 
point is a different mouse analyzed on the same immunoblot.  
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The effect of mGlu5 activation on CaMKII autophosphorylation in brain slices  
Results from the literature show both increases and decreases in CaMKII activation after treatment 
with DHPG depending on the time points examined and the brain region used for analysis (Jin et 
al., 2013a; Mockett et al., 2011). To compare the response of CaMKII to Group I mGlu receptor 
activation in the hippocampus and the striatum, we generated data showing the effect of DHPG 
treatment on CaMKII Thr286 phosphorylation in acutely isolated brain slices. Brain slices 
containing the hippocampus or the striatum were incubated with 100 µM DHPG for 20 min and a 
punch was gathered for analysis. Quantification of immunoblotts for total and pT286 CaMKII 
showed that, after mGlu1/5 activation, there was a trend for a decrease in CaMKII phosphorylation 
at Thr-286 in the hippocampus and a statistically significant reduction in Thr-286 activation in the 
striatum. These data are in agreement with Figure 7.1 where mGlu5-KO mice had increased levels 
of basal CaMKII autophosphorylation. Taken together, these data suggest that mGlu5 can reduce 
the levels of CaMKII autophosphorylation in both the hippocampus and the striatum.  
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Figure 7.2. DHPG reduces CaMKII activation in acute slice pharmacology experiments. A. 
Acutely isolated brain slices containing the hippocampus or the striatum were incubated with 100 
µM DHPG for 20 min. Punches were homogenized and immunoblotted for total and pT286 
CaMKII. Work in this figure was generated by Dr. Johanna Gandy.  
 
The effect of mGlu5-CTD on CaMKII activation in vitro  
The effect seen in Figure 7.1 and 7.2 led us to question if CaMKII binding to mGlu5 could have a 
direct role in regulating CaMKII activation. To investigate this, we used in vitro tools to understand 
the role of the mGlu5-CaMKII interaction on CaMKII activation. We first pre-incubated purified 
CaMKII with GST-mGlu5a-CTD or GST alone and performed an CaMKII autophosphorylation 
assay to determine if the presence of mGlu5 was capable of altering CaMKII autophosphorylation. 
Interestingly, we found that the presence of mGlu5a-CTD increased CaMKII autophosphorylation 
compared to GST (Figure 7.3A). To understand this mechanistically, we continued our studies 
using an assay to measure phosphorylation of a CaMKII synthetic substrate, syntide, in the 
presence of GST-mGlu5a-CTD and increasing concentrations of CaM. The GST-mGlu5a-CTD 
dramatically enhanced cooperativity of CaMKII activation by CaM as measured by an increase in 
the Hill constant (Fig. 7.3B). These findings suggest that mGlu5 can enhance the switch-like 
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activation of CaMKII by suppressing activation until a threshold concentration of Ca2+/CaM is 
exceeded.  
 
Figure 7.3 The mGlu5-CTD enhances CaMKII autophosphorylation and increases the apparent 
cooperativity for CaMKII activation by CaM. A. CaMKII was preincubated with the indicated 
concentrations of either GST-mG5-CTD or GST. Reactions were initiated by addition of Ca2+, 
CaM, and ATP for 1 minute on ice. These conditions are designed to limit the rate of Thr286 
phosphorylation so differences can be detected. Samples were immunoblotted for total and pT286 
CaMKII. B. CaMKII was preincubated with GST-mGlu5-CTD or GST on ice. Reactions were 
started by addition of indicated concentrations of CaM, along with 2 mM Ca2+, 0.4 mM [γ-
32P]ATP, and 0.2 mM syntide-2. After 10 min at 30C, 32P incorporation into syntide-2 was 
measured. GST-mG5-CTD increases the Hill constant from 1.1 to 3.1, indicating an increase in 
apparent cooperativity for activation by CaM.  
 
Discussion  
The results presented in this chapter support the idea that mGlu5 can suppress CaMKII activation 
at low levels of intracellular Ca2+. I report here an enhancement of CaMKII activation in mGlu5 
KO mice, a reduction in CaMKII autophosphorylation after mGlu5 activation in acute brain slices, 
and the ability of mGlu5 to enhance CaMKII cooperativity. Thus, mGlu5 may suppress CaMKII 
A. B. 
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activity under basal conditions (low Ca2+/CaM), and enhance switch-like activation in response to 
modest increased in Ca2+. Such a mechanism could enhance the switch-like responsiveness of the 
pool of CaMKII bound to mGlu5 in cells. 
The effect of mGlu5 activation on CaMKII autophosphorylation at Thr286 has not been clear based 
on previous findings from the literature. It was been reported that there is a quick reduction 
CaMKII autophosphorylation in hippocampal synaptoneurosomes treated with DHPG that is 
followed by a biphasic increase in CaMKII (Mockett et al., 2011) and another lab showed increases 
in CaMKII activation after DHPG application in striatal brain slices (Jin et al., 2013a). Our studies 
show in both the hippocampus and the striatum that mGlu5 activation reduces CaMKII 
autophosphorylation at Thr286. Currently, we are unable to explain the difference in these 
findings, but they may be due to differences in experimental design. It is also possible that the 
developmental switch between mGlu5a and mGlu5b differentially regulates the role of mGlu5 
activity on CaMKII across different age ranges.  It will be interesting to examine differences in 
basal autophosphorylation of CaMKII at Thr286 in the brains of mGlu5 KO mice relative to WT 
mice and the role of mGlu5 activation in affecting CaMKII autophosphorylation more 
systematically across development. We also saw that the mGlu5-CTD was capable of directly 
affecting CaMKII activation and cooperativity for CaM. I would like to repeat these experiments 
with the GST-mGlu5-866-868AAA mutant to confirm that CaMKII binding to mGlu5 is important 
for this result. It will also be useful to determine whether mutation of a Ser901 PKC 
phosphorylation site to Asp, which blocks Ca2+/CaM-binding to the CTD, prevents enhanced 
CaMKII activation. Low levels of mGlu5 activation may play a role in inhibiting CaMKII 
activation during baseline levels of neuronal activity. Lack of mGlu5 is also likely to disrupt the 
proper composition of the molecular PSD complexes that are tightly regulated in dendritic spines. 
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Examining the effect of pharmacological inhibition of mGlu5 on CaMKII activation over time may 
be helpful in addressing some of the issues posed by long-term knockout of mGlu5. Additionally, 
our slice pharmacology studies and those done by other laboratories have examined the effect of 
DHPG which activates both mGlu1 and mGlu5. A clearer picture of mGlu5 activation on CaMKII 
activity can be deduced by using specific protocols to activate mGlu5 such as in our neuronal Ca2+ 
imaging experiments presented in Chapter VI.  
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Chapter VIII 
 
Discussion and Future Directions 
 
Summary 
The work presented in this document provides new insights into the complex regulation of CaMKII 
and its interacting proteins. The multiprotein complexes present in the dendrites of neurons are 
highly regulated and specific. This work has begun to unravel the importance of some of these 
interactions. In this dissertation I focused on the CaMKII and mGlu5 interaction and signaling 
relationship.  
When I began these studies, it had been reported that the membrane proximal region of the mGlu5a-
CTD bound to inactive CaMKII (Jin et al., 2013b). I focused on the novelty of this type of 
interaction because there are few proteins known to bind to CaMKII in their inactive conformation. 
I hoped to further characterize the physical and functional relationship between these key 
regulators of synaptic transmission because of the evidence of their functional interaction in 
physiology (discussed on pg. 51). We confirmed that CaMKIIα and mGlu5 specifically interact in 
mouse brain. However, the binding interaction between mGlu5a and CaMKII was weak in my 
initial in vitro studies using inactive kinase. I was able to show that the mGlu5a-CTD residues 827-
964 bind more strongly to CaMKIIα in an active, Thr286-autophopshorylated conformation, but 
that this interaction is disrupted by excess Ca2+/CaM or by robust CaMKII autophosphorylation at 
additional undefined sites. I showed that the interaction requires three basic residues (Lys866-
Arg867-Arg868) on the mGlu5-CTD. 
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I tested the hypothesis that CaMKII modulates signaling via an interaction with mGlu5 through 
binding or phosphorylation of the receptor by measuring changes in mGlu5 surface expression, 
ERK1/2 activation, and Ca2+ signaling. Active CaMKII increases basal mGlu5 surface expression 
and ERK activation in heterologous cells.  
Careful control of intracellular Ca2+ is important to processes of development, synaptic 
remodeling, transcriptional regulations, and control of synaptic strength (Brini et al., 2014). The 
diverse effects of Ca2+ in neurons can be specific to the cell-type and source of calcium. 
Understanding the precise control of this signaling mechanism has been a major motivation for 
pursuing this work. To study the CaMKII control of mGlu5 Ca2+ signaling in a simple system I 
looked at changes in mGlu5-mediated Ca2+ signals in a heterologous cell system and showed that 
CaMKII decreases the initial amplitude of mGlu5 Ca2+ release, but prolongs the relative Ca2+ 
signal. CaMKII also increases mGlu5 oscillation frequency in cells responding with baseline 
oscillations. All of these effects are prevented by the triple alanine substitution for Lys866-Arg867-
Arg868 in the CTD.  
To understand the regulation of neuronal Ca2+ levels we used cultured hippocampal neurons. Based 
on our HEK cell studies we expected that knockdown of CaMKII would result in enhanced mGlu5 
signaling in neurons, but we saw reduced mGlu5-specific Ca2+ signals. To determine if this effect 
was specific to mGlu5, we also tested the effect of CaMKII knockdown on LTCC influx. 
Knockdown of CaMKII did not affect global LTCC Ca2+ signals, but did result in impairments in 
LTCC E-T coupling. In order to determine a mechanism of how the macro-molecular complex 
associated with mGlu5, CaMKII, and LTCC might be playing a role in these results, we looked at 
the effect of shRNA knockdown of an important scaffolding protein, Shank-3. Unlike CaMKII, 
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knockdown of Shank-3 caused impairments in both LTCC- and mGlu5-mediated Ca2+ signals. We 
also have unpublished evidence that Shank-3 knockdown can impair LTCC E-T coupling 
(unpublished, Tyler Perfitt).  
It had never been demonstrated that CaMKII was capable of phosphorylating mGlu5. I performed 
in vitro phosphorylation assays to show that CaMKII can phosphorylate both isoforms of mGlu5. 
Similar to binding, Ca2+/CaM can compete with CaMKII to inhibit CaMKII phosphorylation of 
the mGlu5-CTD, but this effect on mGlu5a was much more potent than on mGlu5b. I was also able 
to identify putative sites of phosphorylation of both mGlu5a and mGlu5b.  
In the last chapter I show work surrounding the second aim of this project to understand the role 
of mGlu5 on regulating CaMKII. I hypothesized that mGlu5 activation could work as a feedback 
regulator of CaMKII activation in neurons. To determine the CaMKII response to mGlu5 activation 
we showed that mGlu5 activation in acutely isolated brain slices led to decreases in CaMKII 
activation. Additionally, mGlu5 KO mice show largely elevated levels of basal CaMKII 
autophosphorylation at Thr286, and lastly we show that the mGlu5-CaMKII interaction directly 
affects CaMKII cooperativity for CaM.  
CaMKII binding studies  
Contrary to a previous publication (Jin et al., 2013b), we were able to show for the first time that 
CaMKII activation results in stronger binding to mGlu5. This is true for mGlu5a, but we have not 
undertaken these same studies in mGlu5b. An obvious future direction is to systematically test the 
mGlu5b interaction with CaMKII under different activation states. This is of particular interest 
because the mGlu5b specific insert (starting at residue 876) lies very close to the tri-basic residues 
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necessary for CaMKII binding (Lys866-Arg867-Arg868) and the putative phosphorylation site 
identified on mGlu5a (Ser871) in Chapter V. For this reason, the interaction between mGlu5a and 
mGlu5b may be different. It will be interesting to test if triple Ala mutation of Lys866-Arg867-Arg868 
in mGlu5b disrupts CaMKII binding.  
The tribasic residues important for the interaction between mGlu5 and CaMKII are similar to a 
tribasic residue stretch necessary for other CaMKII interactions on the CaV1.3 NTD (Wang et al., 
2017), and Shank-3 (Tyler Perfitt, unpublished). Other GPCRs that bind CaMKII also include 
tribasic residues within their CaMKII binding regions, including mGlu1 and the D2 dopamine 
receptor (Jin et al., 2013a; Zhang et al., 2014) (Figure 3.5). We believe that these tribasic residue 
motifs may constitute a new type of CaMKII binding domain. These tri-basic residue stretches are 
not sufficient to bind CaMKII on their own and the flanking residues are probably an important 
aspect in CaMKII binding to these regions.  
It was reported that mGlu5 could only interact with inactive kinase and that CaMKII 
autophosphorylation inhibited this reaction (Jin et al., 2013b). Using different autophosphorylation 
protocols for CaMKII (Chapter III), I was able to show that active CaMKII can bind more strongly 
to the mGlu5-CTD depending on the autophosphorylation conditions (Figure 3.2). Extensive 
autophosphorylation at unidentified sites on CaMKII reduced the CaMKII interaction with mGlu5 
(Figure 3.2 & Jin et al, 2013b), but not with mGlu1 (Jin et al., 2013a). Because of these reported 
differences, I would hypothesize that the mGlu1 and mGlu5 interactions are distinct and that 
CaMKII regulates these two receptors at different sites of interaction (Figure 8.1). In addition to 
binding to mGlu1, it was also published that CaMKII was capable of binding to the mGlu5 IL-2. I 
was unable to confirm this result (data not shown). Future studies should determine other sites of 
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CaMKII binding on the mGlu5 full-length receptor because triple alanine mutation of Lys866-
Arg867-Arg868 was unable to completely disrupt the CaMKII interaction with full-length receptor.  
 
 
Figure 8.1 mGlu1 and mGlu5 interactions with CaMKII. A. Alignment of the CTD region of mGlu1 
and mGlu5. The CaMKII phosphorylation site on mGlu1 (Jin et al., 2013a) is marked as well as the 
CaMKII phosphorylation site on mGlu5 detected in our studies (Chapter V). B. Schematic showing 
that both mGlu1 and mGlu5 are capable of binding to CaMKII in their Thr286 autophosphorylated 
state, but CaMKII autophosphorylation at unidentified sites that exceed Thr286 phosphorylation 
has no effect on CaMKII binding to mGlu1, but disrupts the interaction with mGlu5 (reported by 
Jin et al., 2013a, b). The differences in sequence homology, suspected phosphorylation sites, and 
ability to bind to CaMKII in different autophosphorylation conditions leads me to hypothesize that 
these interactions occur in distinct binding regions.  
 
It is not clear what CaMKII autophosphorylation sites affect the interaction between mGlu5 and 
CaMKII. It is known that CaMKII does have multiple autophosphorylation sites, but the most well 
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studied have been Thr286, 305, and 306. We demonstrate in our studies that Thr286 
phosphorylation does not differ between a 90 second or 10 minute autophosphorylation protocol, 
but there are large increases at unidentified sites in this extensive autophosphorylation protocol 
(Figure 3.3). This is an important area of study because imbalances in CaMKII 
autophosphorylation have been linked to altered synaptic plasticity and neuronal dysfunction in 
disease models (Table 8.1). For example, increased phosphorylation at both Thr286 and 
Thr305/306, and defects in hippocampal LTP and learning were observed in a mouse model of 
Angelman’s mental retardation syndrome (AS) (Weeber et al., 2003). This is similar to what we 
see in mGlu5-KO mice where CaMKII autophosphorylation at Thr286 is largely increased in the 
hippocampus and striatum.  
A recent study analyzed CaMKII autophosphorylation sites using a proteomics approach and 
identified multiple novel phosphorylation sites including Ser78, Thr261, Ser275, Ser315, 
Thr320/Thr321, Ser331, and Thr378 (Baucum et al., 2015). These newly identified sites of 
autophosphorylation are great targets to understand how CaMKII self-regulation may 
systematically control protein specific interactions. There is evidence that CaMKII 
autophosphorylation sites other than Thr286, 305, and 306 play a role in synaptic function. A group 
recently showed that phosphorylation of CaMKII at Ser331 inhibited CaMKII activity and is 
reversibly regulated in cocaine-associated memory reconsolidation and extinction (Rich et al., 
2016). Another autophosphorylation site, Thr253, did not alter CaMKII activity, but did alter 
CaMKII targeting and the CaMKII interactome (Skelding et al., 2010). Testing phosphomimetic 
mutations of CaMKII for their interactions with mGlu5 and other CaMKAPs may help us to 
understand how CaMKII autophosphorylation can regulate CaMKII targeting in neurons. I also 
report here that the mGlu5-CTD can enhance CaMKII cooperativity (Chapter VII).  Enhanced 
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CaMKII cooperativity may lead CaMKII to be more susceptible to excess phosphorylation in the 
presence of mGlu5. Activation of CaMKII by its interaction with mGlu5 could also direct CaMKII 
to other targets such as GluN2B. This hypothesis is supported by work showing that mGlu5 
activation leads to a reduction in the CaMKII association with mGlu5 and increased association 
with GluN2B (Jin et al., 2013b). If this is the case, the composition of the indirect interface between 
mGlu5 and the NMDAR is likely very important to proper function.  
CaMKII-mGlu5 interaction on mGlu5 receptor localization and signaling 
The regulation of mGlu5-CTD by interacting proteins can regulate cell surface localization and 
intracellular receptor signaling as reviewed in Chapter I. The mGlu5-CTD contains binding sites 
for many proteins that can occupy overlapping binding domains and compete for binding to induce 
regulatory control of mGlu5 signaling (Figure 1.8). In our initial heterologous cell studies we 
examined the role of overexpressing CaMKII on mGlu5 signaling. 
We began our studies in HEK293 cells because they represent a much simpler system than neurons. 
In this system, I demonstrated that CA-CaMKIIα can increase cell surface expression of mGlu5a 
and effect mGlu5a-dependent Ca2+ mobilization. Co-expression of CA-CaMKIIα reduced the 
amplitude of mGlu5a mediated initial Ca2+ peaks but prolonged the duration of the mGlu5-
generated Ca2+ signal. These effects were prevented by the triple alanine substitution for Lys866-
Arg867-Arg868 in the CTD. These findings introduce questions about how CaMKII is capable of 
modulating mGlu5 Ca2+ signals.  
mGlu5–mediated Ca2+ induction activates a number of downstream signaling pathways, and 
involves a number of Ca2+-sensing feedback regulators including CaM, CaMKII, CaN, and PLC. 
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Understanding what is known about the generation of mGlu5-mediated signals and incorporating 
the effects that CaMKII has on mGlu5 Ca2+ oscillations allows us to propose a model for what is 
happening in HEK293 cells in the presence of mGlu5 and CaMKII.   
The activation of Group I mGlu receptors leads to increases in membrane-bound diacylglycerol 
IP3 concentrations, resulting in the release of Ca2+ from intracellular stores, and the activation of 
PKC. mGlu5 activation has most often been reported to give rise to repetitive base-line separated 
Ca2+ oscillations, although we see a number of different types of responses in both HEK293 cells 
and in neurons as reported in Chapters IV and VI.  
A number of different hormones and neurotransmitters activate signaling pathways that 
communicate through increases in intracellular Ca2+. The dynamics of Ca2+ oscillations have been 
studied in order to understand how cells are capable of decoding the universal Ca2+ signal. This 
leads to the complicated question of how different stimuli working through the same messenger 
systems can generate specificity. Some mechanisms of control include spatial and temporal 
patterns coded into the signal. For example, NMDAR LTP and LTD are both triggered by post-
synaptic elevations in Ca2+. Additionally, CaMKII can also play a role in both LTP and LTD (Pi 
et al., 2010). This is evidence that Ca2+ channels and Ca2+ dependent proteins can induce opposing 
processes by interpreting specific Ca2+ signals. Simulations have shown how different frequency 
and amplitudes of neuron stimulation affect activation of different Ca2+ sensors. While Ca2+ 
activates both CaN and CaMKII at all frequencies, higher frequencies shift the relative activation 
from CaN to CaMKII (Li et al., 2012). CaMKII has also been described as a frequency detector, 
as differences in Ca2+ spike frequency can cause differences in the extent of CaMKII activity (De 
Koninck and Schulman, 1998). Changes in Ca2+ influx patterns and different interpretation of the 
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signal can then alter downstream functional outputs such as gene expression (Dolmetsch et al., 
1998). The ability of CaMKII to alter the amplitude and relative duration of mGlu5 Ca2+ signals in 
cells has the potential to alter the cellular interpretation of mGlu5 activation.  
mGlu5-mediated Ca2+ oscillations are accompanied by IP3 oscillations in single cells. Many studies 
have focused on a PKC-dependent “dynamic desensitization” model whereby PKC can 
phosphorylate the receptor initiating cycles of activation/deactivation as first suggested by early 
studies of mGlu5 (Kawabata et al., 1996). The simplest model was proposed as follows: 1. agonist 
activation of mGlu5 increases IP3 and diacylglycerol production, 2. Ca2+ is released from 
intracellular stores by IP3 3. increases in diacylglycerol and Ca2+ activate PKC to inhibit IP3 
production by phosphorylation of mGlu5 4. Ca2+ levels consequently fall and PKC activity is no 
longer sustained, and 5) dephosphorylation by protein phosphatases resets the system to allow IP3 
production to cycle again (Kawabata et al., 1996) 
Later, the hypothesis surrounding mGlu5 oscillations was expanded to include input resulting from 
Ca2+ induced Ca2+ release (CICR) in addition to dynamic uncoupling. Receptor  stimulation  has  
been  shown  to  initiate  Ca2+ oscillations in both PKC-dependent and-independent mechanisms 
(Dale et al., 2001; Kawabata et al., 1996). This led to the IP3-induced Ca2+ signaling “slide  rule” 
(Nash et al., 2002). This model proposes a continuum of Ca2+ responses relative to increases in IP3 
concentration where low concentrations sensitize IP3Rs and lead to CICR. Here, it is thought that 
the frequency of Ca2+ oscillations is dependent on agonist concentration. Both IP3 and Ca2+ 
regulate IP3 receptors, with Ca2+ exerting a biphasic effect that facilitates Ca2+ release at low 
concentrations but is inhibitory as its levels rise (Adkins and Taylor, 1999). Levels of stimulation 
too great to drive oscillatory behavior lead to a peak-plateau response (i.e. Figure 4.6A, red trace) 
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These hypotheses do not take into consideration the multiple proteins that affect mGlu5 surface 
expression and signaling in neurons. However, looking at these simple models and other examples 
from the literature, we can begin to hypothesize the role that CaMKII might be playing in our 
heterologous cell studies.  
When we examined Ca2+ response curves to glutamate, CA-CaMKIIα did not affect the apparent 
EC50 value, but did increase mGlu5 surface expression and ERK activation. Other studies have 
reported similar effects to these in the presence of a phosphoinhibitory mutation of a PKC site, 
Ser901, or in the presence of mGlu5 binding partners Norbin and α-actinin-1 (Cabello et al., 2007; 
Lee et al., 2008; Wang et al., 2009). In the case of the mutation of Ser901, the authors propose that 
increases in mGlu5 surface expression and prolonged half-life of mGlu5 Ca2+ signals were a result 
of enhanced CaM binding to the mGlu5-CTD to stabilize surface expression.  
CaMKII affects the initial Ca2+ signal amplitude of mGlu5 signals. This could be explained by two 
possible scenarios: 1. CaMKII could cause a reduction in the receptor “on” signal, or 2. CaMKII 
could promote a faster “off” signal. In the first scenario, CaMKII binding or phosphorylation could 
reduce mGlu5 coupling to Gq to reduce initial IP3 and DAG production. Alternatively, CaMKII 
could promote a faster “off signal” to induce smaller productions in IP3 by enhancing PKC 
phosphorylation of site responsible for stopping mGlu5 oscillations (Ser839) to promote the off 
signal. CaMKII could also play a similar role to that predicted of CaM, causing enhanced receptor 
surface stability and spatial restrictions that block PKC phosphorylation at Ser901. In this way 
CaM and CaMKII could play complementary roles as discussed in Chapter III.  
One property of mGlu5 oscillations resulting from dynamic uncoupling is that, when a threshold 
concentration of orthosteric agonist is reached, oscillation frequency is unchanged by increasing 
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agonist concentration, but can be modulated by receptor surface expression (Nash et al., 2002). 
CaMKII is capable of increasing mGlu5 surface expression; therefore, I predicted that in cells 
expressing oscillatory patterns that we would see an increase in Ca2+ oscillation frequency. When 
we analyzed cells responding with at least 3 baseline oscillations in response to glutamate, we saw 
that CA-CaMKII caused a significant increase in the frequency of oscillations (average time 
between peaks: mGlu5 65 seconds, mGlu5 + CA-CaMKII 46 seconds, Figure 4.7D). However, I 
would hypothesize that CaMKII is capable of affecting mGlu5-mediated Ca2+ signals in a more 
complex way than simple increased surface expression. To my knowledge, there are no studies 
that show an effect of increased mGlu5 surface expression causing a reduction in mGlu5 Ca2+ 
amplitudes.  
I would hypothesize that the reduction in the intracellular Ca2+ amplitudes correlate with 
reductions in IP3 production, but this measurement alone would not reveal a difference between 
the two hypotheses that I have offered (reduced “on”/enhanced “off” signals). Activation of mGlu5 
results in the synchronized repetitive cytosol to plasma membrane translocation of PKC in a 
heterologous cell system (Dale et al., 2001) and in astrocytes (Codazzi et al., 2001). This 
translocation could present a spatial restriction for PKC phosphorylation of mGlu5, allowing for 
other Ca2+ sensors like CaM or CaMKII to regulate the receptor. It would be interesting to 
determine if CA-CaMKII changed the frequency or extent of PKC translocation in response to 
mGlu5 activation. It would also be interesting to look at the translocation of CaMKII during mGlu5 
activation in both HEK293 cells and neurons. Previous experiments have used co-expression of 
fluorescently tagged CaMKII and a genetically encoded Ca2+ indicator, GCaMP2, to 
simultaneously measure Ca2+ dynamics and spatial and temporal accumulation of CaMKII 
(Lemieux et al., 2012). Combining the live imaging of CaMKII and PKC might reveal if these two 
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proteins translocate in similar or distinct patterns to the cell membrane in cells expressing mGlu5. 
To isolate the effect of CaMKII on this system, one could examine how pharmacological inhibition 
of PKC or PKC phospho-null mGlu5 mutations affect the mGlu5 signal in the presence of CA-
CaMKII. 
We have shown that CaMKII is capable of both binding and phosphorylation of the mGlu5-CTD 
and both are blocked by triple alanine mutation of Lys866-Arg867-Arg868; therefore, our studies 
cannot conclude whether the CaMKII-specific effects that we see in HEK293 cells are induced 
because of CaMKII binding or through phosphorylation at the mGlu5-CTD. Future directions to 
tease apart these systems might identify the CaMKII sites of phosphorylation on the mGlu5-CTD 
to determine if these effects were due to binding or phosphorylation of the receptor.  
It was recently reported that PKA can phosphorylate Ser870 on mGlu5 and that this 
phosphorylation is required for mGlu5 activation of ERK signaling and intracellular Ca2+ 
oscillations (Uematsu et al., 2015). This site is directly adjacent to Ser871, a site of CaMKII 
phosphorylation on mGlu5 identified in our proteomics analysis. It was reported that a 
phosphomimetic mutation of Ser870 allowed for normal ERK activation, but phosphoinhibitory 
mutation of this site inhibited mGlu5 ERK signaling and Ca2+ responses. The coupling of mGlu5 
with Gq/11-protein is an important step in activation of downstream ERK signaling; therefore, it is 
possible that PKA and CaMKII are able to modulate the Gq/11-protein-coupling region in the 
mGlu5-CTD. Phosphorylation of these two sites by PKA and CaMKII might affect receptor 
signaling during different cellular stimulation conditions. A helpful assay to better understand the 
interaction of the kinases capable of phosphorylating mGlu5 might be to perform sequential 
phosphorylation with PKA, PKC, and CaMKII in a simple in vitro system. For instance, an initial 
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phosphorylation of the mGlu5-CTD with PKA could reduce a sequential phosphorylation by 
CaMKII or vice-versa. Understanding preferential phosphorylation in vitro could help us to make 
more educated hypotheses about the regulation of CTD binding and phosphorylation in cellular 
systems. 
Strict control of mGlu5 activity is important for proper synaptic function; therefore, it is important 
to study these processes in a neuronal context. The simple model of mGlu5 Ca2+ signal regulation 
by the two methods of CICR and dynamic uncoupling to PKC becomes much more complicated 
as we examine the mGlu5-CTD interacting partners in neurons. There are a number of proteins that 
can compete with CaM binding to the mGlu5-CTD including CaMKII and α-actinin (Cabello et 
al., 2007; Jin et al., 2013b; Marks et al., 2018). Interestingly, α-actinin, a scaffolding protein that 
links actin filaments, was shown to bind mGlu5b in the CTD region near the Ser901 (Ser 933 in 
mGlu5b) PKC phosphorylation site. The authors showed that α-actinin increased mGlu5 surface 
expression and ERK activation (Cabello et al., 2007). Previous work from our lab showed α-actinin 
is also a CaMKAP that can cause Ca2+-independent activation of CaMKII (Jalan-Sakrikar et al., 
2012). Binding of α-actinin can mimic CaM binding to CaMKII to activate binding to a subset of 
substrates in vitro and in intact cells. In addition, α-actinin can also compete with CaM for binding 
to the NMDAR to promote CaMKII binding (Merrill et al., 2007). Based on this work, I propose 
experiments to determine if α-actinin is capable of increasing the phosphorylation of mGlu5 by 
CaMKII. The α-actinin, CaMKII, mGlu5 complex could allow for CaMKII regulation of mGlu5 
even when intracellular levels of Ca2+/CaM are not capable of fully activating CaMKII. 
The binding site for CaM also overlaps with other regulators of mGlu5 surface expression 
including Norbin, and the E3 ligase Siah-1a (Ishikawa et al., 1999; Ko et al., 2012; Wang et al., 
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2009). These proteins can bind within a very small region of mGlu5 to modulate receptor function. 
It seems as though CaM, Norbin, α-actinin, and CaMKII can all promote increased receptor surface 
expression. Although α-actinin was not tested for effects on mediating mGlu5-dependent Ca2+ 
release, all of these other mGlu5 interaction proteins increased Ca2+ signal half-lives, similar to our 
findings with CaMKII. Alternatively, PKC phosphorylation at Ser901 inhibited CaM binding and 
enhanced Siah-1A binding to increase receptor internalization and lysosomal degradation.  
I would to acknowledge that although I was able to identify effects of CA-CaMKII on mGlu5 
signaling in heterologous cells, these effects were not immediately evident using WT-CaMKII. In 
surface expression, ERK activation, and Ca2+ signaling studies we only identified the effect of 
CaMKII on mGlu5 when we used CA-CaMKII. This is not surprising because we showed that 
active CaMKII binds to mGlu5 much more strongly than inactive kinase, and basal levels of 
CaMKII activation in HEK293 cells is very low. Neurons have detectable Thr286 
autophosphorylation levels that may be able to regulate mGlu5 even under baseline activity.  
Based on our work in HEK293 cells, we hypothesized that CaMKII knockdown in neurons would 
lead to enhanced amplitude of Ca2+ influx. When we examined Ca2+ responses in neurons we saw 
that CaMKII knockdown reduced global mGlu5-mediated Ca2+ signals, but not LTCC influx. The 
macro-molecular complexes formed between CaMKII, mGlu5, Homer, Shank-3, and other Ca2+ 
regulating proteins within the synapse increase the complexity of the system and introduce a 
number of unknown variables within these experiments. Considering the complexity of signaling 
in this system, is not surprising that our results in neuronal Ca2+ imaging studies differ from what 
we would expect from heterologous cell studies.  
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Our neuronal Ca2+ imaging studies confirm that we can distinguish source-specific changes in 
neuronal Ca2+. Although knockdown of CaMKII had no effect on LTCC-mediated Ca2+ responses 
measured in the soma of neurons, there was an impairment of long-range signaling to the nucleus 
as measured by the activation of E-T coupling (Wang et al., 2017). These findings highlight that 
local LTCC signaling is important to mediate the proper downstream effects of LTCC activation 
even when global changes are not detectable. Future experiments should examine if CaMKII 
knockdown can also impair mGlu5-mediated transcriptional activation, as was seen in LTCC 
experiments. Tyler Perfitt, a graduate student in our lab, has begun to collect these data and has 
confirmed that activation of mGlu5 leads to CREB activation in neurons (data not shown).  
A physical interaction as well as a functional interaction between mGlu5 and LTCCs was 
demonstrated in a study where mGlu5 and LTCCs were co-immunoprecipitated from brain lysates  
and mGlu5 facilitated depolarization-evoked calcium currents (Kato et al., 2012). Another link 
between these two proteins is that they are both in complex with the scaffolding protein Shank. 
Shank is important for  CaV1.3 LTCC E-T coupling (Zhang et al., 2005) and mGlu5 surface 
expression, CREB phosphorylation, and synaptic plasticity (Verpelli et al., 2011). 
We were able to show an effect on both LTCC- and mGlu5-mediated Ca2+ responses with the 
knockdown of the scaffolding protein Shank-3. These data show that our methods to measure Ca2+ 
responses in our primary hippocampal neurons are a good model to study LTCC- and mGlu5- 
specific Ca2+ responses. There may be some changes that we are unable to detect with our current 
methods. It will be interesting to use more targeted Ca2+ imaging to determine the effect of CaMKII 
on local LTCC signaling, as discussed in Chapter VI.  
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In addition to the kinase activity of CaMKII, it is also thought to function as an organizer of 
synaptic proteins (Hell, 2014; Incontro et al., 2018). The molecular composition and proximity of 
CaMKII to substrates within the synapse cause highly selective regulation by CaMKII (Tsui et al., 
2005; Tsui and Malenka, 2006). Spatial barriers of substrate phosphorylation are often overcome 
by translocation, or by anchoring to the substrate or a nearby protein. Due to the high degree of 
mGlu5 regulation by CaMKAPs such as CaM, α-actinin, Shank, and Homer, long-term knockdown 
of CaMKII may have unexpected indirect effects on receptor signaling (Cabello et al., 2007; Guo 
et al., 2015; Minakami et al., 1997; Mizutani et al., 2008).  
The importance of CaMKII in synaptic regulation has been demonstrated and knock-down of 
CaMKII is not the most specific manipulation that we can make to answer questions about the 
effect of CaMKII on mGlu5 in neurons. Pharmacological inhibition of CaMKII offers an acute 
perturbation of the system that may be more telling, but I propose that knockdown of mGlu5 and 
re-expression of the mGlu5 binding mutant with Ala mutation at Lys866-Arg867-Arg868 may 
preserve the interaction of CaMKII with other synaptic binding partners and eliminate the 
unknown effects of long-term CaMKII knockdown. Although this manipulation would preserve 
CaMKII binding interactions, it will be important to determine if this mutant disrupts mGlu5 
association with other regulating proteins. 
This work on mGlu5, CaMKII, and other neuronal regulators has added to the evidence supporting 
the importance of proper synaptic signaling complexes. These studies also enhance our 
understanding of the cellular responses associated with mGlu5 activation. The interactions of 
multiple proteins regulating CaMKII-dependent processes that will necessitate the development of 
new tools to explore the role of individual protein contribution to proper neuronal signaling and 
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function. While there is good evidence that modulation of mGlu5 could be helpful to many 
neuronal disorders, some drugs have lacked efficacy in clinical trials (Scharf et al., 2015). 
Understanding the full pharmacological impact of mGlu5 ligands may help in the development of 
more efficacious medical interventions with fewer adverse effects or greater efficacy.  
Differences between mGlu5 isoforms  
Another exciting aspect of this project was the identification of previously unknown differences 
between mGlu5a and mGlu5b. There is a clear developmental regulation of mGlu5 isoforms. mGlu5a 
is most highly expressed in early postnatal development, and mGlu5b, which contains a 32 amino 
acid CTD insert is the dominant variant in adulthood (Romano et al., 1996). Little is known about 
functional differences between these two receptors. One study demonstrated that mGlu5a hinders 
the acquisition of mature neuronal traits and mGlu5b promotes the elaboration and extension of 
neurites (Mion et al., 2001). Studies have shown comparable pharmacological profiles of these 
splice variants. Differential regulation of mGlu5 variants by CaMKII could provide a better 
understanding of developmental changes in synaptic plasticity mechanisms. Studies have shown 
that LFS in rats P9-12 produces an NMDAR and mGlu5 LTD that switches to mGlu5 receptor 
dependent LTP in older animals  (Lante et al., 2006). DHPG treatment in rats P8-15 showed a 
presynaptically induced form of LTD independent of protein synthesis that changed in older rats 
(P21-35) to a form of LTD dependent on AMPAR endocytosis and protein synthesis (Nosyreva 
and Huber, 2005). The study showing the role of CaMKII in DHPG mediated LTD were performed 
in young adult mice (P42-70) (Mockett et al., 2011). Changes in Ca2+ responses also occur 
throughout postnatal development in the central nucleus of the inferior colliculus where larger Ca2+ 
responses were seen at P6 and lower peak plateau responses were see after P13 (Martinez-Galan 
	159	
et al., 2012). These changes correlate with the switch of the mGlu5a/b isoforms and regulation of 
CaMKII could explain some aspects of these changes.  
We identified different sites of phosphorylation by CaMKII within both mGlu5 isoforms, but also 
established that mGlu5a phosphorylation by CaMKII was much more potently inhibited by the 
presence of CaM than mGlu5b. I would hypothesize that the mGlu5b specific sequence in the 
mGlu5-CTD results in a separation of the CaM and CaMKII binding sites on the mGlu5-CTD, 
resulting in differential regulation of mGlu5b (Figure 8.2). mGlu5a binding to CaM, α-actinin, and 
CaMKII may have similar effects in mGlu5a, but I would predict that the separation of these 
binding sites can cause differences in the CaMKII regulation of mGlu5b. 
 
 
Figure 8.2 mGlu5a/b specific residues may affect regulation by mGlu5 binding partners. Schematic 
demonstrating how the mGlu5b-specific residues are capable of separating protein binding sites. 
mGlu5 has two CaM binding sites separated by the mGlu5b specific insert. The C-terminal CaM 
binding site is agreed upon, but there is some debate about if the N-terminal binding site exists. 
The first paper characterizing these two sites did show that the C-terminal CaM site has a higher 
binding affinity (Minakami et al., 1997). This explains why the CaMKII phosphorylation is more 
potently inhibited in mGlu5a than in mGlu5b. 
 
To study this, I propose first looking at the interaction between CaMKII and mGlu5 throughout 
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development. The use of younger mice will bias the interaction of CaMKII with mGlu5a while 
older mice will reveal more information about interactions of CaMKII with mGlu5b. In our studies 
we have routinely used mice of P30-60. Using tissue homogenates fractionated into cytosolic, 
extra-synaptic membrane proteins, and synaptic proteins (as in Figure 7.1), future studies could 
include a co-immunoprecipitation using a mGlu5 or CaMKII antibody and subsequent  
immunoblot analysis for CaMKII and mGlu5. I would predict that although mGlu5 expression is 
reduced in older mice, that there will be a higher ratio of CaMKII associated with mGlu5 in older 
mice expressing higher levels of mGlu5b.  
I also propose using slice pharmacology in acutely isolated brain slices from WT and mGlu5-null 
mice to compare effects of mGlu5 activation on Thr286 autophosphorylation, CaMKII association 
with mGlu5, NMDARs and phosphorylation of multiple physiologically relevant downstream 
substrates such as AMPARs across multiple age ranges. These tissues can also be used to look for 
ERK and mTOR activation by immunoblotting for phosphorylation of ERK1/2 at Thr202/Tyr204, 
mTOR at Ser2448, and phosphorylation of the transcription factor CREB at Ser133 which has 
been shown to transmit mGlu5 signaling to target DNA transcription (Mao et al., 2008a). mGlu5-
KO slices can be used as a control to confirm the specificity of our pharmacological manipulations.  
Although studies have shown that CaMKII inhibition reduces mGlu5-LTD, these studies used 
CaMKII inhibitors KN62 and KN93 (Mockett et al., 2011). These inhibitors are peptides based on 
the autoinhibitory region of CaMKII, but these drugs cannot discriminate between CaMKII and 
CaMKIV, have off-target effects on voltage-gated K+ and Ca2+ channels, and do not inhibit 
autonomous activity of the kinase (Pellicena and Schulman, 2014). I propose performing DHPG- 
induced LTD in the presence of a cell-permeable inhibitor tatCN-21, a CaMKII inhibitor that has 
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no known off-target effects to confirm the result that CaMKII does play a role in DHPG-induced 
LTD. I would predict that blockade of CaMKII in DHPG-induced LTD will have bigger effects in 
mice >P15 compared to mice P9-12. These studies will reveal the role of CaMKII in regulating 
mGlu5a vs mGlu5b signaling. It will also be important to perform single-cell Ca2+ imaging with a 
construct of mGlu5b. We could perform these studies in parallel with cells transfected with mGlu5a 
to determine differences in mGlu5 isoform regulation by CaMKII.  
We have begun to look at Ca2+ signals in cultured hippocampal neurons, but it is also possible to 
perform these types of experiments in brain slices. If we used acutely isolated brain slices we could 
then use genetic manipulations already available in our lab such as mGlu5 KO mice, CaMKII KO 
mice, and Thr286A-KI mice, in which the mutation of CaMKIIα Thr286 to Ala abrogates Thr286 
autophosphorylation, preventing autonomous kinase activity and reducing synaptic targeting of 
CaMKIIα. We could also use genetically encoded GCaMP to target and measure changes in 
specific cell populations. Oscillations in intracellular Ca2+concentrations mediated through mGlu5 
play a critical role in neuronal development in the neocortex (Flint et al., 1999). We could examine 
how acute inhibition of CaMKII or use of Thr286Ala-KI alters mGlu5 responses across different 
age ranges.  
mGlu5 control of CaMKII activation  
In this dissertation I provide results that support the idea that mGlu5 can suppress CaMKII 
activation at low levels of intracellular Ca2+. These findings include an enhancement of CaMKII 
activation in mGlu5 KO mice, a reduction in CaMKII autophosphorylation after mGlu5 activation 
in acute brain slices, and the ability of mGlu5 to enhance CaMKII cooperativity. Thus, mGlu5 may 
suppress CaMKII activity under basal conditions (low Ca2+/CaM), and enhance switch-like 
	162	
activation in response to intracellular Ca2+ increases. Such a mechanism could enhance the switch-
like responsiveness of the pool of CaMKII bound to mGlu5 in cells. 
CaM is important in the induction of synaptic plasticity because of its ability to translate Ca2+ 
signals and regulate different binding proteins including a number of enzymes and receptors (Xia 
and Storm, 2005). Evidence has suggested that smaller increases in Ca2+ work through CaM to 
activate CaN and lead to LTD, and higher Ca2+ concentrations lead to LTP through CaMKII 
activation and increases in dendritic protein synthesis (Li et al., 2012). However, other studies 
have shown activated CaMKII can promote both LTP and LTD (Pi et al., 2010), suggesting that 
the control of these processes are much more complicated than the simple activation of singular 
protein kinases and phosphatases.  
Although there are high concentrations of CaM within the cell, the immense number of CaM 
binding proteins renders the total CaM concentration significantly less than that its partners and 
creates competition for CaM (Sanabria et al., 2008). Both the frequency and amplitude of Ca2+ 
signals can control how CaM binds to its many partners. Some proteins, such as neurogranin, are 
capable of binding CaM in its Ca2+ free state (apoCaM) and these proteins are thought to localize 
CaM to the synapse for proper control and targeting of CaM once Ca2+ has entered the cell 
(Romano et al., 2017; Xia and Storm, 2005). Increases in intracellular Ca2+ cause release of CaM 
from neurogranin. The role of neurogranin in CaMKII regulation has been recently demonstrated 
because neurogranin KO mice show reduced levels of CaMKII autophosphorylation and activity. 
This is predicted to be because of reduced CaM docking in the synapse (Pak et al., 2000; Zhong 
and Gerges, 2010). Additionally, neurogranin overexpression increases synaptic concentrations of 
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CaM and lowers the threshold of Ca2+ signaling and causes increases in synaptic strength (Zhong 
et al., 2009).  
Activation of mGlu receptors and PKC activation leads to phosphorylation of neurogranin, 
releasing apoCaM for targeting to neuronal substrates (Ramakers et al., 1997). This unique 
interaction may explain a way that neurogranin can specifically integrate the mGlu5 signal to CaM 
sensitive processes including activation of the CaM-dependent CaN and CaMKII.  
NMDAR activation can enhance mGlu5 receptor-mediated IP3 production through mGlu5 
dephosphorylation by CaN (Alagarsamy et al., 1999). CaN has also been shown to bind to the 
mGlu5-CTD (Alagarsamy et al., 2005). The ability of CaM and CaN to bind mGlu5 may play a 
role in precise control of CaN regulation of this process.  
We showed that mGlu5 activation in acutely isolated brain slices resulted in a reduction in CaMKII 
autophosphorylation at Thr286 in both the hippocampus and the striatum. Other reports showing 
the effect of mGlu5 activation on CaMKII autophosphorylation have not been consistent. One 
study saw a quick reduction CaMKII autophosphorylation in hippocampal synaptoneurosomes 
treated with DHPG, followed by a biphasic increase in CaMKII (Mockett et al., 2011) while 
another showed increases in CaMKII activation after DHPG application in striatal brain slices (Jin 
et al., 2013a). Our studies show in the hippocampus and the striatum that mGlu5 activation reduces 
CaMKII autophosphorylation at Thr286. Currently, we are unable to explain the difference in these 
findings, but they may be due to differences in experimental design. It is also possible these 
mechanisms are different across development as discussed in the previous section. We saw 
dramatic increases in CaMKII autophosphorylation in our mGlu5-KO mice at an age range 
encompassing P30-60, but it will be interesting to see how autophosphorylation of CaMKII at 
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Thr286 in the brains of mGlu5 KO mice relative to WT mice more systematically across 
development. 
 When reviewing the literature, I was able to identify other models of neuronal disorders that 
caused large increases in CaMKII autophosphorylation including Fragile X Syndrome (Guo et al., 
2015) (Table 8.1).  Another example of CaMKII hyperautophosphorylation was examined in 
ATRX knockout mice. Mutations in the gene encoding ATRX cause mental retardation disorders, 
including α-thalassemia X-linked mental retardation syndrome. These mice show increased 
CaMKII activity associated with decreased expression of PP1 (Shioda et al., 2011). This may also 
give us insight into the role of mGlu5 in controlling basal CaMKII autophosphorylation.  
Table 8.1 Aberrant CaMKII autophosphorylation in models of disease. Examples of rodent 
models of disease and genetic protein deletions that cause deleterious effects with reported changes 
in CaMKII autophosphorylation. Models of neuronal disorder are associated with both increased 
and decreased CaMKII activation.  
 
 
Model CaMKIIAutophos. Reference
Alzheimer’s Disease Decreased Min et al., 2013
Angelman's syndrome Increased Weeber et al., 2003
ATRX KO Increased Shioda et al., 2011
Autism Model E183V CaMKII Decreased Stephenson et al., 2017
Fragile X Syndrome Increased Guo et al., 2015
mGlu5 KO mice Increased Figure X.X
Neurogranin KO Mice Decreased Pak et al., 2000
Parkinson's Disease Increased Picconi et al., 2004
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Interactions have been demonstrated between mGlu5 and PP1 at mGlu5 residues 880-884 
(KSVTW) and a physical association with CaN, mentioned earlier in this chapter (Alagarsamy et 
al., 2005; Croci et al., 2003). Unlike PP1, there is no evidence for dephosphorylation of CaMKII 
by CaN, but CaN may indirectly modulate CaMKII by enzymes that activate PP1 such as DARP-
32 (Colbran, 2004). PP1 dephosphorylation of CaMKII increases CaMKII cooperativity for 
Ca2+/CaM providing ultrasensitive responsiveness to increasing concentrations (Bradshaw et al., 
2003). PP1 has been hypothesized to form a molecular switch controlling synaptic plasticity 
(Lisman and Zhabotinsky, 2001; Zhabotinsky, 2000). It was proposed the translocation of Thr286-
autophosphorylated CaMKII to the PSD causes saturation of local PP1 and allows for sustained 
Thr286 autophosphorylation. Inhibition of PP1 before stimulation with DHPG enhances mGlu5-
mediated ERK2 activation, and this may explain why we see increases in ERK activation in the 
presence of CA-CaMKII (Voulalas et al., 2005). CaMKII recruitment of Thr286-
autophosphorylated CaMKII to mGlu5 may also increase mGlu5 ERK signaling by causing a 
saturation of local mGlu5-docked PP1.  
This emphasizes the importance of the role of the mGlu5-CTD as a docking station of proteins that 
are capable of modulating its activity including CaMKII and PP1. I would hypothesize that 
CaMKII docked near mGlu5, perhaps bound to α-actinin is kept in its inactive conformation 
through dephosphorylation by PP1 docked on mGlu5. This model would support the idea that at 
low intracellular Ca2+ concentrations, mGlu5 is capable of inhibiting CaMKII 
autophosphorylation.  
To test this hypothesis, I propose using acutely isolated brain slices to look at the 
autophosphorylation status of CaMKII after DHPG treatment in the absence or presence of PP1 
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inhibitors in WT and mGlu5 KO mice. Where we previously saw a decrease in Thr286 
autophosphorylation I would suspect to see increases in kinase activation in the presence of PP1 
inhibition. Future directions could also use alanine mutagenesis of the PP1 binding site on mGlu5 
residues 880-884 (KSVTW) to determine the role of PP1 docking on regulation of CaMKII 
activity. Interestingly, the mGlu5b specific sequence separates the CaMKII binding site from the 
PP1 binding site. If PP1 does cause dephosphorylation of CaMKII near mGlu5, this effect may be 
bigger in the context of mGlu5a than in mGlu5b due to a spatial restriction imposed by the mGlu5b 
specific sequences.  
Other proteins have been shown to cause increased cooperativity or Ca2+-independent activation 
of CaMKII. For instance, CaMKII binding to CaV2.1 channels induces Ca2+-independent activity 
of the kinase, which induces CaMKII autophosphorylation and phosphorylation of the neuronal 
substrate synapsin-1 (Magupalli et al., 2013).  Because multiple specific dynamic interactions with 
individual PSD proteins regulate CaMKII activity-dependent targeting and its role in synaptic 
structure, tools that block or enhance CaMKII binding to individual proteins are now necessary to 
explore the individual roles of these interactions in disease and for the development of therapeutics.  
Previously, I discussed the effect of CaMKII in mGlu5-mediated Ca2+ amplitude and duration. This 
effect likely translates to differential activation of Ca2+-sensitive proteins. This promotes the 
specificity of Ca2+ signals where small elevations in cytosolic Ca2+ can activate high affinity 
sensors, but reduce the activation of a low-affinity Ca2+ sensors (or sensors with a greater activation 
threshold). In the mGlu5 complex it seems that multiple Ca2+ sensors could be present including 
CaM, CaMKII, and CaN. A complex harboring a number of Ca2+-binding molecules within close 
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proximity presents a situation where sensors with range of Ca2+ sensitivities are docked and ready 
to respond based on the amplitude of cellular Ca2+ responses.  
Final summary statement 
The work presented in this dissertation has highlighted the importance of the CaMKII interaction 
with the mGlu5-CTD in heterologous cells, cultured neurons, and mouse brains.  
By defining a CaMKII binding domain on mGlu5 and identifying possible phosphorylation sites 
on the mGlu5-CTD, I have generated new tools to continue studies surrounding this interaction.  
We have begun to study the importance of this interaction in cultured neurons to understand the 
interaction of mGlu5 and CaMKII in a synaptic context. These studies will allow us to understand 
the mechanisms important to proper regulation of synaptic activity. This work has laid the 
groundwork for further exploration of the role of CaMKII in regulating synaptic macro-molecular 
complexes that integrate Ca2+ signals into functional changes in synaptic strength.   
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